



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: G01N	A2	(11) International Publication Number: WO 97/21993 (43) International Publication Date: 19 June 1997 (19.06.97)
(21) International Application Number: PCT/US96/20778 (22) International Filing Date: 13 December 1996 (13.12.96) (30) Priority Data: 60/008,543 13 December 1995 (13.12.95) US 60/008,540 13 December 1995 (13.12.95) US 60/008,606 14 December 1995 (14.12.95) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US). (72) Inventors: SCANLAN, Thomas, S.; 2525 Moraga Street, San Francisco, CA 94122 (US). BAXTER, John, D.; 131 San Pablo Avenue, San Francisco, CA 94127 (US). FLETTERICK, Robert, J.; 15 Christopher Avenue, San Francisco, CA 94131 (US). WAGNER, Richard, L.; 1704 Waller Street, San Francisco, CA 94117 (US). KUSHNER, Peter, J.; 1362 Sixth Avenue, San Francisco, CA 94122 (US). APRILETTI, James, L.; 11 Virginia Gardens, Berkeley, CA 94702 (US). WEST, Brian, L.; 142 Anderson Street, San Francisco, CA 94110 (US). SHIAU, Andrew, K.; 34 Hugo Street, San Francisco, CA 94122 (US).		(74) Agents: NAKAMURA, Jackie, N. et al.; Cooley Godward L.L.P., 3000 El Camino Real, Five Palo Alto Square, Palo Alto, CA 94306-2155 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS (57) Abstract The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three-dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as "TR"). Also provided are crystals, nuclear receptor synthetic ligands, and related methods.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS

ACKNOWLEDGMENTS

5 This invention was supported in part by grants from the National Institutes of Health grant number 1 R01 DK43787, and 5 R01 DK 41842. The U.S. Government may have rights in this invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

10 This application claims the benefit of the following provisional applications: United States Ser. No. 60/008,540 and 60/008,543, filed December 13, 1995, and Ser. No. 60/008,606, filed December 14, 1995.

INTRODUCTION

Technical Field

15 This invention relates to computational methods for designing ligands that bind to nuclear receptors, crystals of nuclear receptors, synthetic ligands of nuclear receptors and methods of using synthetic ligands.

Background

20 Nuclear receptors represent a superfamily of proteins that specifically bind a physiologically relevant small molecule, such as hormone or vitamin. As a result of a molecule binding to a nuclear receptor, the nuclear receptor changes the ability of a cell to transcribe DNA, i.e. nuclear receptors modulate the transcription of DNA, although they may have transcription independent actions.
25 Unlike integral membrane receptors and membrane associated receptors, the nuclear receptors reside in either the cytoplasm or nucleus of eukaryotic cells. Thus, nuclear receptors comprise a class of intracellular, soluble ligand-regulated transcription factors.

30 Nuclear receptors include receptors for glucocorticoids (GRs), androgens (ARs), mineralocorticoids (MRs), progestins (PRs), estrogens (ERs), thyroid hormones (TRs), vitamin D (VDRs), retinoids (RARs and RXRs). The so called

"orphan receptors" are also part of the nuclear receptor superfamily, as they are structurally homologous to the classic nuclear receptors, such as steroid and thyroid receptors. To date, ligands have not been identified with orphan receptors but it is likely that small molecule ligands will be discovered in the near future for this class of transcription factors. Generally, nuclear receptors specifically bind physiologically relevant small molecules with high affinity and apparent K_d 's are commonly in the 0.01 - 20 nM range, depending on the nuclear receptor/ligand pair.

Development of synthetic ligands that specifically bind to nuclear receptors has been largely guided by the trial and error method of drug design despite the importance of nuclear receptors in a myriad of physiological processes and medical conditions such as hypertension, inflammation, hormone dependent cancers (e.g. breast and prostate cancer), modulation of reproductive organ modulation, hyperthyroidism, hypercholesterolemia and obesity. Previously, new ligands specific for nuclear receptors were discovered in the absence of information on the three dimensional structure of a nuclear receptor with a bound ligand. Before the present invention, researchers were essentially discovering nuclear receptor ligands by probing in the dark and without the ability to visualize how the amino acids of a nuclear receptor held a ligand in its grasp.

Consequently, it would be advantageous to devise methods and compositions for reducing the time required to discover ligands to nuclear receptors, synthesize such compounds and administer such compounds to organisms to modulate physiological processes regulated by nuclear receptors.

SUMMARY OF THE INVENTION

The present invention provides for crystals of nuclear receptor ligand binding domains with a ligand bound to the ligand binding domain (LBD). The crystals of the present invention provide excellent atomic resolution of the amino acids that interact with nuclear receptor ligand, especially thyroid receptor ligands. The three dimensional model of a nuclear receptor LBD with a ligand bound reveals a previously unknown structure for nuclear receptors and shows that the ligand is bound in a water inaccessible binding cavity of the ligand binding domain of the nuclear receptor.

The present invention also provides for computational methods using three dimensional models of nuclear receptors that are based on crystals of nuclear receptor LBDs. Generally, the computational method of designing a nuclear receptor ligand determines which amino acid or amino acids of a nuclear receptor LBD interact with a chemical moiety (at least one) of the ligand using a three dimensional model of a crystallized protein comprising a nuclear receptor LBD with a bound ligand, and selecting a chemical modification (at least one) of the chemical moiety to produce a second chemical moiety with a structure that either decreases or increases an interaction between the interacting amino acid and the second chemical moiety compared to the interaction between the interacting amino acid and the corresponding chemical moiety on the natural hormone.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram illustrating computational methods for designing ligands that interact with nuclear receptors of the nuclear receptor superfamily.

FIG. 2 is a schematic representation of nuclear receptor structures, indicating regions of homology within family members and functions of the various domains.

FIG. 3 shows the aligned amino acid sequences of the ligand binding domains of several members of the nuclear receptor superfamily.

FIG. 4 is a ribbon drawing of the rat TR- α LBD with secondary structure elements labelled. The ligand (magenta) is depicted as a space-filling model. Alpha helices and coil conformations are yellow, beta strands are blue.

FIG. 5 shows two cross-sections of a space-filling model of rat TR- α exposing the ligand (magenta) tightly packed within the receptor.

FIG. 6 is a schematic of the ligand binding cavity. Residues which interact with the ligand appear approximately at the site of interaction. Hydrogen bonds are shown as dashed lines between the bonding partners; distances for each bond are listed. Non-bonded contacts are shown as radial spokes which face toward interacting atoms.

FIG. 7 is the distribution of crystallographic temperature factors in the refined rat TR- α LBD. The distribution is represented as a color gradation ranging from less than 15 (dark blue) to greater than 35 (yellow-green).

FIG. 8 is a ribbon drawing of the rat TR- α LBD showing the c-terminal activation domain to ligand. Residues which comprise the c-terminal activation domain (Pro393-Phe405) are depicted as a stick representation. Hydrophobic residues, particularly Phe401 and Phe405 (blue) face inwards toward the ligand. Glu403 (red) projects outward into the solvent.

FIG. 9 is an electrostatic potential surface of the rat TR- α LBD, calculated using GRAPH. Negative electrostatic potential is red; positive electrostatic potential is blue. The c-terminal activation domain forms a largely hydrophobic (white). The Glu403 is presented as a singular patch of negative charge (red).

FIG. 10 is a diagram comparing agonists and antagonists for several nuclear receptors.

FIG. 11 is the synthetic scheme for preparation of TS1, TS2, TS3, TS4 and TS5.

FIG. 12 is the synthetic scheme for preparation of TS6 and TS7.

FIG. 13 is the synthetic scheme for preparation of TS8.

FIG. 14 is the synthetic scheme for preparation of TS10.

FIG. 15 depicts the chemical structures of several TR ligands.

FIG. 16 is a graph illustrating competition assays in which T₃ and triac compete with labeled T₃ for binding to human TR- α or human TR- β .

FIG. 17 depicts a Scatchard analysis of labelled T₃ binding to TR- α and TR- β .

FIG. 18 is a chart showing the effect of TS-10 on the transcriptional regulation of the DR4-ALP reporter gene in the presence or absence of T₃ as assayed in TRAF α 1 reporter cells.

FIG. 19 is a chart showing the effect of TS-10 on the transcriptional regulation of the DR4-ALP reporter gene in the presence or absence of T₃ as assayed in TRAF β 1 reporter cells.

FIG. 20 is a chart showing the effect of TS-10 on the transcriptional regulation of the DR4-ALP reporter gene in the presence or absence of T₃ as assayed in HepG2, a liver reporter cell line.

FIG. 21 is a partial ribbon drawing of TR- α LBD with T3 in the ligand binding cavity. Selected interacting amino acids are labelled, including Ile221, Ile222 and Ser260, Ala263, Ile299 and Leu 276.

5 FIG. 22 is a partial ribbon drawing of TR- α LBD with T3 and Dimit superimposed in the ligand binding cavity. Interactions with Ile221, Ile222, Ala260, Ile 299 and Leu276 are labelled.

10 FIG. 23 is a partial ribbon drawing of TR- α LBD with T3, illustrating the three Arginine residues (Arg228, Arg262 and Arg 266 (dark stick figures)) of the polar pocket, three water molecules HOH502, HOH503 and HOH504, with hydrogen bonds indicated by dotted lines.

FIG. 24 is a partial ribbon drawing of TR- α LBD with triac, illustrating the three Arginine residues (dark stick figures) of the polar pocket, water molecules (HOH503, HOH504 and HOH600), with hydrogen bonds indicated by dotted lines.

15 FIG. 25 is a partial ribbon drawing of the TR- α LBD with T3 and triac superimposed in the ligand binding cavity. The drawing shows several interacting amino acid residues in the polar pocket that remain unchanged whether T3 or triac occupies the ligand binding cavity: Arg262, Asn179, HOH503 and HOH504, and Ser277. Both Arg228 and Arg 266 occupy two different positions, depending on
20 whether T3 or triac is bound.

FIG. 26 is a stereochemical representation of the TR α LBD with Dimit bound.

APPENDIX 1 is an appendix of references.

25 APPENDIX 2 is a chart of amino acids that interact with a TR ligand, for TR complexed with Dimit, Triac, IpBr2, and T3.

DETAILED DESCRIPTION OF THE INVENTION

INTRODUCTION

30 The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as "TR"). Previously, the lack of three

dimensional structural information about the ligand binding domain of a nuclear receptor thwarted the field of nuclear receptor drug discovery, especially the absence of three dimensional structural information relating to a nuclear receptor with a ligand bound.

5 Described herein for the first time are crystals and three dimensional structural information from a nuclear receptor's ligand binding domain (LBD) with a ligand bound. Such crystals offer superior resolution at the atomic level and the ability to visualize the coordination of nuclear receptor ligands by amino acids that comprise the LBD. The present invention also provides computational methods
10 for designing nuclear receptor synthetic ligands using such crystal and three dimensional structural information to generate synthetic ligands that modulate the conformational changes of a nuclear receptor's LBD. Such synthetic ligands can be designed using the computational methods described herein and shown, in part, in FIG. 1. These computational methods are particularly useful in designing an
15 antagonist or partial agonist to a nuclear receptor, wherein the antagonist or partial agonist has an extended moiety that prevents any one of a number of ligand-induced molecular events that alter the receptor's influence on the regulation of gene expression, such as preventing the normal coordination of the activation domain observed for a naturally occurring ligand or other ligands that mimic the
20 naturally occurring ligand, such as an agonist. As described herein, synthetic ligands of nuclear receptors will be useful in modulating nuclear receptor activity in a variety of medical conditions.

APPLICABILITY TO NUCLEAR RECEPTORS

25 The present invention, particularly the computational methods, can be used to design drugs for a variety of nuclear receptors, such as receptors for glucocorticoids (GRs), androgens (ARs), mineralocorticoids (MRs), progestins (PRs), estrogens (ERs), thyroid hormones (TRs), vitamin D (VDRs), retinoid (RARs and RXRs) and peroxisomal proliferators (PPAP). The present invention
30 can also be applied to the "orphan receptors," as they are structurally homologous in terms of modular domains and primary structure to classic nuclear receptors, such as steroid and thyroid receptors. The amino acid homologies of orphan

receptors with other nuclear receptors ranges from very low (<15%) to in the range of 35% when compared to rat RAR α and human TR- β receptors, for example. In addition, as is revealed by the X-ray crystallographic structure of the TR and structural analysis disclosed herein, the overall folding of liganded superfamily members is likely to be similar. Although ligands have not been identified with orphan receptors, once such ligands are identified one skilled in the art will be able to apply the present invention to the design and use of such ligands, as their overall structural modular motif will be similar to other nuclear receptors described herein.

Modular Functional Domains Of Nuclear receptors

The present invention will usually be applicable to all nuclear receptors, as discussed herein, in part, to the patterns of nuclear receptor activation, structure and modulation that have emerged as a consequence of determining the three dimensional structures of nuclear receptors with different ligands bound, notably the three dimensional structures or crystallized protein structure of the ligand binding domains for TR- α and TR- β . Proteins of the nuclear receptor superfamily display substantial regions of amino acid homology, as described herein and known in the art see FIG. 2. Members of this family display an overall structural motif of three modular domains (which is similar to the TR three modular domain motif):

- 1) a variable amino-terminal domain;
- 2) a highly conserved DNA-binding domain (DBD); and
- 3) a less conserved carboxyl-terminal ligand-binding domain (LBD).

The modularity of this superfamily permits different domains of each protein to separately accomplish different functions, although the domains can influence each other. The separate function of a domain is usually preserved when a particular domain is isolated from the remainder of the protein. Using conventional protein chemistry techniques a modular domain can sometimes be separated from the parent protein. Using conventional molecular biology techniques each domain can usually be separately expressed with its original function intact or chimerics of two different nuclear receptors can be constructed, wherein the chimerics retain the

properties of the individual functional domains of the respective nuclear receptors from which the chimerics were generated.

FIG. 2 provides a schematic representation of family member structures, indicating regions of homology within family members and functions of the various domains.

Amino Terminal Domain

The amino terminal domain is the least conserved of the three domains and varies markedly in size among nuclear receptor superfamily members. For example, this domain contains 24 amino acids in the VDR and 603 amino acids in the MR. This domain is involved in transcriptional activation and in some cases its uniqueness may dictate selective receptor-DNA binding and activation of target genes by specific receptor isoforms. This domain can display synergistic and antagonistic interactions with the domains of the LBD. For example, studies with mutated and/or deleted receptors show positive cooperativity of the amino and carboxy terminal domains. In some cases, deletion of either of these domains will abolish the receptor's transcriptional activation functions.

DNA-Binding Domain

The DBD is the most conserved structure in the nuclear receptor superfamily. It usually contains about 70 amino acids that fold into two zinc finger motifs, wherein a zinc ion coordinates four cysteines. DBDs contain two perpendicularly oriented α -helixes that extend from the base of the first and second zinc fingers. The two zinc fingers function in concert along with non-zinc finger residues to direct nuclear receptors to specific target sites on DNA and to align receptor homodimer or heterodimer interfaces. Various amino acids in DBD influence spacing between two half-sites (usually comprised of six nucleotides) for receptor dimer binding. For example, GR subfamily and ER homodimers bind to half-sites spaced by three nucleotides and oriented as palindromes. The optimal spacings facilitate cooperative interactions between DBDs, and D box residues are part of the dimerization interface. Other regions of the DBD facilitate DNA-

protein and protein-protein interactions required for RXR homodimerization and heterodimerization on direct repeat elements.

The LBD may influence the DNA binding of the DBD, and the influence can also be regulated by ligand binding. For example, TR ligand binding influences the degree to which a TR binds to DNA as a monomer or dimer. Such dimerization also depends on the spacing and orientation of the DNA half sites.

The nuclear receptor superfamily has been subdivided into two subfamilies: 1) GR (GR, AR, MR and PR) and 2) TR (TR, VDR, RAR, RXR, and most orphan receptors) on the basis of DBD structures, interactions with heat shock proteins (hsp), and ability to form heterodimers. GR subgroup members are tightly bound by hsp in the absence of ligand, dimerize following ligand binding and dissociation of hsp, and show homology in the DNA half sites to which they bind. These half sites also tend to be arranged as palindromes. TR subgroup members tend to be bound to DNA or other chromatin molecules when unliganded, can bind to DNA as monomers and dimers, but tend to form heterodimers, and bind DNA elements with a variety of orientations and spacings of the half sites, and also show homology with respect to the nucleotide sequences of the half sites. ER does not belong to either subfamily, since it resembles the GR subfamily in hsp interactions, and the TR subfamily in nuclear localization and DNA-binding properties.

Ligand Binding Domain

The LBD is the second most highly conserved domain in these receptors. Whereas integrity of several different LBD sub-domains is important for ligand binding, truncated molecules containing only the LBD retain normal ligand-binding activity. This domain also participates in other functions, including dimerization, nuclear translocation and transcriptional activation, as described herein. Importantly, this domain binds the ligand and undergoes ligand-induced conformational changes as detailed herein.

Most members of the superfamily, including orphan receptors, possess at least two transcription activation subdomains, one of which is constitutive and resides in the amino terminal domain (AF-1), and the other of which (AF-2 (also

referenced as TAU 4)) resides in the ligand-binding domain whose activity is regulated by binding of an agonist ligand. The function of AF-2 requires an activation domain (also called transactivation domain) that is highly conserved among the receptor superfamily (approximately amino acids 1005 to 1022). Most LBDs contain an activation domain. Some mutations in this domain abolish AF-2 function, but leave ligand binding and other functions unaffected. Ligand binding allows the activation domain to serve as an interaction site for essential co-activator proteins that function to stimulate (or in some cases, inhibit) transcription.

The carboxy-terminal activation subdomain, as described herein is in close three dimensional proximity in the LBD to the ligand, so as to allow for ligands bound to the LBD to coordinate (or interact) with amino acid(s) in the activation subdomain. As described herein, the LBD of a nuclear receptor can be expressed, crystallized, its three dimensional structure determined with a ligand bound (either using crystal data from the same receptor or a different receptor or a combination thereof), and computational methods used to design ligands to its LBD, particularly ligands that contain an extension moiety that coordinates the activation domain of the nuclear receptor.

Once a computationally designed ligand (CDL) is synthesized as described herein and known in the art, it can be tested using assays to establish its activity as an agonist, partial agonist or antagonist, and affinity, as described herein. After such testing, the CDLs can be further refined by generating LBD crystals with a CDL bound to the LBD. The structure of the CDL can then be further refined using the chemical modification methods described herein for three dimensional models to improve the activity or affinity of the CDL and make second generation CDLs with improved properties, such as that of a super agonist or antagonist described herein.

NUCLEAR RECEPTOR ISOFORMS

The present invention also is applicable to generating new synthetic ligands to distinguish nuclear receptor isoforms. As described herein, CDLs can be generated that distinguish between isoforms, thereby allowing the generation of

either tissue specific or function specific synthetic ligands. For instance, GR subfamily members have usually one receptor encoded by a single gene, with the exception that there are two PR isoforms, A and B, translated from the same mRNA by alternate initiation from different AUG codons. This method is especially applicable to the TR subfamily which usually has several receptors that are encoded by two (TR) or three (RAR, RXR, and PPAR) genes or have alternate RNA splicing and such an example for TR is described herein.

NUCLEAR RECEPTOR CRYSTALS

The invention provides for crystals made from nuclear receptor ligand binding domains with the ligand bound to the receptor. As exemplified in the Examples, TRs are crystallized with a ligand bound to it. Crystals are made from purified nuclear receptor LBDs that are usually expressed by a cell culture, preferably *E. coli*. Preferably, different crystals (co-crystals) for the same nuclear receptor are separately made using different ligands, such as a naturally occurring ligand and at least one bromo- or iodo- substituted synthetic ligand that acts as an analog or antagonist of the naturally occurring ligand. Such bromo- and iodo-substitutions act as heavy atom substitutions in nuclear receptor ligands and crystals of nuclear receptor proteins. This method has the advantage for phasing of the crystal in that it bypasses the need for obtaining traditional heavy metal derivatives. After the three dimensional structure is determined for the nuclear receptor LBD with its ligand bound, the three dimensional structure can be used in computational methods to design a synthetic ligand for the nuclear receptor and further activity structure relationships can be determined through routine testing using the assays described herein and known in the art.

Expression and Purification of other Nuclear Receptor LBD Structures

High level expression of nuclear receptor LBDs can be obtained by the techniques described herein as well as others described in the literature. High level expression in *E. coli* of ligand binding domains of TR and other nuclear receptors, including members of the steroid/thyroid receptor superfamily, such as the estrogen (ER), androgen (AR), mineralocorticoid (MR), progesterone (PR).

RAR, RXR and vitamin D (VDR) receptors can also be achieved. Yeast and other eukaryotic expression systems can be used with nuclear receptors that bind heat shock proteins as these nuclear receptors are generally more difficult to express in bacteria, with the exception of ER, which can be expressed in bacteria.

5 Representative nuclear receptors or their ligand binding domains have been cloned and sequenced: human RAR- α , human RAR- γ , human RXR- α , human RXR- β , human PPAR- α , human PPAR- β , human PPAR- γ , human VDR, human ER (as described in Seielstad et al., *Molecular Endocrinology*, vol 9:647-658 (1995), incorporated herein by reference), human GR, human PR, human MR, and human
10 AR. The ligand binding domain of each of these nuclear receptors has been identified and is shown in FIG. 3. Using the information in FIG. 3 in conjunction with the methods described herein and known in the art, one of ordinary skill in the art could express and purify LBDs of any of the nuclear receptors, including those illustrated in FIG. 3, bind it to an appropriate ligand,
15 and crystallize the nuclear receptor's LBD with a bound ligand.

FIG. 3 is an alignment of several members of the steroid/thyroid hormone receptor superfamily that indicates the amino acids to be included in a suitable expression vector.

Extracts of expressing cells are a suitable source of receptor for purification
20 and preparation of crystals of the chosen receptor. To obtain such expression, a vector is constructed in a manner similar to that employed for expression of the rat TR alpha (Apriletti et al. *Protein Expression and Purification*, 6:368-370 (1995), herein incorporated by reference). The nucleotides encoding the amino acids encompassing the ligand binding domain of the receptor to be expressed, for
25 example the estrogen receptor ligand binding domain (hER-LBD) (corresponding to R at position 725 to L at position 1025 as standardly aligned as shown in the FIG. 3), are inserted into an expression vector such as the one employed by Apriletti et al (1995). For the purposes of obtaining material that will yield good crystals it is preferable to include at least the amino acids corresponding to human
30 TR- β positions 725 to 1025. Stretches of adjacent amino acid sequences may be included if more structural information is desired. Thus, an expression vector for the human estrogen receptor can be made by inserting nucleotides encoding amino

acids from position 700 to the c-terminus at position 1071. Such a vector gives high yield of receptor in *E. coli* that can bind hormone (Seielstad et al. *Molecular Endocrinology* Vol 9:647-658 (1995)). However, the c-terminal region beyond position 1025 is subject to variable proteolysis and can advantageously be excluded from the construct, this technique of avoiding variable proteolysis can also be applied to other nuclear receptors.

TR- α And TR- β As Examples of Nuclear receptor LBD Structure and Function
TR Expression, Purification And Crystallization

As an example of nuclear receptor structure of the ligand binding domain the α - and β - isoforms of TR are crystallized from proteins expressed from expression constructs, preferably constructs that can be expressed in *E. coli*. Other expression systems, such as yeast or other eukaryotic expression systems can be used. For the TR, the LBD can be expressed without any portion of the DBD or amino-terminal domain. Portions of the DBD or amino-terminus can be included if further structural information with amino acids adjacent the LBD is desired. Generally, for the TR the LBD used for crystals will be less than 300 amino acids in length. Preferably, the TR LBD will be at least 150 amino acids in length, more preferably at least 200 amino acids in length, and most preferably at least 250 amino acids in length. For example the LBD used for crystallization can comprise amino acids spanning from Met 122 to Val 410 of the rat TR- α , Glu 202 to Asp 461 of the human TR- β .

Typically TR LBDs are purified to homogeneity for crystallization. Purity of TR LBDs is measured with SDS-PAGE, mass spectrometry and hydrophobic HPLC. The purified TR for crystallization should be at least 97.5 % pure or 97.5%, preferably at least 99.0% pure or 99.0% pure, more preferably at least 99.5% pure or 99.5% pure.

Initially purification of the unliganded receptor can be obtained by conventional techniques, such as hydrophobic interaction chromatography (HPLC), ion exchange chromatography (HPLC), and heparin affinity chromatography.

To achieve higher purification for improved crystals of nuclear receptors, especially the TR subfamily and TR, it will be desirable to ligand shift purify the

5 nuclear receptor using a column that separates the receptor according to charge, such as an ion exchange or hydrophobic interaction column, and then bind the eluted receptor with a ligand, especially an agonist. The ligand induces a change in the receptor's surface charge such that when re-chromatographed on the same column, the receptor then elutes at the position of the liganded receptor are removed by the original column run with the unliganded receptor. Usually saturating concentrations of ligand are used in the column and the protein can be preincubated with the ligand prior to passing it over the column. The structural studies detailed herein indicate the general applicability of this technique for obtaining super-pure nuclear receptor LBDs for crystallization.

10 More recently developed methods involve engineering a "tag" such as with histidine placed on the end of the protein, such as on the amino terminus, and then using a nickle chelation column for purification, Janknecht R., Proc. Natl. Acad. Sci. USA Vol 88:8972-8976 (1991) incorporated by reference.

15 To determine the three dimensional structure of a TR LBD, or a LBD from another member of the nuclear receptor superfamily, it is desirable to co-crystallize the LBD with a corresponding LBD ligand. In the case of TR LBD, it is preferable to separately co-crystallize it with ligands such as T3, IpBr and Dimit that differ in the heavy atoms which they contain. Other TR ligands such as those encompassed by Formula 1 described herein and known in the prior art, can also be used for the generation of co-crystals of TR LBD and TR ligands. Of the compounds encompassed by Formula 1 it is generally desirable to use at least one ligand that has at least one bromo- or iodo- substitution at the R_3 , R_5 , R_3' or R_5' position, preferably such compounds will be have at least two such substitutions and more preferably at least 3 such substitutions. As described herein, such substitutions are advantageously used as heavy atoms to help solve the phase problem for the three dimensional structure of the TR LBD and can be used as a generalized method of phasing using a halogen (e.g. I or Br) substituted ligand, especially for nuclear receptors.

25
30 Typically purified LBD, such as TR LBD, is equilibrated at a saturating concentration of ligand at a temperature that preserves the integrity of the protein.

Ligand equilibration can be established between 2 and 37° C, although the receptor tends to be more stable in the 2-20° C range.

Preferably crystals are made with the hanging drop methods detailed herein. Regulated temperature control is desirable to improve crystal stability and quality. Temperatures between 4 and 25°C are generally used and it is often preferable to test crystallization over a range of temperatures. In the case of TR it is preferable to use crystallization temperatures from 18 to 25°C, more preferably 20 to 23°C, and most preferably 22°C.

Complexes of the TR- α LBD with a variety of agonists, including 3,5,3'-triiodothyronine (T_3), 3'-isopropyl-3,5-dibromothyronine ($IpBr_2$), 3'-isopropyl-3,5-dimethylthyronine (Dimit), and 3,5,3'-triiodothyroacetic acid (triac), are prepared with by methods described herein. Cocrystals of the rTR- α LBD, with ligand prebound, are prepared by vapor diffusion at ambient temperature from 15% 2-methyl-2,4-pentanediol (MPD). The crystals are radiation sensitive, and require freezing to measure complete diffraction data. On a rotating anode X-ray source, the crystals diffract to $\sim 3\text{\AA}$; synchrotron radiation extends the resolution limit significantly, to as high as 2.0\AA for T_3 cocrystals. The composition of the thyroid hormone, combined with the ability to prepare and cocrystallize the receptor complexed with a variety of analogs, permitted the unusual phasing strategy. This phasing strategy can be applied to the ligands of the nuclear receptors described therein by generating I and Br substitutions of such ligands. In this strategy, cocrystals of the TR LBD containing four hormone analogs that differ at the 3,5, and 3' positions (T_3 , $IpBr_2$, Dimit, and triac) provided isomorphous derivatives. For this set of analogs, the halogen substituents (2Br and 3I atoms) function as heavy atoms, while the Dimit cocrystal (3 alkyl groups) acts as the parent. The initial 2.5\AA multiple isomorphous replacement/anomalous scattering/density modified electron density map allowed the LBD to be traced from skeletons created in the molecular graphics program O5 (Jones, T.A. et al. ACTA Cryst, 47:110-119 (1991), incorporated by reference herein). A model of the LBD was built in four fragments, Arg157-Gly184, Trp186-Gly197, Ser199-Pro205, and Val210-Phe405, and refined in XPLOR using positional refinement and simulated annealing protocols. Missing residues were built with the aid of difference

density. The final model was refined to $R_{\text{cryst}} = 21.8\%$ and $R_{\text{free}} = 24.4\%$ for data from 5.0 to 2.2\AA , see Table 3.

This phasing strategy can be applied to the ligands of the nuclear receptors described herein by generating I and Br substitutions of such ligands.

5

THREE DIMENSIONAL STRUCTURE OF TR LBD

Architecture of TR LBD

As an example of the three dimensional structure of a nuclear receptor, the folding of the TR- α LBD is shown in FIG. 4. The TR- α LBD consists of a single structural domain packed in three layers, composed of twelve α -helices, H1-12, and four short β -strands, S1-4, forming a mixed β -sheet. The buried hormone and three antiparallel α -helices, H5-6, H9, and H10, form the central layer of the domain, as shown in FIG. 4. H1, H2, H3 and S1 form one face of the LBD, with the opposite face formed by H7, H8, H11, and H12. The first 35 amino acids of the N-terminus (Met122-Gln156) are not visible in the electron density maps. The three dimensional structure of the heterodimeric RXR:TR DNA-binding domains bound to DNA, amino acids Met 122 - Gln151 of the TR DBD make extensive contacts with the minor groove of the DNA8. The five disordered amino acids (Arg152-Gln156), which reside between the last visible residue of the TR DBD and the first visible residue of the LBD likely represent the effective "hinge" linking the LBD and the DBD in the intact receptor.

15

20

The predominantly helical composition and the layered arrangement of secondary structure is identical to that of the unliganded hRXR α , confirming the existence of a common nuclear receptor fold between two nuclear receptors.

25

30

The TR LBD is visible beginning at Arg157, and continues in an extended coil conformation to the start of H1. A turn of α -helix, H2, covers the hormone binding cavity, immediately followed by short β -strand, S1, which forms the edge of the mixed β -sheet, parallel to S4, the outermost of the three antiparallel strands. The chain is mostly irregular until H3 begins, antiparallel to H1. H3 bends at Ile221 and Ile222, residues which contact the ligand. The chain turns almost 90° at the end of H3 to form an incomplete α -helix, H4. The first buried core helix, H5-6, follows, its axis altered by a kink near the ligand at Gly 253. The helix is

composed of mostly hydrophobic sidechains interrupted by two striking exceptions: Arg262 is solvent inaccessible and interacts with the ligand carboxylate (1-substituent), and Glu256 meets Arg329 from H9 and Arg375 from H11 in a polar invagination. H5-6 terminates in a short β -strand, S2, of the four strand mixed sheet. S3 and S4 are joined through a left-handed turn, and further linked by a salt bridge between Lys284 and Asp272. Following S4, H7 and H8 form an L, stabilized by a salt bridge between Lys268 and Asp277. The turn between H7 and H8 adopts an unusual conformation, a result of interaction with ligand and its glycine rich sequence. H9 is the second core helix, antiparallel to the neighboring H5-6. Again, two buried polar sidechains are found, Glu315 and Gln320. Glu315 forms a buried salt bridge with His358 and Arg356. The oxygen of Gln320 forms a hydrogen bond with the buried sidechain of His 175. The chain then switches back again to form H10, also antiparallel to H9. H11 extends diagonally across the full length of the molecule. Immediately after H11, the chain forms a type II turn, at approximately 90° to H11. The chain then turns again to form H 12, which packs loosely against H3 and H11 as part of the hormone or ligand binding cavity. The final five amino acids at the C-terminus, Glu406 - Val410, are disordered.

20 *TR LBD's Ligand Binding Cavity As An Example Of A Nuclear Receptor's Buried Ligand Cavity*

The three dimensional structure of the TR LBD leads to the startling finding that ligand binding cavity of the LBD is solvent inaccessible when a T3 or its isostere is bound to the LBD. This surprising result leads to a new model of nuclear receptor three dimensional structure and function, as further described herein, particularly in the sections elucidating the computational methods of ligand design and the application of such methods to designing nuclear receptor synthetic ligands that contain extended positions that prevent normal activation of the activation domain.

30 Dimit, the ligand bound to the receptor, is an isostere of T₃ and a thyroid hormone agonist. Therefore the binding of Dimit should reflect that of T₃, and the Dimit-bound receptor is expected to be the active conformation of TR. The ligand

is buried within the receptor, providing the hydrophobic core for a subdomain of the protein, as shown in FIG. 5 a and b. H5-6 and H9 comprise the hydrophobic core for the rest of the receptor.

An extensive binding cavity is constructed from several structural elements.

5 The cavity is enclosed from above by H5-6 (Met 256- Arg266), from below by H7 and H8 and the intervening loop (Leu287- Ile299), and along the sides by H2 (185-187), by the turn between S3 and S4 (Leu276-Ser277), by H3 (Phe215- Arg228), by H11 (His381-Met388) and by H12 (Phe401-Phe405). The volume of the cavity defined by these elements, calculated by GRASP (Columbia University, USA) (600 Å³), is essentially the volume of the hormone (530 Å³). The remaining
10 volume is occupied by water molecules surrounding the amino-propionic acid substituent. FIG. 6 depicts various contacts (or interactions) between TR's LBD and the ligand.

The planes of the inner and outer (prime ring) rings of the ligand are
15 rotated from planarity about 60° with respect to each other, adopting the 3'-distal conformation (in which the 3' substituent of the outer ring projects down and away from the inner ring). The amino-propionic acid and the outer phenolic ring assume the transoid conformation, each on opposite sides of the inner ring. The torsion angle χ_1 for the amino- propionic acid is 300°.

20 The amino-propionic acid substituent is packed loosely in a polar pocket formed by side chains from H2, H4 and S3. The carboxylate group forms direct hydrogen bonds with the guanidium group of Arg228 and the amino N of Ser277. In addition, Arg262, Arg266 and Asn179 interact with the carboxylate through water-mediated hydrogen bonds. The three arginine residues create a significantly
25 positive local electrostatic potential, which may stabilize the negative charge of the carboxylate. No hydrogen bond is formed by the amino nitrogen. The interactions of the amino-propionic acid substituent are consistent with the fact that triac, which lacks the amino nitrogen, has a binding affinity equal to that of T₃, indicating that the amino nitrogen and longer aliphatic chain of T₃ do not
30 contribute greatly to binding affinity.

The diphenyl ether, in contrast, is found buried within the hydrophobic core. The inner ring packs in a hydrophobic-pocket formed by H3, H5-6, and S3.

Pockets for the 3- and 5-methyl substituents are not completely filled, as expected since the van der Waals radius of methyl substituent for Dimit is smaller than the iodine substituent provided by the thyroid hormone T_3 . Such pockets are typically 25 to 100 cubic angstroms (although smaller pocket for substitutes are contemplated in the 40 to 80 cubic angstrom range) and could be filled more tightly with better fitting chemical substitutions, as described herein.

The outer ring packed tightly in a pocket formed by H3, H5-6, H7, H8, H11 and H12, and the loop between H7 and H8. The ether oxygen is found in a hydrophobic environment defined by Phe218, Leu287, Leu276, and Leu292. The absence of a hydrogen bond to the ether oxygen is consistent with its role in establishing the correct stereochemistry of the phenyl rings, as suggested by potent binding of hormone analogs with structurally similar linkages possessing reduced or negligible hydrogen bonding capability. The 3'-isopropyl substituent contacts Gly290 and 291. The presence of glycine at this position in the pocket can explain the observed relationship between activity and the size of 3'-substituents. Activity is highest for 3'-isopropyl, and decreases with added bulk. The only hydrogen bond in the hydrophobic cavity is formed between the phenolic hydroxyl and His381 N ϵ 2. The conformation of His381 is stabilized by packing contacts provided by Phe405, and Met256.

The presence of a 5' substituent larger than hydrogen affects the binding affinity for hormone. The more abundant thyroid hormone, 3,5,3',5'-tetraiodo-L-thyronine (T_4), contains an iodine at this position, and binds the receptor with 2% of the affinity of T_3 . The structure suggests that discrimination against T_4 is accomplished through the combination of steric conflict by Met256 and possibly the constraints imposed by the geometry of the hydrogen bond from His381 to the phenolic hydroxyl. The 5' position is a preferred location for introducing a chemical modification of C-H at the 5' of T_3 or and TR agonist, as described herein, that produces an extension from the prime ring and results in the creation of an antagonist or partial agonist.

Deletion and antibody competition studies suggest the involvement of residues Pro162 to Val202 in ligand binding. The region does not directly contact hormone in the bound structure, although H2 packs against residues forming the

polar pocket that interacts with the amino-propionic acid group. One role for H2, then, is to stabilize these residues in the bound state, H2, with β -strands S3 and S4, might also represent a prevalent entry point for ligand, since the amino-propionic acid of the ligand is oriented toward this region. Studies of receptor binding to T₃ affinity matrices demonstrate that only a linkage to the amino-propionic acid is tolerated, suggesting that steric hindrance present in other linkages prevent binding. Furthermore, the crystallographic temperature factors suggest the coil and β -strand region is most flexible part of the domain FIG. 7. Participation of this region, part of the hinge domain between the DBD and LBD, in binding hormone may provide structural means for ligand binding to influence DNA binding, since parts of the Hinge domain contact DNA.

TR LBD Transcriptional Activation Helix As An Example Of A Nuclear Receptor Activation Domain

In addition to the startling finding that the ligand binding cavity is solvent inaccessible when loaded with a ligand, the activation helix of TR LBD presents a surface to the ligand cavity for interaction between at least one amino acid and the bound ligand. The C-terminal 17 amino acids of the TR, referred to as the activation helix or AF-2 (an example of an LBD activation domain), are implicated in mediating hormone-dependent transcriptional activation. Although, mutations of key residues within the domain decrease ligand-dependent activation it was unclear until the present invention whether such mutations directly affected ligand coordination. Although some mutations of this domain have been noted to reduce or abolish ligand binding, other mutations in more distant sites of the LBD have a similar effect.

Activation domains among nuclear receptors display an analogous three dimensional relationship to the binding cavity, which is a region of the LBD that binds the molecular recognition domain of a ligand, i.e. the activation domain presents a portion of itself to the binding cavity (but necessarily the molecular recognition domain of the ligand). Many nuclear receptors are expected to have such domains, including the retinoid receptors, RAR and RXR, the glucocorticoid receptor GR, and the estrogen receptor ER. Based upon the TR's sequence, the

domain is proposed to adopt an amphipathic helical structure. β -sheet or mixed secondary structures, could be present as activation domains in less related nuclear receptors.

5 Within the activation domain, the highly conserved motif $\Phi\Phi XE\Phi\Phi$, where Φ represents a hydrophobic residue, is proposed to mediate interactions between the receptors and transcriptional coactivators. Several proteins have been identified which bind the TR in a hormone-dependent fashion. One of these, Tripl, is related to a putative yeast coactivator Sug1, and also interacts with both the C-terminal activation domain and a subset of the basal transcriptional
10 machinery, suggesting a role in transactivation by the TR. Other proteins, such as RIP140, SRC1, (Oate, S.A. et. al., *Science* 270:1354-1357 (1995)) and TF-1 (see also Ledouarin, B., et. al., *EMBO J.* 14:2020-2033 (1995)), also interact with other nuclear receptors in a ligand dependent manner through the C-terminal domain. Binding of these proteins can be modulated using the TR ligands
15 described herein especially those TR ligands with extensions that sterically hinder the interaction between the highly conserved motif and other proteins.

 The C-terminal activation domain of the TR forms an amphipathic helix, H12, which nestles loosely against the receptor to form part of the hormone binding cavity. The helix packs with the hydrophobic residues facing inward
20 towards the hormone binding cavity, and the charged residues, including the highly-conserved glutamate, extending into the solvent, as shown in FIG. 8. The activation helix of TR LBD presents Phe 401 to the ligand binding cavity and permits direct coordination with the hormone i.e. such amino acids interact with the ligand forming a van der waals contact with the plane of the outer phenyl ring.
25 Phe 405 also interacts with His 381, perhaps stabilizing its hydrogen bonding conformation, i.e. a favorable hydrogen bond interaction. Participation of Phe 401 and Phe 405 in binding hormone explains how mutation of these residues decreases hormone binding affinity. Furthermore, the impact of these mutations on activation likely derives from a role in stabilizing the domain in the bound
30 structure through increased hydrogen bond interaction of dipole interactions. Glu 403 extends into the solvent, emphasizing its critical role in transactivation. In its observed conformation, presented on the surface as an ordered residue, against a

background of predominantly hydrophobic surface, Glu 403 is available to interact with activator proteins described herein, as shown in FIG. 9. The other charged residues, Glu 405 and Asp 406 are disordered, as the helix frays at Phe 405.

Two other sequences in the TR, $\tau 2$ and $\tau 3$, activate transcription when expressed as fusion proteins with a DNA-binding domain. The sequences, discovered in the TRB, correspond to TR- α residues Pro158-Ile168 in H1 ($\tau 2$), and Gly290-Leu319 in H8 and H9 ($\tau 3$). Unlike the C-terminal activation domain, $\tau 2$ and $\tau 3$ do not appear to represent modular structural units in the rat TR- α LBD, nor present a surface for protein-protein interactions: the critical aspartate/glutamate residues of $\tau 3$ are located on two separate helices, and do not form a single surface; the charged residues of $\tau 2$ are engaged in ion pair interactions with residues of the LBD. Thus, $\tau 2$ and $\tau 3$ may not function as activation domains in the context of the entire receptor.

Computational Methods For Designing A Nuclear Receptor LBD LIGAND

The elucidation of the three dimensional structure of a nuclear receptor ligand binding domain provides an important and useful approach for designing ligands to nuclear receptors using the computational methods described herein. By inspecting the FIGURES it can be determined that the nuclear receptor ligand is bound in a water inaccessible binding cavity in the LBD and that chemical moieties can be added to selected positions on the ligand. Such chemical modifications, usually extensions, can fill up the binding cavity represented in the FIGURES for a tighter fit (or less water) or can be used to disrupt or make contacts with amino acids not in contact with the ligand before the chemical modification was introduced or represented in a figure of the three dimensional model of the LBD. Ligands that interact with nuclear superfamily members can act as agonists, antagonists and partial agonists based on what ligand-induced conformational changes take place.

Agonists induce changes in receptors that place them in an active conformation that allows them to influence transcription, either positively or negatively. There may be several different ligand-induced changes in the receptor's conformation.

Antagonists, bind to receptors, but fail to induce conformational changes that alter the receptor's transcriptional regulatory properties or physiologically relevant conformations. Binding of an antagonist can also block the binding and therefore the actions of an agonist.

5 Partial agonists bind to receptors and induce only part of the changes in the receptors that are induced by agonists. The differences can be qualitative or quantitative. Thus, a partial agonist may induce some of the conformation changes induced by agonists, but not others, or it may only induce certain changes to a limited extent.

10

Ligand-induced Conformational Changes

As described herein, the unliganded receptor is in a configuration that is either inactive, has some activity or has repressor activity. Binding of agonist ligands induces conformational changes in the receptor such that the receptor becomes more active, either to stimulate or repress the expression of genes. The receptors may also have non-genomic actions. some of the known types of changes and/or the sequelae of these are listed herein.

15

Heat Shock Protein Binding

For many of the nuclear receptors ligand binding induces a dissociation of heat shock proteins such that the receptors can form dimers in most cases, after which the receptors bind to DNA and regulate transcription.

5 Nuclear receptors usually have heat shock protein binding domains that present a region for binding to the LBD and can be modulated by the binding of a ligand to the LBD. Consequently, an extended chemical moiety (or more) from the ligand that stabilizes the binding or contact of the heat shock protein binding domain with the LBD can be designed using the computational methods described
10 herein to produce a partial agonist or antagonist. Typically such extended chemical moieties will extend past and away from the molecular recognition domain on the ligand and usually past the buried binding cavity of the ligand.

Dimerization and Heterodimerization

15 With the receptors that are associated with the hsp in the absence of the ligand, dissociation of the hsp results in dimerization of the receptors. Dimerization is due to receptor domains in both the DBD and the LBD. Although the main stimulus for dimerization is dissociation of the hsp, the ligand-induced conformational changes in the receptors may have an additional facilitative
20 influence. With the receptors that are not associated with hsp in the absence of the ligand, particularly with the TR, ligand binding can affect the pattern of dimerization/heterodimerization. The influence depends on the DNA binding site context, and may also depend on the promoter context with respect to other proteins that may interact with the receptors. A common pattern is to discourage
25 monomer formation, with a resulting preference for heterodimer formation over dimer formation on DNA.

 Nuclear receptor LBDs usually have dimerization domains that present a region for binding to another nuclear receptor and can be modulated by the binding of a ligand to the LBD. Consequently, an extended chemical moiety (or
30 more) from the ligand that disrupts the binding or contact of the dimerization domain can be designed using the computational methods described herein to produce a partial agonist or antagonist. Typically such extended chemical moieties

will extend past and away from the molecular recognition domain on the ligand and usually past the buried binding cavity of the ligand.

DNA Binding

5 In nuclear receptors that bind to hsp, the ligand-induced dissociation of hsp with consequent dimer formation allows, and therefore, promotes DNA binding. With receptors that are not associated (as in the absence of ligand), ligand binding tends to stimulate DNA binding of heterodimers and dimers, and to discourage monomer binding to DNA. However, with DNA containing only a single half
10 site, the ligand tends to stimulate the receptor's binding to DNA. The effects are modest and depend on the nature of the DNA site and probably on the presence of other proteins that may interact with the receptors. Nuclear receptors usually have DBD (DNA binding domains) that present a region for binding to DNA and this binding can be modulated by the binding of a ligand to the LBD. Consequently,
15 an extended chemical moiety (or more) from the ligand that disrupts the binding or contact of the DBD can be designed using the computational methods described herein to produce a partial agonist or antagonist. Typically such extended chemical moieties will extend past and away from the molecular recognition domain on the ligand and usually past the buried binding cavity of the ligand.

20

Repressor Binding

Receptors that are not associated with hsp in the absence of ligand frequently act as transcriptional repressors in the absence of the ligand. This appears to be due, in part, to transcriptional repressor proteins that bind to the
25 LBD of the receptors. Agonist binding induces a dissociation of these proteins from the receptors. This relieves the inhibition of transcription and allows the transcriptional transactivation functions of the receptors to become manifest.

Transcriptional Transactivation Functions

30 Ligand binding induces transcriptional activation functions in two basic ways. The first is through dissociation of the hsp from receptors. This dissociation, with consequent dimerization of the receptors and their binding to

DNA or other proteins in the nuclear chromatin allows transcriptional regulatory properties of the receptors to be manifest. This may be especially true of such functions on the amino terminus of the receptors.

The second way is to alter the receptor to interact with other proteins involved in transcription. These could be proteins that interact directly or indirectly with elements of the proximal promoter or proteins of the proximal promoter. Alternatively, the interactions could be through other transcription factors that themselves interact directly or indirectly with proteins of the proximal promoter. Several different proteins have been described that bind to the receptors in a ligand-dependent manner. In addition, it is possible that in some cases, the ligand-induced conformational changes do not affect the binding of other proteins to the receptor, but do affect their abilities to regulate transcription.

Nuclear receptors or nuclear receptor LBDs usually have activation domains that present a region for binding to DNA and can be modulated by the binding of a ligand to the LBD. Consequently, an extended chemical moiety (or more) from the ligand that disrupts the binding or contact of the activation domain can be designed using the computational methods described herein to produce a partial agonist or antagonist. Typically such extended chemical moieties will extend past and away from the molecular recognition domain on the ligand and usually past the buried binding cavity of the ligand and in the direction of the activation domain, which is often a helix as seen in the three dimensional model shown in the **FIGURES** in two dimensions on paper or more conveniently on a computer screen.

Ligand-Induced Conformational Change

Plasma proteins bind hormones without undergoing a conformational change through a static binding pocket formed between monomers or domains. For example, the tetrameric thyroid-binding plasma protein transthyretin forms a solvent-accessible hormone-binding channel at the oligomer interface. The structure of the protein is unchanged upon binding hormone with respect to the appearance of a buried binding cavity with a ligand bound.

However, the structural role for a ligand bound to a nuclear receptor LBD, like rat TR- α LBD, predicts that the receptor would differ in the bound and unbound states. In the absence of hormone, the receptor would possess a cavity at its core, uncharacteristic of a globular protein. A ligand (e.g. hormone) completes the hydrophobic core of the active receptor after it binds to the nuclear receptor. Ligand binding by the receptor is a dynamic process, which regulates receptor function by inducing an altered conformation.

An exact description of the hormone-induced conformational changes requires comparison of the structures of the liganded and the unliganded TR. The structure of the unliganded human RXR α may substitute as a model for the unliganded TR. The rat TR- α LBD and human RXR α LBDs adopt a similar fold, and it is likely that the structural similarity extends to the conformational changes after ligand binding.

There are three major differences between the two structures, which indeed appear to be the result of ligand binding. First, the bound rat TR- α LBD structure is more compact, with the hormone tightly packed within the hydrophobic core of the receptor. By contrast, the unliganded human RXR α LBD contains several internal hydrophobic cavities. The presence of such cavities is unusual in folded proteins, and is likely a reflection of the unliganded state of the receptor. Two of these cavities were proposed as possible binding sites for 9-cis retinoic acid, though these multiple sites only partly overlap with the single buried binding cavity observed in the liganded rat TR- α LBD.

The second difference involves H11 in the rat TR- α LBD, which contributes part of the hormone binding cavity. H11, continuous in the rat TR- α LBD, is broken at Cys 432 in the RXR, forming a loop between H10 and H11 in the hRXR α . This residue corresponds to His381 in the TR, which provides a hydrogen bond to the outer ring hydroxyl of the ligand. Furthermore, the hormone binding cavity occupied by ligand in the rat TR- α LBD is interrupted in the hRXR α by the same loop, forming an isolated hydrophobic pocket in the RXR with H6 and H7. In the bound rat TR- α LBD, the corresponding helices H7 and H8 are contiguous with the binding pocket, and enclose the hormone binding cavity from below.

The third difference between the two receptors is the position of the C-terminal activation domain. While the C-terminal activation domain forms α -helices in both receptors, the domain in the rat TR- α LBD follows a proline-rich turn, and lies against the receptor to contribute part of the binding cavity. In contrast, the activation domain in the unliganded hRXR α , is part of a longer helix which projects into the solvent.

These differences lead to a model for an alternate conformation of the TR LBD assumed in the absence of ligand. In the unliganded TR, the subdomain of the receptor surrounding the hormone binding cavity is loosely packed, with the binding cavity occluded by a partly unstructured H11 providing a partial core for the receptor.

Upon binding hormone, residues which form a coil in the unbound receptor engage the ligand, and continues H11. The ordering of H11 could unblock the hydrophobic cavity, allowing H7 and H8 to interact with hormone. The extended hydrophobic cavity then collapses around the hormone, generating the compact bound structure.

It is possible to predict ligand-induced conformational changes in the C-terminal activation domain that rely, in part, on an extended structure in the unliganded TR that repacks upon ligand binding. The ligand-induced conformation change can be subtle since the amino acid sequence of the rat TR- α in the turn (393-PTLFP-399) significantly reduces the propensity of the peptide chain of the rat TR- α to form an α -helix and therefore repacking can be accomplished with a minor change in volume.

After the ligand-induced conformational change occurs, it is likely that the conformation of the C-terminal activation domain in the bound structure changes packing compared to the unbound form of the receptor. Binding of the ligand improves the stability of the activation domain. The activation domain packs loosely even in the bound structure, as measured by the distribution of packing interactions for the entire LBD. The packing density for the activation domain, defined as the number of atoms within 4.5Å, is 1.5 standard deviations below the mean. For comparison, another surface helix, H1, is 0.5 standard deviations below the mean and the most poorly packed part of the structure, the irregular coil

from residues Ile196-Asp206, is 2.0 standard deviations below the mean. Moreover, the majority of packing contacts for the C-terminal domain in the bound receptor are provided either by residues which interact with ligand, such as His381, or by the ligand itself. The conformation of these residues can be expected to be different in the bound and unbound receptors, and by extension the conformation of C-terminal activation domain which relies upon these interactions. Without the stabilization provided by a bound ligand, it is likely that the C-terminal activation domain is disordered prior to hormone binding.

The interrelation of ligand-induced conformational changes is evident as described herein. For example, His381 from H11 and Phe405 from H12 interact in the bound structure to provide a specific hydrogen bond to the phenolic hydroxyl. The ligand-induced changes which affect H11 and H12 are reinforcing, and lead to the formation of the compact, bound state.

COMPUTATIONAL METHODS USING THREE DIMENSIONAL MODELS AND EXTENSIONS OF LIGANDS

The three-dimensional structure of the liganded TR receptor is unprecedented, and will greatly aid in the development of new nuclear receptor synthetic ligands, such as thyroid receptor antagonists. In addition, this receptor superfamily is overall well suited to modern methods including three-dimensional structure elucidation and combinatorial chemistry such as those disclosed in EP 335 628, U.S. patent 5,463,564, which are incorporated herein by reference. Structure determination using X-ray crystallography is possible because of the solubility properties of the receptors. Computer programs that use crystallography data when practicing the present invention will enable the rational design of ligand to these receptors. Programs such as RASMOL can be used with the atomic coordinates from crystals generated by practicing the invention or used to practice the invention by generating three dimensional models and/or determining the structures involved in ligand binding. Computer programs such as INSIGHT and GRASP allow for further manipulation and the ability to introduce new structures. In addition, high throughput binding and bioactivity assays can be devised using

purified recombinant protein and modern reporter gene transcription assays described herein and known in the art in order to refine the activity of a CDL.

Generally the computational method of designing a nuclear receptor synthetic ligand comprises two steps:

5 1) determining which amino acid or amino acids of a nuclear receptor LBD interacts with a first chemical moiety (at least one) of the ligand using a three dimensional model of a crystallized protein comprising a nuclear receptor LBD with a bound ligand, and

10 2) selecting a chemical modification (at least one) of the first chemical moiety to produce a second chemical moiety with a structure to either decrease or increase an interaction between the interacting amino acid and the second chemical moiety compared to the interaction between the interacting amino acid and the first chemical moiety.

As shown herein, interacting amino acids form contacts with the ligand and
15 the center of the atoms of the interacting amino acids are usually 2 to 4 angstroms away from the center of the atoms of the ligand. Generally these distances are determined by computer as discussed herein and in McRee 1993, however distances can be determined manually once the three dimensional model is made. Examples of interacting amino acids are described in Appendix 2. See also
20 Wagner et al., Nature 378(6558):670-697 (1995) for stereochemical figures of three dimensional models. More commonly, the atoms of the ligand and the atoms of interacting amino acids are 3 to 4 angstroms apart. The invention can be practiced by repeating steps 1 and 2 to refine the fit of the ligand to the LBD and to determine a better ligand, such as an agonist. As shown in the FIGURES the
25 three dimensional model of TR can be represented in two dimensions to determine which amino acids contact the ligand and to select a position on the ligand for chemical modification and changing the interaction with a particular amino acid compared to that before chemical modification. The chemical modification may be made using a computer, manually using a two dimensional representation of the
30 three dimensional model or by chemically synthesizing the ligand. The three dimensional model may be made using Appendix 2 and the FIGURES. As an additional step, the three dimensional model may be made using atomic

coordinates of nuclear receptor LBDs from crystallized protein as known in the art, see McRee 1993 referenced herein.

5 The ligand can also interact with distant amino acids after chemical modification of the ligand to create a new ligand. Distant amino acids are generally not in contact with the ligand before chemical modification. A chemical modification can change the structure of the ligand to make a new ligand that interacts with a distant amino acid usually at least 4.5 angstroms away from the ligand. Often distant amino acids will not line the surface of the binding cavity for the ligand, as they are too far away from the ligand to be part of a pocket or
10 surface of the binding cavity.

The interaction between an atom of a LBD amino acid and an atom of an LBD ligand can be made by any force or attraction described in nature. Usually the interaction between the atom of the amino acid and the ligand will be the result of a hydrogen bonding interaction, charge interaction, hydrophobic interaction,
15 van der waals interaction or dipole interaction. In the case of the hydrophobic interaction it is recognized that this is not a per se interaction between the amino acid and ligand, but rather the usual result, in part, of the repulsion of water or other hydrophilic group from a hydrophobic surface. Reducing or enhancing the interaction of the LBD and a ligand can be measured by calculating or testing
20 binding energies, computationally or using thermodynamic or kinetic methods as known in the art.

Chemical modifications will often enhance or reduce interactions of an atom of a LBD amino acid and an atom of an LBD ligand. Steric hinderance will be a common means of changing the interaction of the LBD binding cavity with
25 the activation domain. Chemical modifications are preferably introduced at C-H, C- and C-OH position in ligands, where the carbon is part of the ligand structure which remains the same after modification is complete. In the case of C-H, C could have 1, 2 or 3 hydrogens, but usually only one hydrogen will be replaced. The H or OH are removed after modification is complete and replaced with the
30 desired chemical moiety.

Because the thyroid receptor is a member of the larger superfamily of hormone-binding nuclear receptors, the rules for agonist and antagonist

development will be recognized by one skilled in the art as useful in designing ligands to the entire superfamily. Examining the structures of known agonists and antagonists of the estrogen and androgen receptors supports the generality of antagonist mechanism of action as shown in FIG. 10.

5 The overall folding of the receptor based on a comparison of the reported structure of the unliganded RXR and with amino acid sequences of other superfamily members reveals that the overall folding of receptors of the superfamily is similar. Thus, it is predicted from the structure that there is a general pattern of folding of the nuclear receptor around the agonist or antagonist
10 ligand.

 The three dimensional structure of a nuclear receptor with a ligand bound leads to the nonobvious observation that a nuclear receptor folds around agonist ligands, as the binding cavity fits the agonist, especially the agonist's molecular recognition domain, and antagonists commonly have chemical structures that
15 extend beyond the ligand, especially the agonist, and would prohibit folding of the receptor around the ligand to form a buried binding cavity or other groups that have the same effect. The location of the extension could affect the folding in various ways as indicated by the structure. Such extensions on antagonists are shown in FIG. 10 for various receptors and compared to the corresponding
20 agonist.

 For example, an extension towards the carboxy-terminal activation helix affects the packing/folding of this helix into the body of the receptor. This in turn can affect the ability of this portion of the nuclear receptor to interact with other proteins or other portions of the receptor, including transcriptional transactivation
25 functions on the opposite end of the linear receptor, or the receptor's amino terminus that may interact directly or indirectly with the carboxy-terminal transactivation domain (including helix 12). Extensions in this direction can also affect the packing of helix 11 of TR (or its analogous helix in nuclear receptors) into the body of the receptor and selectively affect dimerization and
30 heterodimerization of receptors. An extension pointing towards helix 1 can affect the relationship of the DNA binding domain and hinge regions of the receptors with the ligand binding domain and selectively or in addition affect the receptors'

binding to DNA and/or interactions of receptors with proteins that interact with this region of the receptor. Other extensions towards helix 11 can be made to affect the packing of this helix and helices 1 and 10 and thereby dimerization. Such chemical modifications can be assessed using the computational methods described herein. It is also possible that, in some cases, extensions may protrude through the receptor that is otherwise completely or incompletely folded around the ligand. Such protruding extensions could present a steric blockade to interactions with co-activators or other proteins.

The three dimensional structure with the ligand buried in the binding cavity immediately offers a simple description of a nuclear receptor that has a binding cavity that contains hinges and a lid, composed of one or more structural elements, that move to accommodate and surround the ligand. The ligand to TR can be modified on specific sites with specific classes of chemical groups that will serve to leave the lid and hinge region in open, partially open or closed states to achieve partial agonist or antagonist functions. In these states, the biological response of the TR is different and so the structure can be used to design particular compounds with desired effects.

Knowledge of the three-dimensional structure of the TR-T₃ complex leads to a general model for agonist and antagonist design. An important novel feature of the structural data is the fact that the T₃ ligand is completely buried within the central hydrophobic core of the protein. Other ligand-receptor complexes belonging to the nuclear receptor superfamily will have a similarly buried ligand binding site and therefore this model will be useful for agonist/antagonist design for the entire superfamily.

When design of an antagonist is desired, one needs either to preserve the important binding contacts of natural hormone agonist while incorporating an "extension group" that interferes with the normal operation of the ligand-receptor complex or to generate the requisite binding affinity through the interactions of the extensions with receptor domains.

The model applied to antagonist design and described herein is called the "Extension Model." Antagonist compounds for nuclear receptors should contain the same or similar groups that facilitate high-affinity binding to the receptor, and

in addition, such compounds should contain a side chain which may be large and/or polar. This side chain could be an actual extension, giving it bulk, or it could be a side group with a charge function that differs from the agonist ligand. For example, substitution of a CH_3 for CH_2OH at the 21-position, and alteration at the 11-position from an OH group to a keto group of cortisol generates glucocorticoid antagonist activity (Robsseau, G.G., et. al., J. Mol. Biol. 67:99-115 (1972)). However, in most cases effective antagonists have more bulky extensions. Thus, the antiglucocorticoid (and antiprogestin) RU486 contains a bulky side group at the 11-position (Horwitz, K.B. Endocrine Rev. 13: 146-163 (1992)). The antagonist compound will then bind within the buried ligand binding site of the receptor with reasonably high affinity (100 nM), but the extension function will prevent the receptor-ligand complex from adopting the necessary conformation needed for transcription factor function. The antagonism (which could be in an agonist or antagonist) may manifest itself at the molecular level in a number of ways, including by preventing receptor homo/heterodimer formation at the HRE, by preventing coactivator binding to receptor monomers, homodimers or homo/heterodimers, or by a combination of these effects which otherwise prevent transcription of hormone responsive genes mediated by ligand-induced effects on the HRE. There are several antagonist compounds for nuclear receptors in the prior art (see also Horwitz, K.B., Endocrine Rev. 13:146-163 (1992), Raunnaud J.P. et. al., J. Steroid Biochem. 25:811-833 (1986), Keiel S., et. al., Mol. Cell. Biol. 14:287-298 (1994) whose antagonist function can be explained by the extension hypothesis. These compounds are shown in FIG. 10 along with their agonist counterparts. Each of these antagonists contains a large extension group attached to an agonist or agonist analogue core structure. Importantly, these antagonist compounds were discovered by chance and not designed with a structure-function hypothesis such as the extension principle.

One method of design of a thyroid antagonist using the extension hypothesis is provided below as a teaching example. The three-dimensional structure of the TR- α Dimit complex combined with structure-activity data published in the prior art, especially those reference herein, can be used to establish the following ligand-receptor interactions which are most critical for

high-affinity ligand binding. A physical picture of these interactions is shown in FIG. 6. The figure describes the isolated essential contacts for ligand binding. Because the ligand is buried in the center of the receptor, the structural spacing between these isolated interactions is also important. Thus, our present knowledge of this system dictates that, for this example, a newly designed ligand for the receptor must contain a thyronine structural skeleton, or two substituted aryl groups joined by a one-atom spacer.

The general structure for an antagonist designed by the extension hypothesis is exemplified in the following general description of the substituents of a TR antagonist (referring to Formula 1): R₁ can have anionic groups such as a carboxylate, phosphonate, phosphate, sulfate or sulfite and is connected to the ring with a 0 to 3 atom linker, comprising one or more C, O, N, S atoms, and preferably a 2 carbon linker. Such R₁ can be optionally substituted with an amine (e.g. -NH₂). R₃ and R₅ are small hydrophobic groups such as -Br, -I, or -CH₃. R₃ and R₅ can be the same substituents or different. R₃' can be a hydrophobic group that may be larger than those of R₃ and R₅, such as -I, -CH₃, -isopropyl, -phenyl, -benzyl, 5 and 6 ring heterocycles. R₄' is a group that can participate in a hydrogen bond as either a donor or acceptor. Such groups include -OH, -NH₂, and -SH. R₅' is an important extension group that makes this compound an antagonist. R₅' can be a long chain alkyl (e.g. 1 to 9 carbons, straight chain or branched), aryl (benzyl, phenyl and substituted benzyl and phenyl rings (e.g. with halogen, alkyl (1 and 5 carbons) and optionally connected to the ring by a -CH₂-), heterocycle (e.g. 5 or 6 atoms, preferably 5 carbons and 1 nitrogen, or five carbons), which can optionally include polar (e.g. -OH, -NH₂, and -SH), cationic (e.g. -NH₃, N(CH₃)₃), or anionic (carboxylate, phosphonate, phosphate or sulfate) groups. R₅' can also be a polar (e.g. -OH, -NH₂, and -SH), cationic (e.g. -NH₃, -N(CH₃)₃), and anionic (carboxylate, phosphonate, phosphate or sulfate) groups. X is the spacer group that appropriately positions the two aromatic rings. This group is usually a one-atom spacer, such as O, S, SO, SO₂, NH, NZ where Z is an alkyl, CH₂, CHOH, CO, C(CH₃)OH, and C(CH₃)(CH₃). R₂, R₆, R₂' and R₆' can be -F, and -Cl and are preferably H.

A TR ligand can also be described as a substituted phenylated 3,5 diiodo tyrosine with substituted R5' and R3' groups. R5' can be a long chain alkyl (e.g. 4 to 9 carbons, straight chain or branched), aryl (benzyl, phenyl and substituted benzyl and phenyl rings (e.g. with halogen, alkyl (1 and 5 carbons) and optionally connected to the ring by a -CH2-), heterocycle (e.g. 5 or 6 atoms, preferably 5 carbons and 1 nitrogen, or five carbons), which can optionally include polar (e.g. -OH, -NH₂, and -SH), cationic (e.g. -NH₃, N(CH₃)₃), or anionic (carboxylate, phosphonate, phosphate or sulfate) groups. R5' can also be a polar (e.g. -OH, -NH₂, and -SH), cationic (e.g. -NH₃, N(CH₃)₃), and anionic (carboxylate, phosphonate, phosphate or sulfate) groups. R3' can be -IsoPr, halogen, -CH₃, alkyl (1 to 6 carbons) or aryl (benzyl, phenyl and substituted benzyl and phenyl rings (e.g. with halogen, alkyl (1 and 5 carbons) and optionally connected to the ring by a -CH2-), heterocycle (e.g. 5 or 6 atoms, preferably 5 carbons and 1 nitrogen, or five carbons), which can optionally include polar (e.g. -OH, -NH₂, and -SH), cationic (e.g. -NH₃, N(CH₃)₃), or anionic (carboxylate, phosphonate, phosphate or sulfate) groups.

A TR antagonist can also be a modified T₃ agonist (having a diphenyl structure) wherein R₅' is alkyl, aryl, 5- or 6-membered heterocyclic aromatic, heteroalkyl, heteroaryl, arylalkyl, heteroaryl alkyl, polyaromatic, polyheteroaromatic, polar or charged groups, wherein said R₅' may be substituted with polar or charged groups. The R5' groups are defined, as described herein.

Using these methods the ligands of this example preferably have the following properties:

1. The compounds should bind to the TR with high affinity (for example 100 nM).
2. The compounds should bind the receptor in the same basic orientation as the natural hormone.
3. The extension group R5' should project toward the activation helix (C-terminal helix) of the receptor.
4. The appropriate substituent at R5' should perturb the activation helix from its optimal local structure needed for mediating transcription.

Antagonists may also be designed with multiple extensions in order to block more than one aspect of the folding at any time.

TR ligands (e.g. super agonists) can be designed (and synthesized) to enhance the interaction of at least one amino acid with at least one chemical moiety on the ligand's molecular recognition domain. One method is to enhance the charge and polar interactions by replacing the carboxylate of T₃ (R1 position) with phosphonate, phosphate, sulfate or sulfite. This enhances the interaction with Arg 262, Arg 266 and Arg 228. The interaction of at least one amino acid with at least one chemical moiety on the ligand's molecular recognition domain can also be enhanced by increasing the size of R1 group to fill the space occupied by water when Dimit is bound (referring to R1). Preferably the group has a complementary charge and hydrophobicity to the binding cavity.

Another way of improving the interaction of at least one amino acid with at least one chemical moiety on the ligand's molecular recognition domain is to restrict the conformation of the dihedral angle between the two phenyl rings of the thyronine ligand in solution. In solution the planes of two phenyl rings are orthogonal where the dihedral angle is 90°. In the TR Dimit structure, the dihedral angle is close to 60°. A TR ligand design that fixes the angle between the two phenyl rings will lead to tighter binding. Such a ligand may be made by connecting the R6' and the R5 positions of a thyronine or a substituted thyronine-like diphenyl. The size of the cyclic connection can fix the angle between the two phenyl rings. Referring specifically to Formula 1, the following cyclic modifications are preferred: 1) R₅ is connected to R₆', 2) R₃ is connected to R₂' or 3) R₅ is connected to R₆' and R₃ is connected to R2'. The connections can be made by an alkyl or heteroalkyl chain having between 1 to 6 atoms and preferably from 2 to 4 carbon atoms or other atoms. Any position of the heteroalkyl chain can be N, O, P or S. The S and P heteroatoms along said heteroalkyl chain are in any of their possible oxidative states. The N heteroatom or any carbon along the alkyl or heteroalkyl chain may have one or more Z substituents, wherein Z is alkyl, heteroalkyl, aryl, heteroaryl, 5- or 6-membered heterocyclic aromatic. These compounds can be claimed with the proviso that Formula 1 does not include any prior art compound as of the filing date of this application.

The interaction of at least one amino acid with at least one chemical moiety on the ligand's molecular recognition domain can also be enhanced by selecting a chemical modification that fills the unfilled space between a TR ligand and the LBD in the area of the bridging oxygen (such as in T3, triac or Dimit). Thus, a
5 slighter larger moiety that replaces the ether oxygen can enhance binding. Such a linker may be a mono- or geminal- disubstituted carbon group. A group approximately the same size as oxygen but with greater hydrophobicity is preferred as well as small, hydrophobic groups for the disubstituted carbon.

10 TR- α AND TR- β SELECTIVITY FOR THE THYROID HORMONE RECEPTOR

Using the method described herein ligands can be designed that selectively bind to the alpha more than the beta TR. The X-ray crystallographic structure of the rat TR- α LBD provides insight into design of such ligands.

The three dimensional structure reveals that the major difference between
15 the TR- α and TR- β in the ligand binding cavity resides in amino acid Ser 277 (with the side group -CH₂OH) in the rat TR- α and whose corresponding residue is 331, asparagine (with the side group -CH₂CONH₂), in the human TR- β . The side chain in human TR- β is larger, charged and has a different hydrogen bonding potential, which would allow the synthesis of compounds that discriminate between
20 this difference.

For example, in the complex of TR α with triac, Ser277 does not participate in ligand binding. The absence of a role for Ser277 (Asn331 in beta) is consistent with the equal affinity of triac for the alpha and beta isoforms, and indirectly supports the contention that alpha/beta selectivity resides in the amino acid
25 substitution Ser277 to Asn331 and its interaction with Arg228.

In terms of ligand design, these differences mean that for β -selective ligands, some or all of the following differences should be exploited:

1. The presence of a larger side chain asparagine.
2. The ability of the carbonyl group on the side chain to provide a
30 strong hydrogen bond acceptor.
3. The ability of the amido group on the side chain to provide a two
hydrogen-bond donors.

4. Adjustment of polarity to reorganize the trapped water in the T3 pocket.

In terms of pharmaceutical design, these differences mean that for α -selective ligands, some or all of the following differences should be exploited:

- 5 1. The presence of a smaller side group.
2. The ability of the hydroxyl on the -CH₂OH side group carbonyl group on the side chain to provide a weak hydrogen donor.
3. Adjustment of polarity to reorganize the trapped water in the T3 pocket.

10 In both cases these differences can be exploited in a number of ways. For example, they can also be used with a software set for construction of novel organic molecules such as LUDI from Biosym-MSI.

METHODS OF TREATMENT

15 The compounds of Formula 1 can be useful in medical treatments and exhibit biological activity which can be demonstrated in the following tests:

- (i) the induction of mitochondrial α -glycerophosphate dehydrogenase (GPDH:EC 1.1.99.5). This assay is particularly useful since in certain species e.g. rats it is induced specifically by thyroid hormones and thyromimetics in a close-related manner in responsive tissues e.g. liver, kidney and the heart (Westerfield, W.W., Richert, D.A. and Ruegamer, W.R., Endocrinology, 1965, 20 77, 802). The assay allows direct measurement in rates of a thyroid hormone-like effect of compounds and in particular allows measurement of the direct thyroid hormone-like effect on the heart;
- 25 (ii) the elevation of basal metabolic rate as measured by the increase in whole body oxygen consumption (see e.g., Barker et al., Ann. N. Y. Acad. Sci., 86:545-562 (1960));
- (iii) the stimulation of the rate of beating of atria isolated from animals previously dosed with thyromimetics (see e.g., Stephan et al., Biochem. 30 Pharmacol. (1992) 13:1969-1974; Yokoyama et al., J. Med. Chem. 38:695-707 (1995));

(iv) the change in total plasma cholesterol levels as determined using a cholesterol oxidase kit (for example, the Merck CHOD iodine colorimetric kit. see also, Stephan et al. (1992));

5 (v) the measurement of LDL (low density lipoprotein) and HDL (high density lipoprotein) cholesterol in lipoprotein fractions separated by ultracentrifugation; and p (vi) the change in total plasma triglyceride levels as determined using enzymatic color tests, for example the Merck System GPO-PAP method.

10 The compounds of Formula 1 can be found to exhibit selective thyromimetic activity in these tests,

(a) by increasing the metabolic rate of test animals, and raising hepatic GPDH levels at doses which do not significantly modify cardiac GPDH levels.

15 (b) by lowering plasma cholesterol and triglyceride levels, and the ratio of LDL to HDL cholesterol at doses which do not significantly modify cardiac GPDH levels.

20 The compounds of Formula 1 may therefore be used in therapy, in the treatment of conditions which can be alleviated by compounds which selectively mimic the effects of thyroid hormones in certain tissues whilst having little or no direct thyromimetic effect on the heart. For example, compounds of Formula 1 which raise hepatic GPDH levels and metabolic rate at doses which do not significantly modify cardiac GPDH levels are indicated in the treatment of obesity.

25 Agonists of Formula 1 will lower total plasma cholesterol, the ratio of LDL-cholesterol to HDL-cholesterol and triglyceride levels at doses which do not significantly modify cardiac GPDH levels are indicated for use as general antihyperlipidaemic (antihyperlipoproteinaemic) agents i.e. in the treatment of patients having elevated plasma lipid (cholesterol and triglyceride) levels. In addition, in view of this effect on plasma cholesterol and triglyceride, they are also indicated for use as specific anti-hypercholesterolemic and anti-hypertriglyceridaemic agents.

30 Patients having elevated plasma lipid levels are considered at risk of developing coronary heart disease or other manifestations of atherosclerosis as a result of their high plasma cholesterol and/or triglyceride concentrations. -Further,

since LDL-cholesterol is believed to be the lipoprotein which induces atherosclerosis, and HDL-cholesterol believed to transport cholesterol from blood vessel walls to the liver and to prevent the build up of atherosclerotic plaque, anti-hyperlipidemic agents which lower the ratio of LDL-cholesterol to HDL cholesterol are indicated as anti-atherosclerotic agents, herein incorporated by reference U.S. patents 4,826,876 and 5,466,861.

The present invention also provides a method of producing selective thyromimetic activity in certain tissues except the heart which comprises administering to an animal in need thereof an effective amount to produce said activity of a compound of Formula 1 or a pharmaceutically acceptable salt thereof.

The present invention also relates to a method of lowering plasma lipid levels and a method of lowering the ratio of LDL-cholesterol to HDL-cholesterol levels by suitably administering a compound of this invention or a pharmaceutically acceptable salt thereof.

In addition, compounds of Formula 1 may be indicated in thyroid hormone replacement therapy in patients with compromised cardiac function.

In therapeutic use the compounds of the present invention are usually administered in a standard pharmaceutical composition.

The present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of Formula 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Such compositions include those suitable for oral, parenteral or rectal administration.

PHARMACEUTICAL COMPOSITIONS

Compounds of Formula 1 and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids for example syrups, suspensions or emulsions, tablets, capsules and lozenges.

A liquid composition will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example ethanol, glycerine, sorbitol, non-aqueous solvent such as polyethylene glycol, oils or water, with a suspending agent, preservative, surfactant, wetting

agent, flavoring or coloring agent. Alternatively, a liquid formulation can be prepared from a reconstitutable powder.

For example a powder containing active compound, suspending agent, sucrose and a sweetener can be reconstituted with water to form a suspension; and
5 a syrup can be prepared from a powder containing active ingredient, sucrose and a sweetener.

A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid compositions. Examples of such carriers include magnesium stearate, starch, lactose, sucrose,
10 microcrystalline cellulose and binders, for example polyvinylpyrrolidone. The tablet can also be provided with a color film coating, or color included as part of the carrier(s). In addition, active compound can be formulated in a controlled release dosage form as a tablet comprising a hydrophilic or hydrophobic matrix.

A composition in the form of a capsule can be prepared using routine
15 encapsulation procedures, for example by incorporation of active compound and excipients into a hard gelatin capsule. Alternatively, a semi-solid matrix of active compound and high molecular weight polyethylene glycol can be prepared and filled into a hard gelatin capsule; or a solution of active compound in polyethylene glycol or a suspension in edible oil, for example liquid paraffin or fractionated
20 coconut oil can be prepared and filled into a soft gelatin capsule. Compound of Formula 1 and their pharmaceutically acceptable salts which are active when given parenterally can be formulated for intramuscular or intravenous administration.

A typical composition for intra-muscular administration will consist of a suspension or solution of active ingredient in an oil, for example arachis oil or
25 sesame oil. A typical composition for intravenous administration will consist of a sterile isotonic aqueous solution containing, for example active ingredient, dextrose, sodium chloride, a co-solvent, for example polyethylene glycol and, optionally, a chelating agent, for example ethylenediamine tetracetic acid and an anti-oxidant, for example, sodium metabisulphite. Alternatively, the solution can
30 be freeze dried and then reconstituted with a suitable solvent just prior to administration.

Compounds of structure (1) and their pharmaceutically acceptable salts which are active on rectal administration can be formulated as suppositories. A typical suppository formulation will generally consist of active ingredient with a binding and/or lubricating agent such as a gelatin or cocoa butter or other low melting vegetable or synthetic wax or fat.

Compounds of Formula 1 and their pharmaceutically acceptable salts which are active on topical administration can be formulated as transdermal compositions. Such compositions include, for example, a backing, active compound reservoir, a control membrane, liner and contact adhesive.

The typical daily dose of a compound of Formula 1 varies according to individual needs, the condition to be treated and with the route of administration. Suitable doses are in the general range of from 0.001 to 10 mg/kg bodyweight of the recipient per day.

Within this general dosage range, doses can be chosen at which the compounds of Formula 1 lower plasma cholesterol levels and raise metabolic rate with little or no direct effect on the heart. In general, but not exclusively, such doses will be in the range of from 0.5 to 10 mg/kg.

In addition, within the general dose range, doses can be chosen at which the compounds of Formula 1 lower plasma cholesterol levels and have little or no effect on the heart without raising metabolic rate. In general, but not exclusively, such doses will be in the range of from 0.001 to 0.5 mg/kg.

It is to be understood that the 2 sub ranges noted above are not mutually exclusive and that the particular activity encountered at a particular dose will depend on the nature of the compound of Formula 1 used.

Preferably, the compound of Formula 1 is in unit dosage form, for example, a tablet or a capsule so that the patient may self-administer a single dose. In general, unit doses contain in the range of from 0.05-100 mg of a compound of Formula 1. Preferred unit doses contain from 0.05 to 10 mg of a compound of Formula 1.

The active ingredient may be administered from 1 to 6 times a day. Thus daily doses are in general in the range of from 0.05 to 600 mg per day.

Preferably, daily doses are in the range of from 0.05 to 100 mg per day. Most preferably from 0.05 to 5 mg per day.

EXAMPLES

5 **EXAMPLE 1 - SYNTHESIS OF TR LIGANDS**

Many TR ligands are known in the art, including T4 (thyroxine), T3, T2 and TS-9. See Jorgensen, *Thyroid Hormones and Analogs*, in 6 *Hormonal Proteins and Peptides, Thyroid Hormones* 107-204 (Choh Hao Li ed., 1978), incorporated by reference herein..

10 The syntheses of several TR ligands are described below.

Synthesis of TS1, TS2, TS3, TS4, TS5

TS1, TS2, TS3, TS4 and TS5 and analogs thereof can all be prepared by simple acylation of the nitrogen atom of any thyronine analog, including T3 (3,5,3'-triiodo-L-thyronine), T4 (thyroxine) and 3,5-diiodothyronine. TS1 and
15 TS2 are synthesized by reacting T3 with $\text{Ph}_2\text{CHCO}_2\text{NHS}$ (N-hydroxy succinimide-2,2-diphenylacetate) and $\text{C}_{16}\text{H}_{33}\text{CO}_2\text{NHS}$, respectively. TS3 is synthesized by reacting T3 with Fmoc-Cl (fluorenylmethyloxycarbonylchloride). TS4 is synthesized by reacting T3 with tBOC_2O (tBOC anhydride or di-t-butylidicarbonate). TS5, which differs from TS1-4 by having a -H instead of an -I at the R^1_3 position, is synthesized by reacting 3,5-diiodothyronine with tBOC_2O .
20 The general reaction scheme for TS1, TS2, TS3, TS4 and TS5 is depicted in FIG. 11. It should be noted that in the reaction scheme, both TS5 and its precursor both have a hydrogen rather than an iodine at the R^1_3 position.

25

Synthesis of TS6 and TS7

TS6 is synthesized by reacting TS5 with paranitrophenylisocyanate. TS7 is synthesized by reacting TS6 with TFA (trifluoroacetic acid), which cleaves the tBOC group. These reactions are simple organic synthesis reactions that can be
30 performed by anyone of ordinary skill in the art. The synthetic scheme for TS6 and TS7 is diagrammed in FIG. 12.

Synthesis of TS8

TS8 is synthesized by reacting TS5 with Ph_2CHNH_2 (diphenylmethanamine) in the presence of triethylamine and any amide forming condensing reagent, such as TBTU (hydroxybenzotriazoleuronium tetrafluoroborate) or HBTU (hydroxybenzotriazoleuronium hexafluorophosphate). The synthesis scheme for TS8 is depicted in FIG. 13.

SYNTHESIS OF 3,5-DIODO-3'-ISOPROPYLTHYRONINE DERIVATIVES

For designing a class of antagonists, it is important to have a hydrophobic group at the 3' position as well as an extension at the 5' position. Preferred hydrophobic groups at the 3' position include: methyl, benzyl, phenyl, iodo, and heterocyclic structures. The synthesis of a 3,5-diiodo-3'-isopropyl-5'-substituted thyronine is described below. The example provided describes the specific steps for synthesizing the TS10 compound, but this general reaction scheme can be used by one of ordinary skill in the art to synthesize any number of 3,5-diiodo-3'-isopropyl-5'-substituted thyronine derivatives, which are characterized by having an extension at the 5' position. Additional compounds of this class can be synthesized using known organic synthesis techniques.

The synthesis of TS10 is described below and is depicted in FIG. 14.

Numbers used in the reaction scheme for TS10 indicating the reaction product for each step are in parentheses.

2-Formyl-6-isopropylanisole (1): 2-formyl-6-isopropylanisole (10.0 g, 61 mmol), as made by Casiraghi, *et al.* JCS Perkin I, 1862 (1980) (incorporated by reference), is added dropwise to a suspension of sodium hydride (3.7 g, 153 mmol) in 50 mL THF and 50 mL of DMF in a round bottom flask. The addition generates an exothermic reaction and formation of a gray solid. Methyl iodide (26.0 g, 183 mmol) is then added dropwise and the reaction mixture is stirred at room temperature for 5 hours. The reaction mixture is quenched with 20 mL of water, then poured into 500 mL of water, and is extracted with ether (2 x 300 mL). The ether layers are combined, washed with water (5 x 1000 mL), dried over magnesium sulfate and concentrated in vacuo to provide 10.2 g (94%) of the title compound, with the following ^1H NMR (CDCl_3) properties: δ 10.30 (s, 1H),

7.63 (d, 1H, J=3 Hz), 7.50 (d, 1H, J=3 Hz), 7.13 (t, 1H, J=3 Hz), 3.81 (s, 3H), 3.31 (heptet, 1H, J=7.5 Hz), 1.19 (d, 6H, J=7.5 Hz).

2-(2-Hydroxynonyl)-6-isopropylanisole (not shown in scheme):

5 Octylmagnesium chloride (8.4 mL, 16.9 mmol, 2.0 M) is added dropwise to a solution of 1 (1.5 g, 8.4 mmol) in 10 mL THF at -78° C. The reaction mixture is stirred for 2 hours with warming to room temperature. The reaction mixture is diluted with 50 mL ether and poured into 50 mL water. The ether layer is washed with brine (1 x 50 mL), dried over sodium sulfate, and concentrated in vacuo.

10 Flash chromatography (silica gel, 10% ether/hexane → 15% ether/hexane) provides 734 mg (30%) of the title compound with the following ¹H NMR (CDCl₃) properties: d 7.33-7.10 (m, 3H), 5.00 (br. s, 1H), 3.81 (s, 3H), 3.33 (heptet, 1H, J=7 Hz) 1.90-1.19 (m, 14H), 0.86 (t, 3H, J=6.5 Hz); HRMS (EI), found: 292.2404; calc'd: 292.2402.

15 2-nonyl-6-isopropylanisole (2): Compound 2 (663 mg, 2.3 mmol) is dissolved in solution of 5 mL ethanol and 5 mL acetic acid, and a spatula tip of palladium on carbon catalyst is added. The reaction mixture is then charged with hydrogen gas (using a simple balloon and needle) and the mixture is stirred at room temperature overnight. The next day, the reaction mixture is poured into

20 ether (100 mL) and the ether layer is extracted with saturated sodium bicarbonate (3 x 100 mL). The ether layer is dried over sodium sulfate and concentrated *in vacuo* to provide 581 mg (91%) of (2) with the following ¹H NMR (CDCl₃) properties: d 7.14-7.00 (m, 3H), 3.75 (s, 3H), 3.36 (heptet, 1H, J=6.8 Hz), 2.63 (t, 2H, J=7.5 Hz), 1.68-1.15 (m, 14H), 0.86 (t, 3H, J=5.5 Hz); HRMS (EI),

25 mass found: 276.2459; calculated: 276.2453.

Thyronine adduct (4): Fuming nitric acid (0.071 mL) is added to 0.184 mL acetic anhydride chilled to -5° C. Iodine (66 mg) is added to this mixture followed by trifluoroacetic acid (0.124 mL). This mixture is stirred for 1 hour with warming to room temperature, at which point all of the iodine is dissolved.

30 The reaction mixture was then concentrated *in vacuo* to provide an oily semi-solid material. The residue was dissolved in 0.7 mL of acetic anhydride and cooled to -20° C. A solution of anisole (2) (581 mg, 2.1 mmol) in 1.2 mL acetic anhydride

and 0.58 mL TFA is added dropwise. The reaction mixture is stirred at -20° for 1 hour, then stirred overnight with warming to room temperature. The reaction mixture is partitioned between water and methylene chloride. The methylene chloride layer is dried over sodium sulfate and concentrated *in vacuo* to provide the iodonium salt (3) as an oil. This material is not purified or characterized, and is directly introduced into the coupling reaction.


N-Trifluoroacetyl-3,5-diiodotyrosine methyl ester (552 mg, 1.0 mmol) prepared according to the procedure of N. Lewis and P. Wallbank, *Synthesis* 1103 (1987) (incorporated by reference) and all of the crude iodonium salt (3) from above is dissolved in 5 mL of anhydrous methanol. Diazabicyclo[5.4.0]undecane (DBU) (183 mg, 1.2 mmol) and a spatula tip of copper-bronze are added and the resulting mixture is stirred at room temperature overnight. The next day, the reaction mixture is filtered, and the filtrate is concentrated *in vacuo*. The crude residue is purified by flash chromatography (silica gel, 10% ethyl acetate/hexane) to provide 30 mg (4%) of the protected thyronine adduct (4).

Deprotected thyronine (TS10): The protected thyronine 4 (30 mg, 0.04 mmol) is dissolved in a mixture of 2.25 mL acetic acid and 2.25 mL 49% hydrobromic acid. The reaction mixture is heated to reflux for 5 hours. The reaction mixture is cooled to room temperature, and the solvents are removed *in vacuo*. Water is added to triturate the oily residue into a gray solid. This solid material is filtered, washed with water, and dried over P₂O₅ *in vacuo* to provide 24 mg (81%) of the title compound, TS10, with the following ¹H NMR (CDCl₃) properties: δ 7.57 (s, 1H), 6.86 (s, 1H), 6.45 (s, 1H), 6.34 (s, 1H), 4.81 (m, 1H), 3.86 (s, 3H), 3.71 (s, 3H), 3.33-3.05 (m, 3H), 2.58-2.47 (m, 2H), 1.62-0.76 (m, 23H); MS (LSIMS): M⁺ = 817.0.

As mentioned above, this reaction scheme can be modified by one of ordinary skill in the art to synthesize a class of compounds characterized by 3,5-diiodo-3'-isopropylthyronine derivatives, wherein (1) the 3' isopropyl group can be replaced with a hydrophobic group, including methyl, benzyl, phenyl, iodo, and heterocyclic structures, and (2) a wide variety of chemical structures can be incorporated at the 5' position, including alkyl groups, planar aryl, heterocyclic groups, or polar and/or charged groups.

The aldehyde (1) in the above reaction scheme is a versatile synthetic intermediate which allows for the attachment of a variety of chemical moieties to the 5' position of the final thyronine derivative. In addition, a variety of chemical reactions can be used to attach the chemical moieties. These reactions are well known in the art and include organometallic additions to the aldehyde (including Grignard reagents, organolithiums, etc.), reductive amination reactions of the aldehyde with a primary or secondary amine, and Wittig olefination reactions with a phosphorous ylid or stabilized phosphonate anion. Other possibilities include reduction of the aldehyde to a benzyl alcohol allowing for etherification reactions at the 5' position. As mentioned above, these methods allow for a wide variety of chemical structures to be incorporated at the 5' position of the final thyronine derivative, including alkyl groups, planar aryl, heterocyclic groups or polar and/or charged groups.

Synthesis of 3, 5-dibromo-4-(3',5'-diisopropyl-4'-hydroxyphenoxy) benzoic acid (Compound 11).



(a) A mixture of 2,6-diisopropyl phenol (20 g, 0.11 mol), potassium carbonate (62 g, 0.45 mol), acetone (160 ml) and methyl iodide (28 ml, 0.45 mole) is refluxed for three days. The reaction mixture is filtered through celite, evaporated, dissolved in ether, washed twice with 1M sodium hydroxide, dried over magnesium sulphate and concentrated to afford 15.1 g (0.08 mol, 70%) of 2,6-diisopropyl anisole as a slightly yellow oil.

(b) Fuming nitric acid (12.4 ml, 265 mmol) is added dropwise to 31.4 ml of acetic anhydride which is cooled in a dry ice/carbon tetrachloride bath. Iodine

11.3 g, 44.4 mmol) is added in one portion followed by dropwise addition of trifluoroacetic acid (20.5 ml, 266 mmole). The reaction mixture is stirred at room temperature until all the iodine is dissolved. Nitrogen oxides are removed by flushing nitrogen into the vessel. The reaction mixture is concentrated, the residue is dissolved in 126 ml of acetic anhydride and is cooled in a dry ice/carbon tetrachloride bath. To the stirred solution 2,6-diisopropylanisole (51 g, 266 mmol) in 150 ml of acetic anhydride and 22.6 ml of trifluoroacetic acid is added dropwise. The reaction mixture is left to stand at room temperature over night and then is concentrated. The residue is taken up in 150 ml of methanol and treated with 150 ml of 10% aqueous sodium bisulfite solution and 1 liter of 2M sodium borotetrafluoride solution. After the precipitate aggregates, petroleum ether is added and the supernatant is decanted. The precipitate is triturated with petroleum ether, filtered, washed with petroleum ether and dried at room temperature in vacuo. This affords 34 g (57 mmol, 65%) of bis(3,5-diisopropyl-4-methoxyphenyl)iodonium tetrafluoroborate as a white solid.

(c) To a stirred solution of 3,5-dibromo-4-hydroxybenzoic acid (12 g, 40.5 mmol) in 250 ml of methanol, thionyl chloride (3 ml) is added dropwise. The reaction mixture is refluxed for five days, water is added and the precipitated product is filtered off. The residue is dissolved in ethyl acetate. From the aqueous phase, methanol is removed by concentration. The aqueous phase is then saturated with sodium chloride, and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate, filtered and concentrated. This gives 12.5 g (40.5 mmol, 100%) of 3,5-dibromo-4-hydroxymethyl benzoate as a white crystalline solid.

(d) The products obtained in steps b and c are reacted with each other according to the following protocol. To bis(3,5-diisopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (2.86 g, 4.8 mmole) and copper bronze (0.42 g, 6.4 mmole) in 7 ml. of dichloromethane at 0° C is added dropwise a solution of 3,5-dibromo-4-hydroxymethyl benzoate (1.0 g, 3.2 mmole) and triethylamine (0.36 g, 3.5 mmole) in 5 ml of dichloromethane. The reaction mixture is stirred in the dark for eight days and then is filtered through celite. The filtrate is concentrated and the residue is purified by column chromatography

(silica gel, 97:3 petroleum ether/ethyl acetate) to give 0.62 g (1.2 mmole, 39%) of 3,5-dibromo-4-(3',5'-diisopropyl-4'-methoxyphenoxy)methyl benzoate as a solid.

(e) The product from step d (0.2 g, 0.4 mmole) is dissolved in 2 ml. dichloromethane, is put under nitrogen and is cooled at -40° C. To the stirred
5 solution is added 1M BBr₃ (1.2 ml, 1.2 mmole) dropwise. The reaction mixture is allowed to reach room temperature and then is left over night. It is cooled to 0° C and then hydrolyzed with water. Dichloromethane is removed by concentration and the aqueous phase is extracted with ethyl acetate. The organic phase is
10 washed with 1M hydrochloric acid and brine. Then it is dried over magnesium sulphate, filtered and concentrated. The residue is chromatographed (silica, 96:3.6:0.4 dichloromethane/methanol/acetic acid) producing 93 mg (0.2 mmole, 51%) of 3,5-dibromo-4-(3',5'-diisopropyl-4'-hydroxyphenoxy)benzoic acid as a white solid. ¹H nmr (CDCl₃) δ 1.23 (d, 12H, methyl), 3.11 (m, 2H, CH), 6.50 (s, 2H, 2,6-H) 8.33 (s, 2H, 2',6'-H).

15 **TABLE 1** and **FIG. 15** depict the structures of several TR ligands.

FORMULA 1




TABLE 1

Cmpd	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇
T ₁	-I	-O-	-I	-I	-OH	-H	-CH ₂ CH(NH ₂)CO ₂ H
T ₂	-I	-O-	-I	-I	-OH	-I	-CH ₂ CH(NH ₂)CO ₂ H
TS1	-I	-O-	-I	-I	-OH	-H	-CH ₂ CH[NHCOCH(φ ₂)]CO ₂ H
TS2	-I	-O-	-I	-I	-OH	-H	-CH ₂ CH[NHCO(CH ₂) ₁₁ CH ₃]CO ₂ H
TS3	-I	-O-	-I	-I	-OH	-H	-CH ₂ CH[NH-FMOC]CO ₂ H
TS4	-I	-O-	-I	-I	-OH	-H	-CH ₂ CH[NH-tBOC]CO ₂ H
TS5	-I	-O-	-I	-H	-OH	-H	-CH ₂ CH[NH-tBOC]CO ₂ H
TS6	-I	-O-	-I	-H	-OC(O)NH=φ _p NO ₂	-H	-CH ₂ CH[NH-tBOC]CO ₂ H
TS7	-I	-O-	-I	-I	-OC(O)NH=NHφNO ₂	-H	-CH ₂ CH(NH ₂)CO ₂ H
TS8	-I	-O-	-I	-H	-NH-CHφφ	-H	-CH ₂ CH[NH-tBOC]CO ₂ H
TS9	-I	-O-	-I	-IsoPr	-OH	-H	-CH ₂ CH(NH ₂)CO ₂ H
TS10	-I	-O-	-I	-IsoPr	-OH	-(CH ₂) ₆ -CH ₃	-CH ₂ CH(NH ₂)CO ₂ H

25 * Prior Art Compound From SKF

-φ: phenyl

-φpNO₂: para nitro phenyl

EXAMPLE 2 - RECEPTOR BINDING ASSAYS OF TR LIGANDS

To test the ability of synthesized TR ligands to bind to a thyroid receptor (TR), the binding affinity of a TR ligand for TR is assayed using TR's prepared from rat liver nuclei and ^{125}I T_3 as described in J.D. Apriletti, J.B. Baxter, and T.N. Lavin, *J. Biol. Chem.*, 263: 9409-9417 (1988). The apparent K_d 's are calculated using the method described by Apriletti (1995) and Apriletti (1988). The apparent K_d 's are presented in **TABLE 2**. The apparent K_d 's (App. K_d) are determined in the presence of the sample to be assayed, 1 nM [^{125}I] T_3 , and 50 $\mu\text{g}/\text{ml}$ core histones, in buffer E (400 mM KCl, 200 mM potassium phosphate, pH 8.0, 0.5 mM EDTA, 1 mM MgCl_2 , 10% glycerol, 1 mM DTT) in a volume of 0.21 ml. After incubation overnight at 4°C, 0.2 ml of the incubation mixture is loaded onto a Quick-Sep Sephadex G-25 column (2.7 x 0.9 cm, 1.7 ml bed volume) equilibrated with buffer E. The excluded peak of protein-bound [^{125}I] T_3 is eluted with 1 ml of buffer E, collected in a test tube, and counted. Specific T_3 binding is calculated by subtracting nonspecific binding from total binding.

TABLE 2

Compound	App.Kd(nM)	C activation Assay RIP-140	EC ₅₀ (M)
T ₃	0.06	+	10 ⁻¹⁰
T ₄	2	+	10 ⁻⁹
TS1	4	+	10 ⁻⁷
TS2	1400	nd	nd
TS3	4	+	10 ⁻⁸
TS4	8	+	nd
TS5	220	+	10 ⁻⁶
TS6	>10000	nd	nd
TS7	260	+	10 ⁻⁷
TS8	6000	nd	nd
TS9	1	+	10 ⁻¹⁰
TS10	400	+	10 ⁻⁶

+: RIP-140 Binding

-: RIP-140 Binding

nd: Not Determined

EXAMPLE 3 - INCREASED NUCLEAR PROTEIN COACTIVATION BY TR LIGANDS

To test the ability of TR ligands to activate the binding of TR to the nuclear activation protein RIP-140 (a nuclear protein that can bind to nuclear receptors, such as the estrogen receptor), a TR ligand is liganded to TR and then incubated with RIP-140 as described in V. Cavailles, *et al.*, *EMBO J.*, 14(15):3741- 3751 (1995), which is incorporated by reference herein. In this assay, 35_S-RIP-140 protein binds to liganded TR but not unliganded TR. Many TR 35_S ligands can activate RIP-140 binding as shown in TABLE 2.

EXAMPLE 4 - TR LIGAND BINDING AND TR ACTIVATION IN CULTURED CELLS

To test TR activation of transcription in a cellular environment, TR ligands are assayed for their ability to activate a reporter gene, chloramphenicol transferase ("CAT"), which has a TR DNA binding sequence operatively linked to it. Either GC or L937 cells
5 (available from the ATCC) can be used, respectively). In such assays, a TR ligand crosses the cell membrane, binds to the TR, and activates the TR, which in turn activates gene transcription of the CAT by binding the TR DNA binding region upstream of the CAT gene. The effective concentration for half maximal gene activation (EC_{50}) is determined by assaying CAT gene activation at various concentrations as described herein
10 and in the literature. The results of CAT gene activation experiments are shown in TABLE 2.

CAT GENE ACTIVATION ASSAYS

Functional response to thyroid hormone (3,5,3'-triiodo-L-thyronine, T_3) and TR
15 ligands is assessed either in a rat pituitary cell line, GC cells, that contain endogenous thyroid hormone receptors (TRs) or U937 cells that contain exogenous TRs expressed as known in the art. GC cells are grown in 10-cm dishes in RPMI 1640 with 10% newborn bovine serum, 2 mM glutamine, 50 units/ml penicillin and 50 μ g/ml streptomycin. For transfections, cells are trypsinized, resuspended in buffer (PBS, 0.1% glucose) and mixed
20 with a TREtkCAT plasmid (10 mg) or phage in 0.5 ml buffer (15 ± 5 million cells) and electroporated using a Bio-Rad gene pulser at 0.33 kvolts and 960 mF. The TREtkCAT plasmid contains two copies of a T_3 response element (AGGTCAcaggAGGTCA) cloned in the Hind III site of the pUC19 polylinker immediately upstream of a minimal (-32/+45) thymidine kinase promoter linked to CAT (tkCAT) coding sequences. After
25 electroporation, cells are pooled in growth medium (RPMI with 10% charcoal-treated, hormone stripped, newborn bovine serum), plated in 6-well dishes and treated with either ethanol or hormone. CAT activity is determined 24 hours later as described D. C. Leitman, R. C. J. Ribeiro, E. R. Mackow, J. D. Baxter, B. L. West, *J. Biol. Chem.* 266, 9343 (1991), which is incorporated by reference herein.

EFFECT OF TS-10 ON THE TRANSCRIPTIONAL REGULATION OF THE DR4-ALP REPORTER GENE IN THE PRESENCE OR ABSENCE OF T3.

Characteristics of the TRAF cells: TRAFa1 are CHO K1 cells stably transformed with an expression vector encoding the human thyroid hormone receptor α 1 and a DR4,ALP
5 reporter vector; TRAFb1 are CHO K1 cells stably transformed with an expression vector encoding the human thyroid hormone receptor β 1 and a DR4-ALP reporter vector.

Interpretation of the effect of compound TS-10 on the transcriptional regulation of the DR4-ALP reporter gene in the presence or absence of T3.

10

TRAFa1 reporter cells: TS-10 alone (open circles) induces a partial activation of the expression of the ALP reporter protein amounting to approximately 27% of the maximal effect by the natural thyroid hormone T3. In the presence of T3 (filled circles), TS-10 has a weak antagonistic effect. The EC50 concentration for the agonistic effect of TS-10
15 and the EC50 concentration for its T3 antagonistic effect, respectively, is indicated in FIG. 18.

In FIG. 18, open and filled circles with dotted lines show the dose-dependent effect of TS-10/T3 on the toxicity marker (MTS/PMS), reduction of tetrazolium salt in the
20 mitochondria, displayed on the right y-axis as optical density. There is no obvious toxic effect of TS-10 on the MTS-PMS marker but there is a clear effect on the morphology of the cells, as can be seen under the light microscope, at the highest concentration of TS-10 (32 mM) both in the absence and presence of T3, respectively (not shown in the figure).

25 TRAFb1 reporter cells: TS-10 alone (open circles) induces a partial activation of the expression of the ALP reporter protein amounting to approximately 35% of the maximal effect by T3. The EC50 concentration for the agonistic effect of TS-10 is indicated in FIG. 19. In the presence of T3 (filled circles), TS-10 shows, if anything, a slight
30 inhibitory effect of TS-10 at its highest concentration used (32 mM) is a toxic effect rather than T3 antagonism.

In FIG. 19, open and filled circles with dotted lines show the dose-dependent effect of TS-10/T3 on the toxicity marker (MTS/PMS), reduction of tetrazolium salt in the mitochondria, displayed on the right y-axis as optical density. There is no obvious toxic effect of TS-10 on the MTS-PMS marker but a clear effect on the morphology of the cells
5 can be observed, under the light microscope, at the highest concentration of TS-10 (32 mM) both in the absence and presence of T3, respectively (not shown in the figure).

HepG2 (HAF18) reporter cells: TS-10 alone (open circles) induces a partial activation of the expression of the ALP reporter protein amounting to slightly more than 50% of the
10 maximal effect by T3. The EC50 concentration for the agonistic effect of TS-10 is indicated in FIG. 20. In the presence of T3 (filled circles), TS-10 shows no effect i.e. no T3 antagonism nor potentiation/additive effect to T3. Open and filled circles with dotted lines show the dose-dependent effect of TS-10/T3 on the toxicity marker (MTS/PMS), reduction of tetrazolium salt in the mitochondria, displayed on the right y-
15 axis as optical density. There is no obvious toxic effect of TS-10 on the MTS/PMS marker or on the morphology of the cells, as can be observed using a light microscope, at any concentration of TS-10/T3 used.

Example 5 - Comparisons of Human TR- α and Human TR- β

20 Competition for [125 I]T₃ binding to TR LBD by T₃ and Triac

The drug, triac, is a thyroid hormone agonist. Triac is 3,5,3'-triiodothyroacetic acid and is described in Jorgensen, *Thyroid Hormones and Analogs in 6 Hormonal Proteins and Peptides, Thyroid Hormones* at 150-151 (1978). Another compound that can be used in place of triac is 3,5-diiodo-3'-isopropylthyroacetic acid. Competition assays
25 are performed to compare the displacement of [125 I]T₃ from binding with human TR- α LBD or human TR- β LBD by unlabeled T₃ or triac. The results of such assays are depicted in FIG. 16.


Standard binding reactions are prepared containing 1 nM [125 I]T₃, 30 fmol of human TR- α (empty symbols) or β (solid symbols), and various concentrations of
30 competing unlabeled T₃ (circles) or triac (triangles). Assays are performed in duplicate.

Scatchard Analysis of [125 I]T₃ Binding to TR

Human TR- α (left panel) or human TR- β (right panel) is assayed for T₃ binding in the presence of increasing concentrations of [125 I]T₃. The apparent equilibrium dissociation constant (20 pM for α and 67 pM for β) is calculated by linear regression analysis and is depicted in FIG. 17.

3, 5-DIBROMO-4-(3',5'-DIISOPROPYL-4'-HYDROXYPHENOXY) BENZOIC ACID IS A TR-A SELECTIVE SYNTHETIC LIGAND.

10



15 3, 5-dibromo-4-(3',5'-diisopropyl-4'-hydroxyphenoxy) benzoic acid (Compound 11), the structure of which is drawn above, is assayed for binding to the two different isoforms of the TR, TR α and TR β . Compound 11 exhibits an IC₅₀ of 1.6 μ M for binding to TR α and an IC₅₀ of 0.91 μ M for binding to TR β . Assays for determining selective binding to the TR α or TR β LBD can include reporter assays, as described
20 herein. See also Hollenberg, et al., J. Biol. Chem., 270(24)14274-14280 (1995).

EXAMPLE 6 - PREPARATION AND PURIFICATION OF A TR-A LBD

Rat TR- α LBD, residues Met122 - Val410, is purified from *E. coli* ("LBD-122/410"). The expression vector encoding the rat TR- α LBD is freshly transfected into
25 *E. coli* strain BL21(DE3) and grown at 22°C in a 50-liter fermenter using 2x LB medium. At an A₆₀₀ of 2.5-3, IPTG is added to 0.5 mM and growth is continued for 3 h before harvesting. The bacterial pellet is quickly frozen in liquid nitrogen and stored at -70°C until processed. Extraction and purification steps are carried out at 4°C. The bacteria are thawed in extraction buffer (20MM Hepes, pH 8.-, 1 mM EDTA, 0.1%
30 MTG, 0.1 mM PMSF, and 10% glycerol) at a ratio of 10 ml buffer/g bacteria. Bacteria are lysed by incubation for 15 min. with 0.2 mg/ml lysozyme and sonicated at maximum power while simultaneously homogenized with a Brinkmann homogenizer (Model PT

10/35 with generator PTA 35/2) until the solution loses its viscosity. After centrifugation for 10 min at 10,000 g, the supernatant is adjusted to 0.4 M KCl, treated with 0.6% PEI to precipitate fragmented DNA, and centrifuged for 10 min at 10,000 g. The rat TR- α LBD in the supernatant is then precipitated with 50% ammonium sulfate and centrifuged 5 for 10 min at 10,000 g. The precipitate is resuspended with buffer B (20 mM Hepes, pH 8.0, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, 0.01% Lubrol, and 10% glycerol) to a final conductivity of 9 mS/cm (approx. 0.7 M ammonium sulfate) and centrifuged 1 h at 100,000g. The supernatant is frozen in liquid nitrogen and stored at -70°C.

The crude extract is thawed, bound with a tracer amount of [125 I]T₃, and loaded 10 directly onto a phenyl-Toyopearl hydrophobic interaction column (2.6 x 18 cm, 95 ml bed volume) at 1.5 ml/min. The column is eluted with a 2-h gradient from 0.7 ammonium sulfate, no glycerol to no salt, 20% glycerol in buffer C (20 mM Hepes, pH 8.0, 0.5 mM EDTA, 1 mM DTT, 0.2 mM PMSF). The rat TR- α LBD prebound to tracer [125 I]T₃ (less than 0.005% of total rat TR- α LBD) is detected using a flow-through gamma 15 emission detector, whereas unliganded rat TR- α LBD is assayed by postcolumn [125 I]T₃ binding assays (described herein).

The phenyl-Toyopearl unliganded rat TR- α LBD peak fractions are pooled, diluted with buffer B to a conductivity of 0.5 mS/cm (equivalent to approx. 20 mM ammonium sulfate), loaded onto a TSK-DEAE anion-exchange column (2 x 15 cm, 47 ml bed 20 volume) at 4 ml/min, and eluted with a 60-min gradient from 50 to 200 mM NaCl in buffer B.

The unliganded rat TR- α LBD peak fractions from TSK-DEAE are pooled, diluted twofold with buffer B, loaded at 0.75 ml/min on a TSK-heparin HPLC column (0.8 x 7.5 cm, 3 ml bed volume), and eluted with a 50 to 400 mM NaCl gradient in buffer B.

25 The pool of unliganded rat TR- α LBD peak fractions from the TSK-heparin column is adjusted to 0.7 M ammonium sulfate, loaded at 0.75 ml/min on a TSK-phenyl HPLC column (0.8 x 7.5 cm, 3 ml bed volume), and eluted with a 60-min gradient from 0.7 M ammonium sulfate without glycerol to no salt with 20% glycerol in buffer C. The fractions containing unliganded rat TR- α LBD are pooled and incubated with a five fold 30 excess of hormone for 1 h, the salt concentration is adjusted to 0.7 M ammonium sulfate, and the sample is reloaded and chromatographed on the same column as described above.

EXAMPLE 7 - CRYSTALLIZATION OF LIGANDED TR- α LBD

Material from a single LBD-122/410 preparation is divided into batches, and quantitatively bound with one of the following ligands: Dimit, T₃, or triac IpBr₂ (3,5dibromo-3'-isopropylthyronine) for the final purification step.

- 5 To maintain full saturation of rat TR- α LBD with a ligand, and to prepare the complex for crystallization, the ligand-bound rat TR- α LBD is concentrated and desalted in an Amicon Centricon-10 microconcentrator (McGrath et al, *Biotechniques*, 7:246-247 (1989), incorporated by reference herein), using 10 mM Hepes (pH 7.0), 3.0 mM DTT, and 1.0 nM to 10 nM ligand.
- 10 Factorial crystallization screening trials (Jancarik & Kim, *J. Appl. Crystallogr.* 24:409-411 (1991) incorporated by reference herein) are carried out for rat TR- α LBD bound to selected ligands using hanging-drop vapor diffusion at 17°C (with 1 μ l protein solution, 1 μ l precipitant solution and a 0.5 ml reservoir using silanized coverslip (McPherson, *Preparation and Analysis of Protein Crystals* (1982), incorporated by
- 15 reference herein). Rat TR- α LBD is not stable at 4°C and is stored at -80°C, where it maintains its avidity for hormone and its crystallizability for approximately two to three months. These procedures are carried out as described in McGrath, M.E. *et al.*, *J. Mol. Biol.* 237:236-239 (1994) (incorporated by reference). Crystals are obtained in condition
- 20 Wedge-shaped crystals are reproducibly obtained with hanging-drop vapor fusion at 22°C with 15% 2-methyl-2,4-pentanediol (MPD), 0.2 M ammonium acetate and 0.1 M sodium cacodylate (pH 6.7), 3 mM DTT, with 2 μ l protein solution, 1 μ l precipitant solution and a 0.6 ml reservoir using silanized coverslip, and with 8.7 mg/ml (Dimit), 5.5 mg/ml (IpBr₂), 5 mg/ml (triac), or 2.3 mg/ml (T₃) over a period of three days. Under these
- 25 conditions, diffraction quality crystals (dimension 0.5 x 0.2 x 0.0075 mm³) can be grown at ambient temperature (22°C). The best crystals have a limiting dimension of approximately 100 μ m and are obtained at a protein concentration between 2.3 and 8.7 mg/ml in the presence of 3 mM DTT. The crystals are of the monoclinic space group C2, with one monomer in the asymmetric unit.

EXAMPLE 8 - CRYSTALLIZATION OF HUMAN TR- β LBD COMPLEXED WITH T₃ OR TRIAC

Human TR- β LBD complexed with T₃ and human TR- β LBD complexed with triac are purified according to the same procedures described above for the rat TR- α LBD, with the following modifications.

The expression of human TR- β LBD differs from the rat TR- α LBD in that the human TR- β LBD residues extend from the amino acid at position 716 through the amino acid at position 1022, according to the amino acid numbering scheme for the various nuclear receptor LBDs depicted in FIG. 3. FIG. 3 illustrates a numbering scheme applicable to all of the nuclear receptors listed as well as to any additional homologous nuclear receptors. The vertical lines on FIG. 3 at position 725 and at position 1025 delineate the preferred minimum amino acid sequence necessary to obtain adequate binding of ligand. The amino acid sequence from position 716 to position 1022 according to the numbering scheme of FIG. 3 corresponds to the amino acid positions 202 to 461 according to the conventional numbering of the amino acid sequence of human TR- β which is publicly available. Also, the human TR- β LBD is expressed with a histidine tag, as described in Crowe et al., Methods in Molecular Biology 31:371-387 (1994), incorporated by reference herein.

The purification of human TR- β LBD is the same as that described above for the rat TR- α LBD with the following exceptions. First, before the purification step using the hydrophobic interaction column, a step is added in which the expressed human TR- β LBD is purified using a nickel NTA column (commercially available from Qiagen, Chatsworth, CA) according to manufacturer's instructions, and eluted with 200 mM imidazole. The second difference is that in the purification of the human TR- β LBD, the purification step using a heparin column is omitted.

The crystallization of human TR- β LBD bound to T₃ or triac is as follows. Crystals are obtained in condition 7 of the factorial screen using hanging drops as before at ambient temperature (22°C) using the factorial crystallization screening trials of Jancarik & Kim (1991) and using the commercially available product from Hampton Research, Riverside). The following are optimum conditions: hexagonal bipyramidal crystals are grown at 4°C for 2-3 days from hanging drops containing 1.0-1.2 M sodium acetate (pH-unadjusted) and 0.1 M sodium cacodylate (pH 7.4), 3 mM-DTT, with either

a 1 μ l protein solution, 1 μ l precipitant solution or 2 μ l protein solution, 1 μ l precipitant solution and a 0.6 ml reservoir using silanized coverslip, at a protein concentration of 7-10 mg/ml. The best crystals have a limiting dimension of 200 μ m.

The crystal system for human TR- β LBD bound to T₃ or triac is trigonal with the
5 space group p3₁21. The unit cell dimensions are cell length a = cell length b = 68.448 angstroms, cell length c = 130.559 angstroms. The angles are $\alpha = 90^\circ$, $\beta = 90^\circ$, $\gamma = 120^\circ$.

EXAMPLE 9 - DETERMINATION OF LIGANDED TR- α LBD CRYSTAL STRUCTURE

10 Data from each of three cocrystals (Rat TR- α LBD with Dimit, T₃ and IpBr₂) is measured on a Mar area detector at Stanford Synchrotron Radiation Laboratory beamline 7-1 ($\lambda = 1.08$ angstroms) using 1.2° oscillations.

Data from the T₃ cocrystal is measured with the b* axis approximately parallel with the spindle. The crystals are flash frozen at -178°C in a nitrogen gas stream with the
15 MPD mother liquor serving as the cryosolvent. An orientation matrix for each crystal is determined using REFLX (Kabsch, W., *J. Appl. Crystallogr.* 26:795-800 (1993) incorporated by reference). Reflections are integrated with DENZO (commercially available from Molecular Structure Corp., The Woodlands, Texas), and are scaled with SCALEPACK (as described in Otwinowski, Z, *Proceedings of the CCP4 Study Weekend*:
20 "Data Collection and Processing," 56-62 (SERC Daresbury Laboratory, Warrington, UK 1993) incorporated by reference).

For the T₃ data set, Bijvoet pairs are kept separate, and are locally scaled using MADSYS (W. Hendrickson (Columbia University) and W. Weis (Stanford University)).

Cocrystals prepared from the three isosteric ligands are isomorphous. MIR
25 analysis is performed using programs from the CCP4 suite (Collaborative Computational Project, N.R. *Acta Crystallogr.* D50:760-763 (1994), incorporated by reference herein). Difference Pattersons is calculated for both T₃ and IpBr₂, taking the Dimit cocrystal as the parent. The positions of the three iodine atoms in the T₃ difference Patterson are unambiguously determined from the Harker section of the density map as peaks of 11 σ
30 above background. The positions for the two bromine atoms in the IpBr₂ cocrystals, are located independently, as peaks 8 σ above the noise level. Phases for the LBD-122/410 are calculated from the solution to the IpBr₂ difference Patterson, and are used to confirm the

location of the unique third iodine of the T₃ cocrystal. Halogen positions are refined with MLPHARE, including the anomalous contributions from the iodine atoms (Otwinowski, Z., *Proceedings of the CCP4 Study Weekend* 80-86 (SERC Daresbury Laboratory, Warrington, UK 1991)). The MIRAS phases are improved through solvent
 5 flattening/histogram matching using DM (Cowtan, K., *Joint CCP4 and ESF-EACBM Newsletter on Protein Crystallography* 31: 34-38 (1994), incorporated by reference herein).

A model of the LBD-122/410 with Dimit bound is built with the program O from the solvent flattened MIRAS 2.5 angstrom electron density map (Jones et al., *Acta*
 10 *Crystallogr. A* 47:110-119 (1991), incorporated by reference herein). The initial model, without ligand, (R_{cryst} = 40.1%), is refined using least-squares protocols with XPLOR. The Dimit ligand is built into unambiguous Fo-Fc difference density during the following round. Subsequent refinement employs both least-squares and simulated annealing protocols with XPLOR (Brunger et al., *Science* 235:458-460 (1987), incorporated by
 15 reference herein). Individual atomic B-factors are refined isotropically. As defined in PROCHECK, all residues are in allowed main-chain torsion angle regions as described in Laskowski et al., *J. Appl. Crystallogr.* 26:283-291 (1993), incorporated by reference herein. The current model is missing 34 residues (Met₁₂₂-Gln₁₅₆) at the N-terminus, and 5 residues (Glu₄₀₆-Val₄₁₀) at the C-terminus.

20 In addition, the following residues are not modeled beyond C β due to poor density: 184, 186, 190, 198, 206, 209, 240, 301, 330, 337, 340, 343, 359, and 395. The average B-value for protein atoms is 34.5 Å². The final model consists of the LBD-122/410, residues Arg₁₅₇-Ser₁₈₃, Trp₁₈₅-Gly₁₉₇, Ser₁₉₉-Asp₂₀₆ and Asp₂₀₈-Phe₄₀₅; three cacodylate-modified cysteines: Cys₃₃₄, Cys₃₈₀ and Cys₃₉₂; and 73 solvent molecules
 25 modeled as water (2003 atoms).

$$*R_{\text{sym}} = 100 \times \sum_{hkl} \sum_i |I_i - \bar{I}| / \sum_{hkl} \sum_i I_i$$

$$\dagger R_{\text{der}} = 100 \times \sum_{hkl} |F_{\text{PH}} - F_{\text{H}}| / \sum_{hkl} |F_{\text{P}}|$$

The occupancy for the two bromine sites is set to 35 electrons. The occupancies of the iodine sites are relative to this value.

30 §Phasing power = $\langle FH \rangle / \langle \epsilon \rangle$, where $\langle FH \rangle$ is the mean calculated heavy atom structure factor amplitude and $\langle \epsilon \rangle$ is the mean estimated lack of closure.

$R_{\text{cullis}} = \langle \epsilon \rangle / \langle \text{iso} \rangle$, where $\langle \epsilon \rangle$ is the mean estimated lack of closure and $\langle \text{iso} \rangle$ is the isomorphous difference.

$R_{\text{cryst}} = 100 \times \sum_{hkl} |F_o - F_c| / \sum_{hkl} |F_o|$ where F_o and F_c are the observed and calculated structure factor amplitudes (for data $F/\sigma > 2$). The R_{free} was calculated using

5 3% of the data, chosen randomly, and omitted from the refinement.

$\text{Correlation coefficient} = \sum_{hkl} (|F_o| - |F_c|) \times (|F_o| - |F_c|) / \sum_{hkl} (|F_o| - |F_c|)^2 \times \sum_{hkl} (|F_o| - |F_c|)^2$

EXAMPLE 10. PHASING OF THE rTRA LBD COMPLEX WITH TRIAC

- 10 Due to the possible non-isomorphism of the rTR α LBD complex with Triac, a molecular replacement solution is determined using AMORE (Navaza, J., Acta Crystallographica Section A-Fundamentals of Crystallography 50:157-63 (1994) from a starting model consisting of rTR α LBD complex with T₃, but with the ligand, all water molecules, and the following residues omitted: Asn 179, Arg228, Arg262, Arg266, and Ser 277. Strong
- 15 peaks are obtained in both the rotation and translation searches, with no significant (> 0.5 times the top peak) false solutions observed (Table 3). Strong positive density present in both the anomalous and conventional difference Fourier maps confirm the solution. Maps are calculated using sigma-A weighted coefficients output by REFMAC (Murshudov, et al. "Application of Maximum Likelihood Refinements," in the
- 20 Refinement of Protein Structures, Proceedings of Daresbury Study Weekend (1996)) after 15 cycles of maximum likelihood refinement. Triac, the omitted residues, and water molecules 503, 504, 534 (following the numbering convention for the TR complex with T₃) are built into the resulting difference density using O (Jones et. al.); the conformations of these residues are further confirmed in a simulated-annealing omit map
- 25 (Brunger et. al.). The complete model is then refined using positional least-squares, simulated annealing, and restrained, grouped B factor refinement in XPLOR to an R_{cryst} of 23.6% and an R_{free} of 24.1%

EXAMPLE 11. CONNECTING QSAR WITH STRUCTURE IN THE THYROID HORMONE

30 RECEPTOR

The conclusions of classic thyroid hormone receptor quantitative structure-activity relationships may be summarized as follows:

64.


- 1) the R_4' -hydroxyl group functions as a hydrogen bond donor;
- 2) the amino-propionic acid interacts electrostatically through the carboxylate anion with a positively charged residue from the receptor;
- 3) the preferences of R_3/R_5 substituent are $I > Br > Me > > H$;
- 5 4) the preferences of the R_3' -substituent are $Ipr > I > Br > Me > > H$.

The structure of the thyroid hormone receptor ligand binding domain complexed with the agonists 3,5,3'-triiodothyronine (T_3), 3,5-dibromo-3'-isopropylthyronine ($IpBr_2$), 3,5-dimethyl-3'-isopropylthyronine (Dimit), and 3,5,3'-triiodothyroacetic acid (Triac), as provided herein, permits:

- 10 1) the identification of receptor determinants of binding at the level of the hydrogen bond;
- 2) the association of these determinants with the predictions of classic thyroid hormone receptor QSAR; and
- 3) prediction as to which determinants of binding are rigid, and which are
- 15 flexible, for both the ligand and the receptor.

This classification for the agonists of the type (R_1 =amino-propionic, acetic acid; $R_3, R_5=I, Br, Me$; $R_3'=Ipr, I$) is given below (for the representative ligand T_3);

F = Fiducial (always satisfied)
 20 A = Adjustable



30

Based upon the methods and data described herein, the following is an embodiment of the computational methods of the invention, which permit design of nuclear receptor ligands based upon interactions between the structure of the amino acid residues of the receptor LBD and the four different ligands described herein. The small molecule structures for the ligands can be obtained from Cambridge Structural Database (CSD), and three dimensional models can be constructed using the methods described throughout the specification. The following are factors to consider in designing synthetic ligands:

- 1) Histidine 381 acts as a hydrogen bond acceptor for the R_4' hydroxyl, with the optimal tautomer maintained by water molecules. See FIG. 23 and FIG 24. Histidine is the only hydrophilic residue in this hydrophobic pocket that surrounds the R_4' substituent. Histidine can be either a hydrogen bond acceptor or donor, depending on its tautomeric state. It is preferably a hydrogen bond donor, but can tolerate being a hydrogen bond acceptor, as for example, when there is a methoxy at the R_4' position of the ligand;
- 2) Arginines 228, 262, and 266 interact directly and through water-mediated hydrogen bonds with the R_1 -substituent, with the electrostatic interaction provided by Arginine 266 (as in the Triac complex). This polar pocket is illustrated by FIG. 23 - FIG. 25. FIG. 23 depicts T_3 in the $TR\alpha$ ligand binding cavity, where T_3 's aminopropionic R_1 - substituent interacts with Arg 228, H0H502, H9H503 and H0H504 via hydrogen bonds. FIG. 24 depicts triac in the ligand binding cavity, with its $-COOH$ R_1 substituent in the polar pocket. In FIG. 24, Arg 228 no longer shares a hydrogen bond with the ligand, but the $-COOH$ R_1 substituent forms hydrogen bonds with Arg 266. FIG. 25 superimposes T_3 and triac in the ligand binding cavity and shows several positionally unchanged amino acids and water molecules, and selected changed interacting amino acids and water molecules. The three figures illustrate parts of the polar pocket that can change and those parts that do not move upon binding of different ligands. For example, the Arg 262 at the top of the polar pocket does not move, even when the R_1 substituent has changed from a $-COOH$ to an aminopropionic acid group. However, the other two Arginines, Arg 228 and Arg 266, demonstrate flexibility in the polar pocket to respond to the change in the size or chemical nature of the R_1 substituent.;

- 3) Inner and outer pockets for the R_3/R_5 substituents are formed by Ser260, Ala263, Ile299, and Phe 218, Ile221, Ile222, respectively. See FIGS. 21 and 22. The

inner pocket is filled by either the R_3 or the R_5 substituent, regardless of the size of the substituent, and may act as a binding determinant by positioning the ligand in the receptor. Optimally, the inner pocket amino acids interact with an R_3 or R_5 substituent that is no larger than an iodo group. If the inner pocket is filled by the R_3 substituent, 5 then the outer pocket interacts with the R_5 substituent and vice versa. The outer pocket can adjust to the size of its substituent through main chain motion centered at the break in helix 3 (Lys220-Ile221), suggesting that the bending of H3, and motion of the N-terminal portion of H3, may represent a conformational change induced on ligand binding. The outer pocket has greater flexibility than does the inner pocket in terms of accommodating 10 a larger substituent group.

4) A pocket for the R_3' -substituent is formed by Phe 215, Gly290, Met388. The pocket is incompletely filled by the R_3' -iodo substituent, and accommodates the slightly larger 3'-isopropyl substituent by movement of the flexible Met388 side chain and the H7/H8 loop. This pocket can accommodate R_3' substituents that are even larger than 15 isopropyl, for example, a phenyl group.


The above information will facilitate the design of high affinity agonists and antagonists by improving automated QSAR methodologies and informing manual modeling of pharmaceutical lead compounds. For example, the inclusion of discrete water molecules provides a complete description of hydrogen bonding in the polar pocket 20 for use with pharmacophore development: also, the identification of mobile and immobile residues within the receptor suggests physically reasonable constraints for use in molecular mechanics/dynamics calculations.

EXAMPLE 12. DESIGN OF AN INCREASED AFFINITY LIGAND

25 Direct interaction between the receptor and the ligand is limited in the polar pocket, which interacts with the R_1 substituent. While the lack of complementarity may contain implications for biological regulation, it also provides an opportunity for increasing affinity by optimizing the interaction between the amino acids of the polar pocket and the R_1 substituent of a synthetic ligand. The structure of the receptor-ligand 30 interactions described herein enables design of an increased affinity synthetic ligand having two complementary modifications:

- 1) Remove the positively charged amine. The strongly positive electrostatic potential predicted for the polar pocket suggests that the positively charged amine of the aminopropionic acid R_1 substituent may be detrimental to binding. Suitable groups for substitution are suggested by the nature of nearby hydrogen bond partners: for example, Thr 275 O or Ser 277 N. See e.g. Tables in Appendix 2. For example, any negatively charged substituent would be compatible for interacting with the amino acids of the polar pocket, including carboxylates, carbonyl, phosphonates, and sulfates, comprising 0 to 4 carbons. Another example of an R_1 substitution is an oxamic acid that replaces the amine of the naturally occurring ligand with one or more carbonyl groups.
- 2) Incorporate hydrogen bond acceptor and donor groups into the R_1 -substituent to provide broader interactions with the polar pocket scaffold. Such hydrogen bond acceptor and donor groups incorporated into the R_1 -substituent will allow interactions that would otherwise occur with water molecules in the polar pocket. Specific waters include HOH 504 (hydrogen bonds with Ala 225 O and Arg 262 NH); and HOH 503 hydrogen bonds with Asn 179 OD1, Ala 180 N), both of which are present in all four complexes (TR LBD complexed with T3, TR LBC complexed with IpBr₂, TR LBD complexed with Dimit and TR LBD complexed with Triac). Analysis of the hydrogen bonding network in the polar pocket suggests replacement of HOH 504 with a hydrogen bond acceptor, and HOH 503 with an hydrogen bond donor (although the chemical nature of asparagine probably permits flexibility at this site). Thus, incorporating a hydrogen bond acceptor in an R_1 substituent that could take the place of the HOH504 or incorporating a hydrogen bond acceptor in an R_1 substituent that could positionally replace the HOH503, or a combination thereof, are methods of designing novel synthetic TR ligands.
- These two design approaches can be used separately or in combination to design synthetic ligands, including those in Table 4 (below).
- A corollary to this approach is to design specific interactions to the residues Arg262 and Asn 179. The goal is to build in interactions to these residues by designing ligands that have R_1 substituents that form hydrogen bonds with water molecules or charged residues in the polar pocket.

Table 4: Synthetic TR Ligands




	R1	R2	R3	R5	R6	X	R'2	R'3	R'4	R'5	R'6
10	CO2H	H	Me	Me	H	O	H	Me	OH	Me	H
	CH2CO2H		I	I		S		Et	SH	Et	
	CH2CH2CO2H		Br	Br				nPr	NH2	nPr	
	CH2CH(NH2)CO2H		Cl	Cl				iPr		iPr	
	OCH2CO2H		Et	Et				Ph		nBu	
15	OCH2CH2CO2H		OH	OH				I		nPen	
	NHCH2CO2H		NH2	NH2				Br		nHex	
	NHCH2CH2CO2H		SH	SH				Cl		Ph	
	CH2COCOCO2H									hetero	
										cycle	
20	NHCOCOCO2H									aryl	
	COCO2H										
	CF2CO2H										
	COCH2CO2H										

25 Any combination of the above substituents in the biphenyl ether scaffold structure shown above may result in a potentially pharmacologically useful ligand for the thyroid hormone receptor. These novel ligands may be antagonists of the thyroid receptor.

69.


A strategy for designing synthetic ligands using the computational methods described herein is summed below:

5



For example,

10



15

A = Hydrogen Bond Acceptor

D = Hydrogen Bond Donor

$$O = -OH, -CO$$

R10 can be -OH, -CO

20

R20 can be -CO

R30 can be -COOH, -CONH₂

See also Table of synthetic TR Ligands

TABLE 3: LBD-122/410

		Dimit	T3	IpBr ₂	Triac
Data collection					
Cell dimensions					
5	a (Å)	117.16	117.19	117.18	118.19
	b (Å)	80.52	80.20	80.12	81.37
	c (Å)	63.21	63.23	63.13	63.73
	β (°)	120.58	120.60	120.69	121.00
	Resolution (Å)	2.2	2.0	2.1	2.45
10	Obs. Reflections, (no.)	57031	64424	66877	83573
	Unique Reflections, (no.)	22327	21023	23966	18453
	Completeness, (%)	87.0	82.4	93.7	96.0
15	*R _{sym} (%)	3.9	3.5	4.5	7.5
Phasing (15.0 - 2.5Å)					
	†R _{der} (%)	-	19.6	11.6	
	No. of sites	-	3	2	
	‡Occupancy	-	44.6 (19.8)	35.0	
20	(Anomalous)	-	50.2 (23.7)	35.0	
			39.2 (22.3)		
§F_H/E					
centric (acentric)					
	15.0-5.0 Å	-	3.67 (4.61)	2.25 (3.09)	
25	5.0-3.0 Å	-	2.23 (2.75)	1.25 (1.85)	
	3.0-2.5 Å	-	1.64 (1.99)	1.15 (1.57)	
¶R_{culis} (%)					
	15.0-5.0 Å	-	33	44	
	5.0-3.0 Å	-	45	63	
30	3.0-2.5 Å	-	60	65	
	Mean figure of merit	0.62	-	-	
MR Phasing (10-3.5Å)					
Rotation Search:					
35	Eyler Angles (°)				$\Theta_1 = 309.37$ $\Theta_2 = 48.96$ $\Theta_3 = 127.28$
§ correlation coefficient					
					34.3
Translation Search:					
40	Fractional coordinates				x = 0.1571

				y = 0.000
				z = 0.3421
				65.8
5	§ correlation Coefficient			
	'R factor			31.2
	Refinement	15.0-2.2	5.0 - 2.0	15.0 - 2.2
	Resolution (Å)			25-2.5
	<u>R_{cryst} (%)</u>	20.5	22.1	21.4
	R _{free} (%)	22.7	24.0	22.4
10				24.1

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

- 15 The nuclear receptor ligands, particularly the TR ligands, of these references are herein incorporated by reference and can be optionally excluded from the claimed compounds with a proviso.

Headings and subheadings are presented only for the convenience of the reader and should not be used to construe the meaning of terms used within such headings and
20 subheadings.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

APPENDIX I

- Andrea, T.A., *et al.* *J Med Chem* 22, 221-232 (1979).
- Andrews *et al.*, U.S. Patent No. 4,741,897, issued May 3, 1989.
- Apriletti, J.W., Baxter, J.D., Lau, K.H & West, B.L. *Protein Expression and Purification* 6, 363-370 (1995).
- 5 Apriletti, J.W., Baxter, J.D. & Lavin, T.N. *J. Biol. Chem.* 263, 9409-9417 (1988).
- Au-Fliegner, M., Helmer, E., Casanova, J., Raaka, B.M. & Samuels, H.H. *Mol Cell Biol* 13, 5725-5737 (1993).
- 10 Baniahmad, A., *et al.* *Mol Cell Biol* 15, 76-86 (1995).
- Barettino, D., Vivanco Ruiz, M.M. & Stunnenberg, H.G. *Embo J* 13, 3039-3049 (1994).
- Beck-Peccoz, P., *et al.* *J Clin Endocrinol Metab* 78, 990-993 (1994).
- Bhat, M.K., McPhie, P. & Cheng, S.Y. *Biochem Biophys Res Commun* 210, 464-471 (1995).
- 15 Blake, C.C. & Oatley, S.J. *Nature* 268, 115-120 (1977).
- Blake, C.C., Geisow, M.J., Oatley, S.J., Rerat, B. & Rerat, C. *J Mol Biol* 121, 339-356 (1978).
- Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H. & Moras, D. *Nature* 375, 377-382 (1995).
- 20 Brent, G.A. *N Engl J Med* 331, 847-853 (1994).
- Brunger, A.T., Kuriyan, J. & Karplus, M. *Science* 235, 458-460 (1987).
- Casanova, J., *et al.* *Mol Cell Biol* 14, 5756-5765 (1994).
- Cavaillès, V., *et al.* *Embo J* 14, 3741-3751 (1995).
- 25 Chin *et al.*, U.S. Patent No. 5,284,999, issued February 8, 1994.
- Collaborative Computational Project, N.4. *Acta Crystallogr.* D50, 760-763 (1994).
- Collingwood, T.N., Adams, M., Tone, Y & Chatterjee, V.K. *Mol Endocrinol* 8, 1262-1277 (1994).
- Cowtan, K. *Joint CCP4 and ESF-EACBM Newsletter on Protein Crystallography* 31, 34-38 (1994).
- 30 Damm, K. & Evans, R.M. *Proc Natl Acad Sci U S A* 90, 10668-10672 (1993).

- Danielian, P.S., White, R., Lees, J.A. & Parker, M.G. *Embo J* 11, 1025-1033 (1992).
- Davies *et al*, U.S. Patent No. 5,322,933, issued June 21, 1994.
- Dawson *et al*, U.S. Patent No. 5,466,861, issued November 14, 1995.
- 5 DeGroot *et al*, U.S. Patent No. 5,438,126, issued August 1, 1995.
- Dietrich, S.W., Bolger, M.B., Kollman, P.A. & Jorgensen, E.C. *J Med Chem* 20, 863-880 (1977).
- Durand, B., *et al*. *Embo J* 13, 5370-5382 (1994).
- Ellis *et al*, U.S. Patent No. 4,766,121, issued August 23, 1988.
- 10 Ellis *et al*, U.S. Patent No. 4,826,876, issued May 2, 1989.
- Ellis *et al*, U.S. Patent No. 4,910,305, issued March 20, 1990.
- Emmett *et al*, U.S. Patent No. 5,061,798, issued October 29, 1991.
- Evans, R.M. *Science* 240, 889-895 (1988).
- Evans *et al*, U.S. Patent No. 5,171,671, issued December 15, 1992.
- 15 Evans *et al*, U.S. Patent No. 5,312,732, issued May 17, 1994.
- Fawell, S.E., Lees, J.A., White, R. & Parker, M.G. *Cell* 60, 953-962 (1990).
- Forman, B.M. & Samuels, H.H. *Mol. Endocrinol.* 4, 1293-1301 (1990).
- Gewirth, D.T. & Sigler, P.B. *Nature Structural Biology* 2, 386-394 (1995).
- Glass, C.K. *Endocr Rev* 15, 391-407 (1994).
- 20 Hayashi, Y. Sunthornthepvarakul, T. & Refetoff, S. *J Clin Invest* 94, 607-615 (1994).
- Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard. *Acta Crystallogr A* 47, 110-119 (1991).
- Jorgensen, E.C. in *Hormonal Peptides and Proteins* (eds. Li, C.H.) 107-204 (Academic Press, New York, 1978).
- 25 Kabsch, W. *J. Appl. Crystallogr.* 26, 795-800 (1993).
- Kabsch, W. & Sander, C. *Biopolymers* 22, 2577-2637 (1983).
- Laskowski, R.A., Macarthur, M.W., Moss, D.S. & Thornton, J.M. *J. Appl. Crystallogr.* 26, 283-291 (1993).
- 30 Latham, K.R., Apriletti, J.W., Eberhardt, N.L. & Baxter, J.D. *J Biol Chem* 256, 12088-12093 (1981).

- Laudet, V., Hanni, C., Coll, J., Catzeflis, F. & Stehelin, D. *Embo J* 11, 1003-1013 (1992).
- LeDouarin, B., *et al.* *Embo J* 14, 2020-2033 (1995).
- Lee, J.W., Ryan, F., Swaffield, J.C., Johnston, S.A. & Moore, D.D. *Nature* 5 374, 91-94 (1995).
- Lee, J.W., Choi, H.S., Gyuris, J., Brent, R. & Moore, D.D. *Molec. Endocrinol.* 9, 243-254 (1995).
- Leeson, P.D., Emmett, J.C., Shah, V.P., Showell, G.A., Novelli, R., Prain, H.D., Benson, M.G., Ellis, D., Pearce, N.J. & Underwood, A.H. *J. Med. Chem.* 10 32, 320-336 (1989).
- Leeson, P.D., Ellis, D., Emmett, J.D., Shah, V.P., Showell, G.A. & Underwood, A.H. *J. Leng, X., et al. Mol Cell Biol* 15, 255-263 (1995).
- Leng, X., Tsai, S.Y., O'Malley, B.W. & Tsai, M.J. *J Steroid Biochem Mol Biol* 46, 643-661 (1993).
- 15 Lin, K.H., Parkison, C., McPhie, P. & Cheng, S.Y. *Mol. Endocrinol.* 5, 485-492 (1991).
- Luisi, B.F., *et al.* *Nature* 352, 497-505 (1991).
- McGrath, M.E., *et al.* *J. Mol. Biol.* 237, 236-239 (1994).
- McRee, D.E., *Practical Protein Crystallography*, Academic Press, N.Y. (1993),
20 especially chapters 1, 2 and 3.
- Meier, C.A., *et al.* *Mol. Endocrinol.* 6, 248-258 (1992).
- Miura *et al.*, U.S. Patent No. 5,116,828, issued May 26, 1992.
- Monaco, H.L., Rizzi, M. & Coda, A. *Science* 268, 1039-1041 (1995).
- Nicholls, A., Sharp, K.A. & Honig, B. *Proteins* 11, 281-296 (1991).
- 25 O'Donnell, A.L., Rosen, E.D., Darling, D.S. & Koenig, R.J. *Mol. Endocrinol.* 5, 94-99 (1991).
- Otwinowski, Z. *Proceedings of the CCP4 Study Weekend 80-86 (SERC Daresbury Laboratory, Warrington, U.K., 1991).*
- Otwinowski, Z. *Proceedings of the CCP4 Study Weekend: "Data Collection and*
30 *Processing"* 56-62 (SERC Daresbury Laboratory, Warrington, U.K., 1993).
- Ozato, U.S. Patent No. 5,403,925, issued April 4, 1995.

- Rastinejad, R., Perlmann, T., Evans, R.M. & Sigler, P.B. *Nature* 375, 203-211 (1995).
- Refetoff, S., Weiss, R.E. & Usala, S.J. *Endocr. Rev.* 14, 348-399 (1993).
- Ribeiro, R.C.J., Kushner, P.J. & Baxter, J.D. *Annu. Rev. Med.* 46, 443-453 (1995).
- 5 Ribeiro, R.C.J., *et al.* *Ann. N. Y. Acad. Sci.* 758, 366-389 (1995).
- Ribeiro, R.C., Kushner, P.J., Apriletti, J.W., West, B.L. & Baxter, J.D. *Mol. Endocrinol.* 6, 1142-1152 (1992).
- Saatcioglu, F., Bartunek, P., Deng, T., Zenke, M. & Karin, M. *Mol. Cell Biol.* 10 13, 3675-3685 (1993).
- Schwabe, J.W., Chapman, L., Finch, J.T. & Rhodes, D. *Cell* 75, 567-578 (1993).
- Selmi, S. & Samuels, H.H. *J. Biol. Chem.* 266, 11589-11593 (1991).
- Swaffield, J.C., Melcher, K. & Johnston, S.A. *Nature* 374, 88-91 (1995).
- 15 Toney, J.H. *et al.* *Biochemistry* 32, 2-6 (1993).
- Tsai, M.J. & O'Malley, B.W. *Annu. Rev. Biochem.* 63, 451-486 (1994).
- Zenke, M., Muñoz, A., Sap, J., Vennstrom, B. & Beug, H. *Cell* 61, 1035-1049 (1990).

Interactions of Dimit with Thyroid Hormone Receptor Amino Acids

Dimit Atom	Amino Acid In full length α	Amino Acid Atom	Distance Å
C16	215-PHE	CD1	3.98
C16	215-PHE	CE1	3.88
C19	218-PHE	O	3.69
C16	218-PHE	CB	3.89
C18	218-PHE	CB	3.92
C19	218-PHE	CB	4.13
C18	218-PHE	CD2	3.77
C16	218-THR	CG2	3.68
C19	221-ILE	CG1	4.11
C8	222-ILE	CD1	4.18
C8	222-ILE	CD1	3.72
C10	222-ILE	CD1	3.53
C12	222-ILE	CD1	3.85
O1	222-ILE	CD1	4.13
C13	225-ALA	CB	3.64
O4	225-ALA	CB	4.02
O4	228-ARG	CZ	3.98
C17	228-ARG	NH2	3.36
O3	228-ARG	NH2	3.58
O4	228-ARG	NH2	2.88
C10	258-MET	SD	3.70
C12	258-MET	SD	3.89
C10	258-MET	CE	3.88
C12	258-MET	CE	3.83
C11	259-MET	C	4.03
C11	259-MET	O	3.68
C15	259-MET	O	3.42
N1	259-MET	O	3.71
C1	259-MET	CB	4.20
C11	259-MET	CB	3.87
C13	259-MET	CB	4.09
C15	262-ARG	CB	4.03
C17	262-ARG	CB	3.58
O3	262-ARG	CB	3.82
O4	262-ARG	CB	3.85
C17	262-ARG	CD	4.10
O4	262-ARG	CD	3.81
N1	263-ALA	N	3.71
C17	263-ALA	CA	3.69
N1	263-ALA	CB	3.46
O3	268-ARG	NH1	3.93
N1	275-THR	O	3.62
N1	278-LEU	CA	3.51
N1	278-LEU	C	3.92
C5	278-LEU	CD1	4.05
C19	278-LEU	CD1	4.04
C7	278-LEU	CD2	4.09
C9	278-LEU	CD2	3.95
C11	278-LEU	CD2	4.13
N1	278-LEU	CD2	4.17
C13	277-SER	N	4.14
C15	277-SER	N	3.78

Appendix 2

	Dimit Atom	Amino Acid in full length α	Atom	Distance A
5	C17	277-SER	N	3.69
	N1	277-SER	N	3.30
	O3	277-SER	N	3.19
	C17	277-SER	CA	3.92
	O3	277-SER	CA	3.35
10	C13	277-SER	OG	3.92
	C7	287-LEU	CO2	3.90
	C18	290-GLY	C	4.04
	C18	290-GLY	O	3.54
	C18	291-GLY	CA	4.04
15	C18	292-LEU	N	4.20
	C2	292-LEU	CG	4.18
	C4	292-LEU	CG	3.88
	C6	292-LEU	CG	4.01
	C2	292-LEU	CD1	3.88
20	C4	292-LEU	CD1	4.02
	O2	292-LEU	CD1	4.07
	C4	292-LEU	CD2	4.05
	C6	292-LEU	CD2	3.72
	C8	292-LEU	CD2	3.69
25	C10	292-LEU	CD2	3.98
	O1	292-LEU	CD2	4.16
	C20	299-ILE	CD1	3.87
	C8	381-HIS	CD2	3.90
	C10	381-HIS	CD2	3.84
30	O1	381-HIS	GO2	3.40
	O1	381-HIS	CE1	3.72
	C8	381-HIS	NE2	3.47
	C10	381-HIS	NE2	3.51
	O1	381-HIS	NE2	2.64
35	C8	388-MET	CE	3.90
	C8	401-PHE	CE1	4.19
	O1	401-PHE	CE1	3.37
	C16	401-PHE	CZ	3.97
	O1	401-PHE	CZ	3.28
40	C17	3-H ₂ O	O1	3.77
	O3	502	O1	3.13
	O4	3-H ₂ O	O1	3.72
	C15	2-H ₂ O	O1	4.04
	C17	2-H ₂ O	O1	3.84
45	N1	2-H ₂ O	O1	3.35
	O3	503	O1	2.56
	C17	4-H ₂ O	O1	3.92
	O4	504	O1	2.72

Legend to Table XX. The table lists the interactions with Dimit (DMT). The column headings

are as follows:

#1 The atom of Dimit that interacts with the amino acid of the receptor. These are also numbered in figure X.

#2 The amino acid in the full length rTR α that interacts with the ligand.

#3 The name of the atom in the amino acid (standard nomenclature) where the interaction occurs.

#4 The distance in A between Dimit and the protein atom.

	Triac Atom	Amino Acid in full length α	Amino Acid At m	Distance A
5	I1	218-PHE	O	3.52
	I1	221-ILE	CD1	4.16
	I1	222-ILE	CA	4.15
	I1	222-ILE	CB	4.03
	I1	221-ILE	CG1	3.92
10	C8	222-ILE	CD1	4.12
	C10	222-ILE	CD1	3.77
	C12	222-ILE	CD1	3.79
	C13	225-ALA	CB	4.17
	C3	225-ALA	CB	3.86
15	C10	258-MET	SD	3.45
	C12	258-MET	SD	3.73
	C10	258-MET	CE	3.66
	C12	256-MET	CE	3.77
	C11	256-MET	C	3.68
20	C11	256-MET	O	3.24
	C1	259-MET	O	3.93
	C11	259-MET	O	3.24
	O3	259-MET	O	4.09
	C1	259-MET	CB	3.89
25	C13	259-MET	O	3.74
	C14	259-MET	O	3.96
	C1	259-MET	CB	3.89
	C11	259-MET	CB	3.68
	C13	259-MET	CB	4.01
30	C14	262-ARG	CB	4.07
	O4	262-ARG	CB	3.60
	C17	282-ARG	CD	
	O4	262-ARG	CD	
	O3	263-ALA	N	3.79
35	O3	263-ALA	CA	3.67
	O3	283-ALA	CB	3.49
	C11	107-ALA	CB	4.00
	O3	107-ALA	CB	3.49
	O3	266-ARG	NH1	3.00
40	O3	275-THR	O	3.20
	O3	278-LEU	CA	3.11
	N1	276-LEU	C	3.52
	O3	120-LEU	N	4.04
	C14	120-LEU	CA	3.98
45	O3	120-LEU	CA	3.11
	C14	120-LEU	C	3.98
	O3	120-LEU	CB	3.95
	O2	276-LEU	CD1	4.03
	I1	276-LEU	CD1	4.10
50	C7	276-LEU	CD2	3.84
	C9	276-LEU	CD2	3.73
	C11	276-LEU	CD2	4.06
	O2	276-LEU	CD2	4.10

	Triac At m	Amino Acid in full length α	Amino Acid Atom	Distance A
	C13	277-SER	N	4.06
	C14	277-SER	N	3.13
	O4	277-SER	N	3.28
	O3	277-SER	N	3.05
5	C14	277-SER	CA	3.76
	O4	277-SER	CA	3.52
	C3	277-SER	OG	3.87
	I2	290-GLY	O	3.57
	I2	292-LEU	CG	3.94
10	C4	292-LEU	CG	3.95
	C6	292-LEU	CG	3.65
	C2	292-LEU	CD1	4.11
	C4	292-LEU	CD1	3.85
	I2	292-LEU	CD2	3.98
15	C4	292-LEU	CD2	4.11
	C6	292-LEU	CD2	3.44
	C8	292-LEU	CD2	3.28
	C10	292-LEU	CD2	3.88
	O1	292-LEU	CD2	3.35
20	I3	299-ILE	CD1	3.77
	C8	381-HIS	CD2	3.87
	C10	381-HIS	CD2	3.90
	O1	381-HIS	GO2	3.20
	O1	381-HIS	CE1	3.81
25	C8	381-HIS	NE2	3.51
	C10	381-HIS	NE2	3.52
	O1	381-HIS	NE2	2.64
	O1	388-MET	CE	4.03
	O1	401-PHE	CE1	3.86
30	O1	401-PHE	CZ	3.70

Legend to Table XX. The table lists the interactions with triac. The column headings are as follows:

#1 The atom of triac that interacts with the amino acid of the receptor. These are also numbered in figure X.

#2 The amino acid in the full length rTR α that interacts with the ligand.

#3 The name of the atom in the amino acid (standard nomenclature) where the interaction occurs.

#4 The distance in A between triac and the protein atom.

	lpBR ₂ At m	Amino Acid in full length α	Amino Acid At m	Distance A
5	C16	215-PHE	CD1	4.01
	C16	215-PHE	CE1	3.78
	BR1	218-PHE	O	3.24
	BR1	218-PHE	C	3.98
	C16	218-PHE	CB	3.81
10	C18	218-PHE	CB	3.92
	BR1	218-PHE	CB	4.08
	C18	218-PHE	CD2	3.92
	C18	219-THR	CG2	3.45
	BR1	221-ILE	CG1	3.81
15	BR1	221-ILE	CD1	4.07
	C6	222-ILE	CD1	4.07
	C8	222-ILE	CD1	3.64
	C10	222-ILE	CD1	3.50
	C12	222-ILE	CD1	3.82
20	O1	222-ILE	CD1	4.08
	C13	225-ALA	CB	3.76
	O4	225-ALA	CB	4.01
	O4	228-ARG	CZ	3.92
	C17	228-ARG	NH2	3.26
25	O3	228-ARG	NH2	3.43
	O4	228-ARG	NH2	2.79
	C10	256-MET	SD	3.65
	C12	256-MET	SD	3.71
	C10	256-MET	CE	3.90
30	C12	256-MET	CE	3.75
	BR2	256-MET	CE	4.03
	C11	259-MET	C	3.98
	C11	259-MET	O	3.52
	C15	259-MET	O	3.44
	N1	259-MET	O	3.76
	C11	259-MET	CB	3.87
	C15	262-ARG	CB	4.03

	IpBR ₂ Atom	Amino Acid in full length α	Amino Acid Atom	Distance A
5	C17	262-ARG	CB	3.56
	O3	262-ARG	CB	3.55
	O4	262-ARG	CB	3.91
	C17	262-ARG	CD	4.09
	O4	262-ARG	CD	3.71
10	N1	263-ALA	N	3.61
	N1	263-ALA	CA	3.59
	N1	263-ALA	CB	3.54
	O3	268-ARG	NH1	3.93
	N1	275-THR	O	3.43
15	N1	276-LEU	CA	3.46
	N1	276-LEU	C	3.83
	C5	276-LEU	CD1	4.02
	C7	276-LEU	CD2	4.00
	C9	276-LEU	CD2	3.81
20	C11	276-LEU	CD2	3.91
	C13	277-SER	N	3.79
	C15	277-SER	N	3.63
	C17	277-SER	N	3.70
	N1	277-SER	N	3.17
25	O3	277-SER	N	3.37
	C17	277-SER	CA	3.89
	O3	277-SER	CA	3.43
	C13	277-SER	OG	3.66
	O2	287-LEU	CD1	4.05
30	C18	290-GLY	C	4.04
	C18	290-GLY	O	3.48
	C18	291-GLY	CA	4.02
	C4	292-LEU	CG	3.89
	C6	292-LEU	CG	4.02
	C2	292-LEU	CD1	3.79
	C4	292-LEU	CD1	3.96
	O2	292-LEU	CD1	3.97

	IpBr ₂ Atom	Amino Acid in full length α	Amino Acid Atom	Distance A
5	C4	292-LEU	CD2	4.07
	C6	292-LEU	CD2	3.75
	C8	292-LEU	CD2	3.67
	C10	292-LEU	CD2	3.92
	BR2	299-ILE	CD1	3.68
10	C8	361-HIS	CD2	3.67
	C10	381-HIS	CD2	3.92
	O1	381-HIS	GD2	3.50
	O1	381-HIS	CE1	3.62
	C8	381-HIS	NE2	3.36
15	C10	381-HIS	NE2	3.34
	O1	381-HIS	NE2	2.62
	C8	401-PHE	CE1	4.02
	O1	401-PHE	CE1	3.19
	C16	401-PHE	CZ	4.03
20	O1	401-PHE	CZ	3.06
	C17	3-H ₂ O	O1	
	O3	502H ₂ O	O1	3.40
	O4	3-H ₂ O	O1	
	C15	2-H ₂ O	O1	
25	C17	2-H ₂ O	O1	
	N1	502H ₂ O	O1	3.12
	O3	503H ₂ O	O1	2.27
	C17	4-H ₂ O	O1	
	O4	504H ₂ O	O1	1.78

Legend to Table XX. The table lists the interactions with IpBr₂. The column headings are as follows:

- #1 The atom of IpBr₂ that interacts with the amino acid of the receptor. These are also numbered in figure X.
- #2 The amino acid in the full length rTR α that interacts with the ligand.
- #3 The name of the atom in the amino acid (standard nomenclature) where the interaction occurs.
- #4 The distance in A between IpBr₂ and the protein atom.

	T3 Atom	Amino Acid in full length α	Amino Acid Atom	<u>Distance</u> A
5	I2	215-PHE	CD1	4.08
	I1	218-PHE	O	3.19
	I1	218-PHE	CB	3.99
	C4	218-PHE	CB	4.04
	I1	218-PHE	CB	3.99
10	I1	221-ILE	CG1	4.01
	C8	222-ILE	CD1	3.99
	C10	222-ILE	CD1	3.99
	C12	222-ILE	CD1	3.57
	O1	222-ILE	CD1	3.68
15	C13	225-ALA	CB	3.66
	C3	225-ALA	CB	4.04
	O4	228-ARG	NH1	3.23
	O4	228-ARG	CZ	3.45
	C15	228-ARG	NH2	3.54
20	O3	228-ARG	NH2	3.90
	O4	228-ARG	NH2	2.86
	C10	256-MET	SD	3.73
	C12	256-MET	SD	3.90
	C10	256-MET	CE	3.97
25	C12	256-MET	CE	3.92
	C11	259-MET	C	3.95
	C11	259-MET	O	3.59
	C14	259-MET	O	3.51
	N1	259-MET	O	3.88
30	C1	259-MET	CB	4.06
	C11	259-MET	CB	3.77
	C13	259-MET	CB	3.96
	C15	262-ARG	CB	3.61
	C14	262-ARG	CB	4.02
	O3	262-ARG	CB	3.65
	O4	262-ARG	CB	3.92
	O4	282-ARG	CD	3.72

	T3 Atom	Amino Acid in full length α	Amino Acid Atom	<u>Distance</u> A
5	N1	263-ALA	N	3.81
	N1	263-ALA	CA	3.81
	N1	263-ALA	CB	3.63
	N1	275-THR	O	3.54
	N1	276-LEU	CA	3.38
10	N1	276-LEU	C	3.73
	C5	276-LEU	CD1	4.00
	C7	276-LEU	CD1	4.05
	C7	276-LEU	CD2	3.80
	C9	276-LEU	CD2	3.70
15	C11	276-LEU	CD2	4.01
	C14	277-SER	N	3.67
	C15	277-SER	N	3.62
	O4	228-ARG	NH1	3.23
	N1	277-SER	N	3.07
20	O3	277-SSER	N	3.24
	C15	277-SER	CA	3.77
	O3	277-SER	CA	3.34
	C13	277-SER	OG	3.92
	I2	290-GLY	O	3.50
25	C4	292-LEU	CG	3.95
	C8	292-LEU	CG	3.83
	C2	292-LEU	CD1	4.07
	C4	292-LEU	CD1	3.99
	C4	292-LEU	CD2	4.09
30	C6	292-LEU	CD2	3.58
	C8	292-LEU	CD2	3.50
	C10	292-LEU	CD2	3.96
	O1	292-LEU	CD2	3.71
	I3	299-ILE	CD1	3.74
	C8	381-HIS	CD2	3.94
	C10	381-HIS	CD2	3.97
	O1	381-HIS	CD2	3.39

	T3 Atom	Amino Acid in full length α	Amino Acid Atom	Distance
				A
5	O1	381-HIS	CD1	3.82
	C8	381-HIS	NE2	3.47
	C10	381-HIS	NE2	3.55
	O1	381-HIS	NE2	2.70
	O1	388-MET	CE	3.88
	O1	401-PHE	CE1	3.52
	O1	401-PHE	CZ	3.32
	O3	502	O1	2.51
10	O4	3-H ₂ O	O1	
	N1	2-H ₂ O	O1	
	O3	503	O1	2.81
	O4	504	O1	2.73

- Legend to Table XX. The table lists the interactions with T3. The column headings are as follows:
- 15 #1 The atom of T3 that interacts with the amino acid of the receptor. These are also numbered in figure X.
- #2 The amino acid in the full length rTR α that interacts with the ligand.
- #3 The name of the atom in the amino acid (standard nomenclature) where the interaction
- 20 occurs.
- #4 The distance in A between T3 and the protein atom.

Coordination Structure of Thyroid Hormone Receptor and Dimit

Coordination Structure	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂	X
	-CH ₂ -CH(NH ₂)(CO ₂)H	-H	-CH ₃	-CH ₃	-H	-H	-CH(CH ₃) ₂	-OH	-H	-H	-H	O	
Amino Acid								215					
Secondary Structure								H3					
Amino Acid			218					218					
Secondary Structure			H3					H3					
Amino Acid								219					
Secondary Structure								H3					
Amino Acid			221										
Secondary Structure			H3										
Amino Acid								222	222	222	222		
Secondary Structure								H3	H3	H3	H3		
Amino Acid	225												
Secondary Structure	H3												
Amino Acid	228												
Secondary Structure	H3												
Amino Acid										258	258		
Secondary Structure										H5-H8	H5-H8		
Amino Acid	259				259								
Secondary Structure	H5-H8				H5-H8								
Amino Acid	282												
Secondary Structure	H5-H8												
Amino Acid	283												
Secondary Structure	H5-H8												
Amino Acid	268												
Secondary Structure	loop												
Amino Acid	275												
Secondary Structure	S3												
Amino Acid	278		278	278	278								
Secondary Structure	S3		S3	S3	S3								
Amino Acid	277												
Secondary Structure													
Amino Acid								290-291					
Secondary Structure								loop					
Amino Acid						292	292	292	292			292	
Secondary Structure						loop	loop	loop	loop			loop	
Amino Acid				299									
Secondary Structure				H8									
Amino Acid								381	381				
Secondary Structure								H11	H11				
Amino Acid								388					
Secondary Structure								H11					
Amino Acid								401	401				
Secondary Structure								H12	H12				
Amino Acid	HOHSO ₂ , HOHSO ₃ , HOHSO ₄												
Secondary Structure													

Coordination Structure of Thyroid Hormone Receptor and Triac

Coordination Structure	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	X
	-CH ₂ COOH	-H	-I	-I	-H	-H	-I	-OH	-H	-H		O
Amino Acid							215					
Secondary Structure							H3					
Amino Acid			218				218					
Secondary Structure			H3				H3					
Amino Acid							219					
Secondary Structure							H3					
Amino Acid			221									
Secondary Structure			H3									
Amino Acid							222	222	222	222		
Secondary Structure							H3	H3	H3	H3		
Amino Acid	225											
Secondary Structure	H3											
Amino Acid	228											
Secondary Structure	H3											
Amino Acid									258	258		
Secondary Structure									H5-H8	H5-H8		
Amino Acid	259				259							
Secondary Structure	H5-H8				H5-H8							
Amino Acid	282											
Secondary Structure	H5-H8											
Amino Acid	283											
Secondary Structure	H5-H8											
Amino Acid	268											
Secondary Structure	loop											
Amino Acid	275											
Secondary Structure	S3											
Amino Acid	278		278	278	278							
Secondary Structure	S3		S3	S3	S3							
Amino Acid	277											
Secondary Structure												
Amino Acid							290-291					
Secondary Structure							loop					
Amino Acid						292	292	292	292			292
Secondary Structure						loop	loop	loop	loop			loop
Amino Acid				299								
Secondary Structure				H8								
Amino Acid								381	381			
Secondary Structure								H11	H11			
Amino Acid							388					
Secondary Structure							H11					
Amino Acid							401	401				
Secondary Structure							H12	H12				
Amino Acid	HOHSO ₂ , HOHSO ₃ , HOHSO ₄											
Secondary Structure												

Coordination Structure of Thyroid Hormone Receptor and IpBr2


Coordination Structure	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂	X
	-CH ₂ -CH(NH ₂)(CO ₂)H	-H	-Br	-Br	-H	-H	-CH(CH ₃) ₂	-OH	-H	-H	-H	O	
Amino Acid							215						
Secondary Structure							H3						
Amino Acid			218				218						
Secondary Structure			H3				H3						
Amino Acid							219						
Secondary Structure							H3						
Amino Acid			221										
Secondary Structure			H3										
Amino Acid							222	222	222	222			
Secondary Structure							H3	H3	H3	H3			
Amino Acid	225												
Secondary Structure	H3												
Amino Acid	228												
Secondary Structure	H3												
Amino Acid									258	258			
Secondary Structure									H5-H8	H5-H8			
Amino Acid	259				259								
Secondary Structure	H5-H8				H5-H8								
Amino Acid	282												
Secondary Structure	H5-H8												
Amino Acid	283												
Secondary Structure	H5-H8												
Amino Acid	268												
Secondary Structure	loop												
Amino Acid	275												
Secondary Structure	S3												
Amino Acid	278		278	278	278								
Secondary Structure	S3		S3	S3	S3								
Amino Acid	277												
Secondary Structure													
Amino Acid							290-291						
Secondary Structure							loop						
Amino Acid						292	292	292	292			292	
Secondary Structure						loop	loop	loop	loop			loop	
Amino Acid				299									
Secondary Structure				H8									
Amino Acid								381	381				
Secondary Structure								H11	H11				
Amino Acid							388						
Secondary Structure							H11						
Amino Acid							401	401					
Secondary Structure							H12	H12					
Amino Acid	HOH502, HOH503, HOH504												
Secondary Structure													

Coordination Structure of Thyroid Hormone Receptor and T3

Coordination Structure	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	X
	-CH ₂ -CH(NH ₂)(CO ₂)H	-H	-I	-I	-H	-H	-I	-OH	-H	-H	-H	O
Amino Acid							215					
Secondary Structure							H3					
Amino Acid			218				218					
Secondary Structure			H3				H3					
Amino Acid							219					
Secondary Structure							H3					
Amino Acid			221									
Secondary Structure			H3									
Amino Acid							222	222	222	222		
Secondary Structure							H3	H3	H3	H3		
Amino Acid	225											
Secondary Structure	H3											
Amino Acid	228											
Secondary Structure	H3											
Amino Acid									258	258		
Secondary Structure									H5-H8	H5-H8		
Amino Acid	259				259							
Secondary Structure	H5-H8				H5-H8							
Amino Acid	262											
Secondary Structure	H5-H8											
Amino Acid	263											
Secondary Structure	H5-H8											
Amino Acid	266											
Secondary Structure	loop											
Amino Acid	275											
Secondary Structure	S3											
Amino Acid	278		278	278	278							
Secondary Structure	S3		S3	S3	S3							
Amino Acid	277											
Secondary Structure												
Amino Acid							290-291					
Secondary Structure							loop					
Amino Acid						292	292	292	292		292	
Secondary Structure						loop	loop	loop	loop		loop	
Amino Acid				299								
Secondary Structure				H8								
Amino Acid								381	381			
Secondary Structure								H11	H11			
Amino Acid								388				
Secondary Structure								H11				
Amino Acid								401	401			
Secondary Structure								H12	H12			
Amino Acid	HOH5C2 HOH5C3 HOH5C4											
Secondary Structure												

WHAT IS CLAIMED IS:

1. A crystal of a TR LBD comprising:
 - 1) a TR LBD and a TR LBD ligand or
 - 2) a TR LBD without a TR LBD ligand;
- 5 wherein said crystal diffracts with at least a 2.0 to 3.0 angstrom resolution and has a crystal stability within 5% of its unit cell dimensions.
2. The crystal of claim 1, wherein said TR LBD has at least 200 amino acids.
- 10 3. The crystal of claim 2, wherein said TR LBD is from a TR protein selected from the group consisting of TR amino acid sequence 122 to 410 of rat TR- α , 157 to 410 rat TR- α and 202 to 461 of human TR- β .
4. The crystal of claim 2, wherein said TR LBD ligand is a compound being of a
15 formula:



wherein R₁ is

- O-CH₂CO₂H, -NHCH₂CO₂H,
- 30 -CO₂H, -CH₂CO₂H, -CH₂CH₂CO₂H, -CH₂CH₂CH₂CO₂H,

-CH₂CH(NH₂)CO₂H, -CH₂CH[NHCOCH ϕ ₂]CO₂H, -CH₂CH[NHCO(CH₂)₁₅CH₃]
CO₂H, -CH₂CH[NH-FMOC]CO₂H, -CH₂CH[NH-tBOC]CO₂H, or a carboxylate
connected to the ring with a 0 to 3 carbon linker,

5 -PO₃H₂, -CH₂PO₃H₂, -CH₂CH₂PO₃H₂, -CH₂CHNH₂PO₃H₂,
-CH₂CH[NHCOCH ϕ ₂]PO₃H₂, -CH₂CH[NHCO(CH₂)₁₅CH₃]PO₃H₂,
-CH₂CH[NH-FMOC]PO₃H₂, -CH₂CH[NH-tBOC]PO₃H₂, or a phosphate or
phosphonate connected to the ring with a 0 to 3 carbon linker,

10 -SO₃H, -CH₂SO₃H, -CH₂CH₂SO₃H, -CH₂CHNH₂SO₃H,
-CH₂CH[NHCOCH ϕ ₂]SO₃H, -CH₂CH[NHCO(CH₂)₁₅CH₃]SO₃H,
-CH₂CH[NH-FMOC]SO₃H, -CH₂CH[NH-tBOC]SO₃H, or a sulfate or sulfite
connected to the ring with a 0 to 3 carbon linker,

15 or acts as the functional equivalent of CH₂CH(NH₂)CO₂H of T3 in the molecular
recognition domain when bound to a TR, wherein said R₁ can be optionally
substituted with an amine,

wherein R₂ is

20

H, halogen, CF₃, OH, NH₂, SH, CH₃, -Et,
or acts as the functional equivalent of H in the molecular recognition domain when
bound to a TR,

25 wherein R₃ is

-H, halogen, -CF₃, -OH, -NH₂, -N₃, -SH, -CH₃, -Et,
or acts as the functional equivalent of I in the molecular recognition domain when
bound to a TR,

30

wherein R₅ is

-H, halogen, -CF₃, -OH, -NH₂, -N₃, -SH, -CH₃, -Et, or acts as the functional equivalent of I in the molecular recognition domain when bound to a TR, and R₃ can be identical to R₅,

5 wherein R₆ is

-H, halogen, -CF₃, -OH, -NH₂, -SH, -CH₃, or acts as the functional equivalent of H in the molecular recognition domain when bound to a TR, and R₂ can be identical to R₆,

10

wherein R₂' is

-H, halogen, -CF₃, -OH, -NH₂, -N₃, -SH, -CH₃, -Et, or acts as the functional equivalent of H in the molecular recognition domain when bound to a TR,

15

wherein R₃' is any hydrophobic group, including

halogen, -CF₃, -SH, alkyl, aryl, 5- or 6-membered heterocyclic, cyano, or acts as the functional equivalent of I in the molecular recognition domain when bound to a
20 TR,

wherein R₄' is

25

-H, halogen, -CF₃, -OH, -NH₂, NH₃, -N(CH₃)₃, carboxylate, phosphonate, phosphate or sulfate, -SH, -CH₃, -Et, or alkyl, aryl or 5- or 6-membered heterocyclic aromatic attached through urea or carbamate linkages to O or N or S at the R₄' position, or acts as the functional equivalent of OH in the molecular recognition domain when bound to a TR,

30 wherein R₅' is

-H, -OH, -NH₂, -N(CH₃)₂, -SH, -NH₃, -N(CH₃)₃, carboxylate, phosphonate, phosphate, sulfate, branched or straight chain alkyl having 1 to 9 carbons, substituted or unsubstituted aryl, wherein said substituted aryl is substituted with halogen or 1 to 5 carbon alkyl and wherein said aryl is optionally connected to the ring by a -CH₂-, aromatic heterocycle having 5 to 6 atoms, wherein said heterocycle may be substituted with one or more groups selected from -OH, -NH₂, -SH, -NH₃, -N(CH₃)₃, carboxylate, phosphonate, phosphate, sulfate, heteroalkyl, heteroaryl, arylalkyl, heteroaryl alkyl, polyaromatic, polyheteroaromatic, wherein said R₅' may be substituted with polar or charged groups,

10

wherein R₆' is

-H, halogen, -CF₃, -OH, -NH₂, -SH, -CH₃, -Et, or acts as the functional equivalent of H in the molecular recognition domain when bound to a TR,

15

wherein X is

O, S, SO₂, NH, NR₇, CH₂, CHR₇, CR₇R₇, wherein R₇ is alkyl, aryl or 5- or 6-membered heterocyclic aromatic,

20 and wherein said TR LBD ligand has an apparent K_d for binding TR LBD of 1 μM or less.

5. The crystal of claim 2, wherein said crystal of TR LBD ligand has the following unit cell dimensions in angstroms: a=117.00 ± 2%, b=80.00 ± 2%, c=63.00 ± 2%, at a β angle of 120.00 ± 2% degrees and a monoclinic space group C2.

25

6. The crystal of claim 5, wherein said crystal coordinates said TR LBD ligand and said crystal is selected from the group consisting of crystals having one of the following sets of properties:

30

- 1) unit cell dimensions in angstroms: $a=117.16$, $b=80.52$, $c=63.21$, at a β angle of 120.58 degrees, a monoclinic space group C2, 2.2 angstrom resolution and completeness value of 87.0%,
- 5 2) unit cell dimensions in angstroms: $a=117.19$, $b=80.20$, $c=63.23$, at a β angle of 120.60 degrees, a monoclinic space group C2, 2.0 angstrom resolution and completeness value of 82.4%, and
- 10 3) unit cell dimensions in angstroms: $a=117.18$, $b=80.12$, $c=63.13$, at a β angle of 120.69 degrees, a monoclinic space group C2, 2.2 angstrom resolution and completeness value of 93.7%.
7. The crystal of claim 2, wherein said crystal further comprises a human protein.
- 15 8. The crystal of claim 7, wherein said crystal has the following unit cell dimensions in angstroms: $a=b=68.448 \pm 2\%$ and $c=130.559 \pm 2\%$ at an α angle of 90.00° , a β angle of 90.00° and a γ angle of 120.00° and having a trigonal space group $p3(1)21$.
9. The crystal of claim 8, wherein said crystal further comprises a human protein.
- 20 10. A computational method of designing a nuclear receptor synthetic ligand comprising:
 - 1) using a three dimensional model of a crystallized protein comprising a nuclear receptor LBD with a bound ligand to determine at least one interacting amino acid of the nuclear receptor LBD that interacts with at least one first chemical moiety of said bound
 - 25 ligand, and
 - 2) selecting at least one chemical modification of said first chemical moiety to produce a second chemical moiety with a structure that either decreases or increases an interaction between said interacting amino acid and said second chemical moiety compared to said interaction between said interacting amino acid and said first chemical
 - 30 moiety.
11. The method of claim 10, wherein steps 1 and 2 are repeated.

12. The method of claim 10, further comprising generating said three dimensional model of said crystallized protein comprising a TR LBD with a bound TR ligand.

13. The method of claim 12, wherein said three dimensional model is generated by
5 comparing isomorphous ligand derivatives to produce improved phasing.

14. The method of claim 13, wherein said isomorphous ligand derivatives are provided by substituting at least one of the R5, R3, 'R5 and 'R3 positions of a thyronine derivative with Br or I.

10

15. The method of claim 14, further comprising determining a change in interaction between said interacting amino acid and said ligand after chemical modification of said first chemical moiety.

15 16. The method of claim 12, wherein said selecting uses said first chemical moiety that interacts with at least one of the said interacting amino acids listed in APPENDIX 2.

17. The method of claim 16, wherein said chemical modification enhances hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van Der Waals
20 interaction or dipole interaction between said second chemical moiety and said interacting amino acid compared to said first chemical moiety and said interacting amino acid.

18. The method of claim 17, wherein said chemical modification reduces hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van Der Waals
25 interaction or dipole interaction between said second chemical moiety and said interacting amino acid compared to said first chemical moiety and said interacting amino acid.

19. The method of claim 18, wherein said first chemical moiety is at least 4.5 angstroms away from at least one distant amino acid and said distant amino acid is not
30 any of the said interacting amino acids listed in claim 17.

20. The method of claim 18, wherein said first chemical moiety is 6 to 12 angstroms away from a distant amino acid.

21. The method of claim 19, wherein said chemical modification extends toward said
5 distant amino acid and produces hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van Der Waals interaction or dipole interaction between said second chemical moiety and said distant amino acid.

22. The method of claim 19, wherein said chemical modification sterically hinders said
10 distant amino acids from binding other amino acids but does not sterically hinder said interacting amino acids.

23. The method of claim 17 or 19 further comprising determining a change in interaction between said interacting amino acid and said ligand after said chemical
15 modification, wherein said determining and modifying are performed using a computer program to represent chemical structures of said interacting amino acid and ligand.

24. The method of claim 22, wherein said chemical modification is at a R₃' position of a thyronine derivative.
20

25. The method of claim 24, wherein said chemical modification sterically hinders activation helix function.

26. The method of claim 25, wherein said chemical modification does not interfere
25 with an interaction between said interacting amino acid and an atom from R 1 to 6 positions of said ligand.

27. The method of claim 26, wherein said activation helix is helix H12.

30 28. The method of claim 27, wherein said chemical modification comprises a planar structure, equivalent in length to at least a 3 carbon alkyl that projects out from the plane of the prime-ring of said thyronine derivative at least 30°.

29. The method of claim 10 further comprising generating said three dimensional model of a nuclear receptor other than TR using said nuclear receptor's LBD amino acid sequence and using said crystallized protein comprising a TR LBD with a bound TR LBD ligand.

5

30. The method of claim 29, wherein said chemical modification enhances hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van Der Waals interaction or dipole interaction between said second chemical moiety and said interacting amino acid compared to said first chemical moiety and said interacting amino acid.

10

31. The method of claim 30, wherein said chemical modification reduces hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van Der Waals interaction or dipole interaction between said second chemical moiety and said interacting amino acid compared to said first chemical moiety and said interacting amino acid.

15

32. The method of claim 31, wherein said chemical modification is only of said first chemical moiety that is at least 3 angstroms away from at least one distant amino acid and said distant amino acid is different from said interacting amino acid.

20 33. The method of claim 33, wherein said first chemical moiety is 4 to 12 angstroms away from a distant amino acid.

34. The method of claim 33, wherein said chemical modification extends toward said distant amino acid and produces hydrogen bonding interaction, charge interaction,
25 hydrophobic interaction, Van Der Waals interaction or dipole interaction between said second chemical moiety and said distant amino acid.

35. The method of claim 34, wherein said chemical modification sterically hinders said distant amino acids from binding other amino acids but does not sterically hinder said
30 interacting amino acids.

36. The method of claim 35, wherein said first chemical moiety comprises C-H or C-OH.
37. The method of claim 36, wherein said second chemical moiety comprises a longest entity equivalent to at least 4 double bonded carbons in length and a volume of at least 4
5 double bonded carbons.
38. A computational method of designing a nuclear receptor antagonist from a nuclear receptor agonist comprising:
- 1) determining a structure of a molecular recognition domain of said agonist using
10 a three dimensional model of a crystallized protein comprising a nuclear receptor LBD, and
 - 2) selecting at least one chemical modification of said agonist that provides a ligand structure that extends beyond a binding site for said agonist and in the direction of at least one protein domain important in nuclear receptor function.
- 15
39. The method of claim 38, wherein said protein domain is either:
- a) a transcription activation domain of said LBD,
 - b) a repressor binding domain of said LBD,
 - c) a DNA binding domain of said nuclear receptor,
 - 20 d) a heat shock protein binding domain of said nuclear receptor,
 - e) a dimerization domain of said LBD, or
 - f) a hinge region to said DNA binding domain.
40. The method of claim 38, wherein said crystallized protein comprises said nuclear
25 receptor LBD bound to a nuclear receptor ligand.
41. The method of claim 40 further comprising generating said three dimensional model of said crystallized protein comprising a TR LBD with a bound TR ligand.
- 30 42. The method of claim 40 wherein said three dimensional model is for a TR LBD.
-

43. The method of claim 41 further comprising generating said three dimensional model of a nuclear receptor other than TR using said nuclear receptor's LBD amino acid sequence.

5 44. The method of claim 39 wherein said three dimensional model is for an ER LBD.

45. The method of claim 42 wherein said LBD is from a receptor selected from a group consisting of glucocorticoid receptor, estrogen receptor, retinoid receptor and vitamin D receptor.

10

46. The method of claim 39, wherein said chemical modification minimizes a loss of hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van Der Waals interaction or dipole interaction between said molecular recognition domain and said antagonist compared agonist hydrogen bonding interaction, charge interaction, 15 hydrophobic interaction or dipole interaction with said molecular recognition domain.

47. The method of claim 39, wherein said chemical modification reduces hydrogen bonding interaction, charge interaction, hydrophobic interaction or dipole interaction between said molecular recognition domain and said antagonist compared with the agonist 20 hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van Der Waals interaction or dipole interaction with said molecular recognition domain but said chemical modification still permits said antagonist to bind to said nuclear receptor with an affinity of 100nM Kd or less.

25 48. The method of claim 39 or 47, wherein said molecular recognition domain is at least 3 angstroms away from at least one distant amino acid and said distant amino acid does not contribute significantly to binding said molecular recognition domain.

49. The method of claim 48, wherein said first molecular recognition domain is 4 to 30 12 angstroms away from a distant amino acid.

50. The method of claim 49, wherein said chemical modification extends toward said distant amino acid and produces a hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van Der Waals interaction or dipole interaction between said distant amino acid and said molecular recognition domain.

5

51. The method of claim 50, wherein said chemical modification sterically hinders said distant amino acids from binding other amino acids but does not sterically hinder amino acids that bind said molecular recognition domain.

10 52. The method of claim 51, wherein said chemical modification of said ligand is at a C-H or C-OH.

53. The method of claim 52, wherein said second chemical modification consists of a longest entity equivalent to at least 4 double bonded carbons in length and has volume of
15 at least 4 double bonded carbons in length.

54. The method of claim 44, wherein said three dimensional model is represented in two dimensions.

20 55. A computational method of designing a nuclear receptor super agonist or antagonist comprising:

1) determining at least one interacting amino acid of a nuclear receptor LBD that interacts with at least one first chemical moiety of said ligand using a three dimensional model of a crystallized protein comprising a nuclear receptor LBD with a bound ligand,

25 and

2) selecting at least one chemical modification of said first chemical moiety to produce a second chemical moiety with a structure to reduce or enhance an interaction between said interacting amino acid and said second chemical moiety compared to said interaction between said interacting amino acid and said first chemical moiety.

30

56. The method of claim 55, wherein said chemical modification enhances hydrogen bonding interaction, electrostatic interaction, charge interaction, hydrophobic interaction,

Van Der Waals interaction or dipole interaction between said second chemical moiety and said interacting amino acid compared to said first chemical moiety and said interacting amino acid.

5 57. The method of claim 55, wherein said chemical modification changes a carboxylate moiety of said first chemical moiety to a phosphonate or phosphate to make said second chemical moiety.

58. The method of claim 55, wherein said nuclear receptor is TR and said chemical
10 modification enhances said interaction between said second chemical moiety and at least one of the following arginines: Arg 262, Arg 266 or Arg 228 of the rat α -TR or an arginine of human α -TR or β -TR that corresponds in its three dimensional position in said three dimensional model to either said arginines: Arg 262, Arg 266 or Arg 228.

15 59. The method of claim 58, wherein said chemical modification changes a side group to fill space normally occupied by water when an agonist or naturally occurring ligand is bound to said LBD.


60. The method of claim 59, wherein said chemical modification snugly fits into a
20 pocket or surface of a binding cavity of said LBD and complements to a charge or hydrophobicity or both of said pocket or surface.

61. The method of claim 60, wherein said chemical modification changes said first
chemical moiety either a first carbon bonded either to 1) a first phenyl at R1 of T3 or 2)
25 a first phenyl at R1 of a T3 agonist with a T3 carboxylate group to a second chemical moiety a two carbon space group.

62. The method of claim 55, wherein said chemical modification changes said first
chemical moiety either 1) a carbon linking a first phenyl at R4 of T3 to a second phenyl
30 ring of T3 or 2) a carbon linking a first phenyl at R4 of a T3 agonist with a second phenyl ring of said T3 agonist to a second chemical moiety mono- or geminal-substituted carbon group.

63. The method of claim 55, wherein said chemical modification changes said first chemical moiety either 1) a carbon linking a first phenyl at R4 of T3 to a second phenyl ring of T3 or 2) a carbon linking a first phenyl at R4 of a T3 agonist with a second phenyl ring of said T3 agonist.

64. A compound of the formula:



wherein R_1 is

-O-CH₂CO₂H, -NHCH₂CO₂H,
 -CO₂H, -CH₂CO₂H, -CH₂CH₂CO₂H, -CH₂CH₂CH₂CO₂H,
 -CH₂CH(NH₂)CO₂H, -CH₂CH[NHCOCH₂]₂CO₂H, -CH₂CH[NHCO(CH₂)₁₅CH₃]
]CO₂H, -CH₂CH[NH-FMOC]CO₂H, -CH₂CH[NH-tBOC]CO₂H, or a carboxylate
 connected to the ring with a 0 to 3 carbon linker,

-PO₃H₂, -CH₂PO₃H₂, -CH₂CH₂PO₃H₂, -CH₂CHNH₂PO₃H₂,
 -CH₂CH[NHCOCH₂]₂PO₃H₂, -CH₂CH[NHCO(CH₂)₁₅CH₃]PO₃H₂,
 -CH₂CH[NH-FMOC]PO₃H₂, -CH₂CH[NH-tBOC]PO₃H₂, or a phosphate or
 phosphonate connected to the ring with a 0 to 3 carbon linker,

-SO₃H, -CH₂SO₃H, -CH₂CH₂SO₃H, -CH₂CHNH₂SO₃H,
 -CH₂CH[NHCOCH₂]₂SO₃H, -CH₂CH[NHCO(CH₂)₁₅CH₃]SO₃H,
 -CH₂CH[NH-FMOC]SO₃H, -CH₂CH[NH-tBOC]SO₃H, or a sulfate or sulfite
 connected to the ring with a 0 to 3 carbon linker,

or acts as the functional equivalent of $\text{CH}_2\text{CH}(\text{NH}_2)\text{CO}_2\text{H}$ of T3 in the molecular recognition domain when bound to a TR, wherein said R_1 can be optionally substituted with an amine,

5 wherein R_2 is

H, halogen, CF_3 , OH, NH_2 , SH, CH_3 , -Et,

or acts as the functional equivalent of H in the molecular recognition domain when bound to a TR,

10

wherein R_3 is

-H, halogen, $-\text{CF}_3$, -OH, $-\text{NH}_2$, $-\text{N}_3$, -SH, $-\text{CH}_3$, -Et,

or acts as the functional equivalent of I in the molecular recognition domain when bound to a TR,

15

wherein R_5 is

-H, halogen, $-\text{CF}_3$, -OH, $-\text{NH}_2$, $-\text{N}_3$, -SH, $-\text{CH}_3$, -Et, or acts as the functional equivalent of I in the molecular recognition domain when bound to a TR, and R_3 can be identical to R_5 ,

20

wherein R_6 is

-H, halogen, $-\text{CF}_3$, -OH, $-\text{NH}_2$, -SH, $-\text{CH}_3$, or acts as the functional equivalent of H in the molecular recognition domain when bound to a TR, and R_2 can be identical to R_6 ,

25

wherein R_2' is

-H, halogen, $-\text{CF}_3$, -OH, $-\text{NH}_2$, $-\text{N}_3$, -SH, $-\text{CH}_3$, -Et, or acts as the functional equivalent of H in the molecular recognition domain when bound to a TR,

30

wherein R_3' is any hydrophobic group, including

halogen, $-CF_3$, $-SH$, alkyl, aryl, 5- or 6-membered heterocycle, cyano, or acts as the functional equivalent of I in the molecular recognition domain when bound to a

5 TR,

wherein R_4' is

10 $-H$, halogen, $-CF_3$, $-OH$, $-NH_2$, NH_3 , $-N(CH_3)_3$, carboxylate, phosphonate, phosphate or sulfate, $-SH$, $-CH_3$, $-Et$, or alkyl, aryl or 5- or 6-membered heterocyclic aromatic attached through urea or carbamate linkages to O or N or S at the R_4' position, or acts as the functional equivalent of OH in the molecular recognition domain when bound to a TR,

15 wherein R_5' is

20 $-H$, $-OH$, $-NH_2$, $-N(CH_3)_2$, $-SH$, $-NH_3$, $-N(CH_3)_3$, carboxylate, phosphonate, phosphate, sulfate, branched or straight chain alkyl having 1 to 9 carbons, substituted or unsubstituted aryl, wherein said substituted aryl is substituted with halogen or 1 to 5 carbon alkyl and wherein said aryl is optionally connected to the ring by a $-CH_2-$, aromatic heterocycle having 5 to 6 atoms, wherein said heterocycle may be substituted with one or more groups selected from $-OH$, $-NH_2$, $-SH$, $-NH_3$, $-N(CH_3)_3$, carboxylate, phosphonate, phosphate or sulfate, heteroalkyl, arylalkyl, heteroaryl alkyl, polyaromatic, or polyheteroaromatic, wherein said R_5' 25 may be substituted with polar or charged groups,

wherein R_6' is

30 $-H$, halogen, $-CF_3$, $-OH$, $-NH_2$, $-SH$, $-CH_3$, $-Et$, or acts as the functional equivalent of H in the molecular recognition domain when bound to a TR,

wherein X is

O, S, SO₂, NH, NR₇, CH₂, CHR₇, CR₇R₇, wherein R₇ is alkyl, aryl or 5- or 6-membered heterocyclic aromatic,

and wherein said TR LBD ligand has an apparent K_d for binding TR LBD of 1 μM or 5 less.

65. The compound of claim 64, wherein
- R₁ is carboxylate, phosphonate, phosphate or sulfite and is connected to the ring with a 0 to 3 carbon linker,
- 10 R₂ is H,
- R₃ is -I, -Br, or -CH₃,
- R₅ is -I, -Br, or -CH₃,
- R₆ is -H,
- R₂' is -H,
- 15 R₃' is -I, -Br, -CH₃, -iPr, -phenyl, benzyl, or 5- or 6-membered ring heterocycles,
- R₄' is -OH, -NH₂, and -SH,
- R₅' is -H, -OH, -NH₂, -N(CH₃)₂-SH -NH₃, -N(CH₃)₃, carboxylate, phosphonate, phosphate, sulfate, branched or straight chain alkyl having 1 to 9 carbons, substituted or unsubstituted aryl, wherein said substituted aryl is substituted with
- 20 halogen or 1 to 5 carbon alkyl and wherein said aryl is optionally connected to the ring by a -CH₂-, aromatic heterocycle having 5 to 6 atoms, wherein said heterocycle may be substituted with one or more groups selected from -OH, -NH₂, -SH, -NH₃, -N(CH₃)₃, carboxylate, phosphonate, phosphate or sulfate, heteroalkyl, arylalkyl, heteroaryl alkyl, polyaromatic, or polyheteroaromatic, wherein said R₅'
- 25 may be substituted with polar or charged groups, and
- R₆' is H.

66. The compound of claim 65, wherein said compound is made by the method of claim 13.

30 67. The compound of claim 65, wherein said compound is made by the method of claim 39.

68. The compound of claim 65, wherein said compound is a TR antagonist.

107.

69. The compound of claim 65, wherein said compound is a TR agonist.
70. The compound of claim 65, wherein said compound is a TR α selective ligand.
71. The compound of claim 65, wherein said compound is a TR β selective ligand.
72. A pharmaceutical composition having selective thyromimetic activity comprising a
5 compound as claimed in claim 65 and a pharmaceutically effective carrier.
73. The composition of claim 72, wherein R5' is an alkyl having from 1 to 9 carbons and being straight chain or branched.
74. A method of lowering the ratio of LDL-cholesterol to HDL-cholesterol levels comprising administering an effective amount of the compound of claim 65.
- 10 75. A method of lowering plasma lipid levels which comprises administering to an animal in need thereof an effective amount of the compound of claim 65.
76. A method of treating thyroid hormone deficiency in patients with compromised cardiac function, comprising administering an effective amount of the compound of claim 65.

Figure 1. Design of Ligands that Interact with Nuclear Superfamily Members




Figure 1

MECHANISM OF HORMONE ACTION WITH RECEPTORS

Figure 2 shows steps in the actions of the nuclear hormone receptors. Ligands for these receptors circulate bound to varying extents to plasma proteins. Following dissociation from these proteins, these ligands enter cells and bind specifically to their receptors. Steroids and vitamin D probably enter cells through passive diffusion; thyroid hormone and retinoic acid entry might involve specific transport processes (5).

DOMAINS:

NH ₂ -TERMINAL	DNA BINDING	LIGAND BINDING
---------------------------	-------------	----------------

HOMOLOGY: Hypervariable > 40% About 20%

FUNCTION: Transactivation DNA binding Ligand binding
Dimerization
Transactivation
Nuclear translocation
Hsp binding

Figure 2

	1						60
rTRalpha	
hTRalpha	
hTRbeta	
hRARalpha	
hRARGamma	
hRXRalpha	
hRXRbeta	
hPPARalpha	
hPPARbeta	
hPPARGamma	
hVDR	
hER	
hGR	
hPR	MTLKAKGPR	APHVAGGPPS	PEVGSPLLCR	PAAGPFPCSQ	TSDTLPEVSA	IPISLDGLLF	
hMR	...METKGYH	SLPEGLDMER	RWGQVSQAVE	RSSLGPTERT	DENNYMEIVN	VSCVSGAIPN	
hAR	
	61						120
rTRalpha	
hTRalpha	
hTRbeta	
hRARalpha	
hRARGamma	
hRXRalpha	
hRXRbeta	
hPPARalpha	
hPPARbeta	
hPPARGamma	
hVDR	
hER	
hGR	
hPR	PRPCQGQDPS	DEKTDQDQSL	SDVEGAYSRA	EATRGAGGSS	SSPPEKDSGL	LDSVLDTLA	
hMR	NSTQCSSKEK	QELLPCLOQD	NNRPGILTSD	IKTELESKEL	SATVAESHGL	YMSVVRDADY	
hAR	
	121						180
rTRalpha	
hTRalpha	
hTRbeta	
hRARalpha	
hRARGamma	
hRXRalpha	
hRXRbeta	
hPPARalpha	
hPPARbeta	
hPPARGamma	
hVDR	
hER	
hGR	GATVKVSASS	PSLAVASQS.	
hPR	PSGPGQSQPS	PPACEVTSSW	CLFGPELPED	PPAAPATQRV	LSPLHSRSGC	KVGDSSGTAA	
hMR	SYEQNQQGS	HSPAKIYQNV	EQLVKFYKGN	GHRPSTLSCV	NTPL..RSFM	SDSGSSVNGG	
hAR	
	181						240
rTRalpha	
hTRalpha	
hTRbeta	

Fig. 3a

Fig. 3b

```

hPPARgamma ..... / .....
hVDR .....
hER .....MTM
hGR IDENCLLSPL AGEDDSFLE CNSNEDCKPL ILPDTKPKIK DNGDLVLSSP SNVTLPQVKT
hPR SSTPVAVGDF P..DCAYPPD AEPKDDAYPL YSDFQPPALK IKEEEEGAEA SARSPRSYLV
hMR TLRDVVPSPD TQEKGAQEVF FPKTEEVEA ISNGVTGQLN IVQYIKPEPD GAFSSSSCLGG
hAR .....

421 480

rTRalpha .....
hTRalpha .....
hTRbeta .....
hRARalpha .....
hRARgamma .....
hRXRalpha .....
hRXRbeta AKECIVGSAT ALAGSRSGGG GGGGRRRTTN PGACARGWTG RDGRH..GRD SRSPSSSSPN
hPPARalpha .....
hPPARbeta .....
hPPARgamma .....
hVDR .....M DTEDLPANNA PLTVNEQLLG SCTLKFPAQD AQVIVMSGQE TIRVLEVEVD
hER TLHTKASGMA LLHQIQGNEL EPLNRPLQKI PLERPLGEVY LDSSKPAVYN YPEGAAEFN
hGR EKEDFIELCT PGVIKQEKLG TVYCQASFPG ANIIG.....NK HSAISVHGVS
hPR AGANPAAFPD FPLGPPPLP PR.ATPSRPG EAAVT.....AA PASASVSSAS
hMR NSKINSOSSF SVPIKQESTK HSCSGTSFKG NPTVNPFFPM DCSYFSFMD DYYSLSGIL
hAR .....GG CGGEA.....GA VAPYGYTRP.

481 540

rTRalpha .....MEQKPSK VECGSDPEEN
hTRalpha .....MEQKPSK VECGSDPEEN
hTRbeta .....HTPNSHTE NGLTAWDKPK HCPDREHDKR LVGMSEACLH
hRARalpha .....
hRARgamma .....M ATNKERLFAA CALGPCGCGYP
hRXRalpha .LTSPTGR..GSHAAPSLHP SLGPGICSPG .QLHSPISTL SSPINGHGPP FSVISSPHGP
hRXRbeta PLPQGVPP..PSPGCPPLPP STAPTLCGSG .APPPP....PMPPPPLGSP FSVISSPHGS
hPPARalpha ..MVDTESPL CPLSPLEAGD LESPLSEEF LQEMGNIEIS QSIGEDSSGS FCFTEYQYLG
hPPARbeta .....MEQKPSK EEAP.....EVREEEEXE EVAEAECAPE LNGGPQHALP
hPPARgamma .....MVD TEMPFWPTNF ....GISSVD LSHMDHSHS FDIKPTTTVD
hVDR TALSSAGAAE SCGDEEGSCG SLEATEEAQL DGPVTTSTT AVTVEVSAPV VQTVVSKAAI
hER AAAAANAQVY CQTGLPYGPG SEAAAFGSNG LGGFPPLNSV SPSPMLLHP PPQLSPFLQP
hGR TSGGQMYHYD MNTASLSQQQ DQ.....XPIFNVIP IPVGSZ.....
hPR SSGSTLECIL YKAEAGAPPQ GPFAPPPCKA PGASGCLLPR DGLPSTS...
hMR GPPVPGFDGN CEGSGFPVGI KQEPDDGSYY PEASIPSSAI VGVNSGGQSF HYRIGAQGTI
hAR .....PQGLAQE SDFTAPDVWY PGG...MVSR VPYPSFT...

541 600

rTRalpha SARSPDGKRX RXN.GQCP.. ....LKSSM .....SGYI
hTRalpha SARSPDGKRX RXN.GQCS.. ....LKTSM .....SGYI
hTRbeta RKSHSERRST LKN.EQSSPH LIQTWTSSI FHLHDHVDND QSVSSAQTFQ TEEKKCKGYI
hRARalpha .....PN SNHVASGAGE AAJETQSSSS EEIVPSPPSP
hRARgamma GAGFPFAFFG ALR.GSPFFE HLSPSFRGLG QPDLPKEMAS LSVETQSTSS EEMVPSPPSP
hRXRalpha HSMVSP....TTPTLCFST GSPQLSS...PMNPVSSSE DIKPFLLGNG VLKVPAPHPSG
hRXRbeta PGLPPP....APPGFSGPV SSPQINSTVS LPGGCGSPPE DVKPPVLGVR GLHCPPPPCCG
hPPARalpha SCPGSDGSVI TDTLSPA... .....SSPS..SVT YPVVPGSVDE
hPPARbeta SSSYTD....LSRS... .....SSPP..SLD DQLQMGCC.DG
hPPARgamma FSSISAPHYE DIPFTRADPH VADYKYDLKL QEYQSAIKVE PASPPYYSEK AQLYNRPHEE
hVDR SVSPAQQTSTV PITVQACPV LTQDGLASLM TGLAQSSSL GQPLLIPLSM AGSVGGQGCL
hER HQQVPPYYLE NEPSGYTVRE AGPP....AF YRPNSDNRRQ GGRERLASTN DKGSMAHESA
hGR ..WNRQCQSG DDNLTSGLTL NFGRTVFSN CYSSPSMRPD V.....SSPPSSSST
hPR ..ASAAAAGA APALYPALGL NGLPQLGYQA AVLKEGLPQV YPPYLNLRP DSEASQSPQY
hMR SLRSARDQS-FQHLSSFPVP NTLVESWKS HGLSSRRSDG YPVLEYIPEN VSSSTLRSVS

```

Fig. 3C

6/32

hAR ...CVKSEMG7 WMDSYSG... ..PYOD' MRLTAPDHW LP...

601 660

rTRalpha	PSYLDKDEQC	VVCGDKATGY	HYRCITCEGC	KGFFRRTIQK	NLHPTYSCXY	DS.....
hTRalpha	PSYLDKDEQC	VVCGDKATGY	HYRCITCEGC	KGFFRRTIQK	NLHPTYSCXY	DS.....
hTRbeta	PSYLDKDELC	VVCGDKATGY	HYRCITCEGC	KGFFRRTIQK	NLHPSYSCXY	EG.....
hRARalpha	PPLPRIYKPC	FVCQDKSSGY	HYGVSAECGC	KGFFRRTIQK	NH..VYTCHR	DK.....
hRARGamma	PPPPRVYKPC	FVCNDKSSGY	HYGVSSCEGC	KGFFRRTIQK	NH..VYTCHR	DK.....
hRXRalpha	NMASFTKHIC	AICGDRSSCK	HYGVYSCEGC	KGFFKRTVRK	DL..TYTCRD	NK.....
hRXRbeta	PGAG..KRLC	AICGDRSSCK	HYGVYSCEGC	KGFFKRTVRK	DL..TYTCRD	NK.....
hPPARalpha	SPSGALNIEC	RICGDKASGY	HYGVHACEGC	KGFFRRTIRL	KLVD...KC	DR.....
hPPARbeta	ASCGSLNMEC	RVCQDKASCF	HYGVHACEGC	KGFFRRTIRH	KLEYE...KC	ER.....
hPPARGamma	PSNSLMAIEC	RVCQDKASGF	HYGVHACEGC	KGFFRRTIRL	KLIYD...RC	DL.....
hVDR	AVLTLPATV	ATLPGLAAAS	PAGGLLKLPP	AGLQAATVLN	SVQTLQAP	QAVLQPMHSA
hER	KET....RYC	AVCNDYASGY	HYGVWSCEGC	KAFFKRSIQG	HN..DYMCPA	TN.....
hGR	ATTGPPPKLC	LVCSDASGC	HYGVLTCGSC	KVFFKRAVEG	QHNYLCAGRN	D.....
hPR	SFESLPQKIC	LICGDEASGC	HYGVLTCGSC	KVFFKRAVEG	QHNYLCAGRN	D.....
hMR	TGSSRPSKIC	LVCGDEASGC	HYGVVTCGSC	KVFFKRAVEG	QHNYLCAGRN	D.....
hARPQKTC	LICGDKASGC	HYGALTCGSC	KVFFKRAAEG	KQKYLCAARN	D.....

661 720

rTRalpha	.CCVIDKTR	NQCQLCRFKX	CIAGMHAMD	VLDDSKRVAK	RKLIEQNRE	RRK...EEMIR
hTRalpha	.CCVIDKTR	NQCQLCRFKX	CIAGMHAMD	VLDDSKRVAK	RKLIEQNRE	RRK...EEMIR
hTRbeta	.KCVIDKVTR	NQCQECRFX	CIYVGHATDL	VLDDSKRLAK	RKLIEENREK	RRR...EELQK
hRARalpha	.NCIINKVTR	NRCQYCRLOK	CFEVMSKES	VRND.....RNK	KKK...EVPKP
hRARGamma	.NCIINKVTR	NRCQYCRLOK	CFEVMSKEA	VRND.....RNK	KKK...EVKEE
hRXRalpha	.DCLIDKRQR	NRCQYCRYQK	CLAMGHKREA	VQEERQRG..KDRNEN	EVE..STSSA
hRXRbeta	.DCTVDKRQR	NRCQYCRYQK	CLATGMKREA	VQEERQRG..KDRNEN	EVE..STSSA
hPPARalpha	.SCKIQKKNR	NKCQYCRFX	CLSVGMSHNA	IRFG.....	.RMPSEKAK	LKA..EILTC
hPPARbeta	.SCKIQKKNR	NKCQYCRFX	CLALGMSHNA	IRFG.....	.RMPAEKAK	LVA..GLTAN
hPPARGamma	.NCRIHKKSR	NKCQYCRFX	CLAVGMSHNA	IRFG.....	.RMPQAEKEX	LLA..EISS
hVDR	LQAMQQTQT	AATTASIVQK	ASEPSVSVAT	LQTAGLSINP	AIISAASLGA	QPQFISSLT
hER	.QCTIDKNRR	KSCQACRLRK	CYEVGMMKGG	IRKDRAGCRM	LKHKRQRDDG	EGR..GEVGS
hGR	..CIIDKIRR	KNCPACRYRK	CLQAGMNLGA	RKTKK...KIX	GIQ..QATT.
hPR	..CIIDKIRR	KNCPACRLRK	CCQAGMVLGG	RKFKFKNKVR	VVR..ALDAV
hMR	..CIIDKIRR	KNCPACRLRK	CLQAGMNLGA	RKSKKLGLKX	GIH..EEQPQ
hAR	..CTIDKFR	KNCPSCRLRK	CYEAGMTLGA	RKLKLGCLNK	LQE..EGEAS

721 minimal start site 725 780

rTRalpha	SLQQRPEPTP	EEWDLIHVAT	EAHRSTNAQG	SHWKQRRKFL	PDDICQSPIV
hTRalpha	SLQQRPEPTP	EEWDLIHVAT	EAHRSTNAQG	SHWKQRRKFL	PDDICQSPIV
hTRbeta	SIGHXPEPTD	EEWELIKTVT	EAHVATNAQG	SHWKQPKFL	PEDICQAPIV
hRARalpha	ECSESYTLTP	EVGELIEKVR	KAHQETFPAL	CQL...GKYT	TNNSSEQRV.
hRARGamma	GSPESYELSP	QLEELITKVS	KAHQETFPAL	CQL...GKYT	TNNSADHRV.
hRXRalpha	NEDHPVERIL	EAEAVEPKT	ETIVE..ANM	GLNPS.....SP..
hRXRbeta	PEENPVDRIL	EAEAVEPKT	DQVEGPGGT	GGSGS.....SP..
hPPARalpha	EHDIEDSETA	DLKSLAKRIY	EAYLKNFN.M	NKVKARVILS	GKASNNPPFV	IHDMETLCHA
hPPARbeta	EGSQYNPQVA	DLKAFSKHIY	NAYLKNFN.M	TKXKARSILT	GKASHTAPFV	IHDIELWQA
hPPARGamma	DIDQLNPESA	DLRALAKHLY	DSYIKSFP.L	TKAKARAILT	GKTTDKSPFV	IYDMNSLMHG
hVDR	TPIITSAMSN	VAGLTSQLIT	NAQQQVIGTL	PLLVPASLA	CAAAASA...LPA
hER	AGDMRAANLW	PSPLMIKRSK	KNSLALSITA	DQMSALLDA	EPPILYSE..
hGRGVSQ	ETSENPCKNT	IVPATLPQIT	PTLV.....LL.....
hPR	ALPPLGVN	ESQALSQFT	FSPQDIQLI	PPLIN.....LL.....
hMR	QQQPPPPPP	PQSPEEGTTY	IAPAKPSVN	TALVPQLSTI	SRALTPSPVM	VL.....
hAR	STTSP.....	.TEETTQKLT	VSHIEGYEQ	PIFLN.....VL.....

781 840

rTRalphaSMPDGDKVD	LEAFSEFTKI	ITPAITRVVD	FAXKLPMFSE	LPCEQDIIILL
hTRalphaSMPDGDKVD	LEAFSEFTKI	ITPAITRVVD	FAXKLPMFSE	LPCEQDIIILL
hTRbetaNAPEGKVD	LEAFSHFTKI	ITPAITRVVD	FAXKLPMFCE	LPCEQDIIILL

Fig. 3d

hRARalpha SLD IDLWDFSEL STKCIKTVE FAXQLP
 hRARgamma QLD LGLWDFSEL ATKCIKTVE FAXRL
 hRXRalpha NDPVTNICQ A..... ADKQFLTLVE WAKRIPHFSE LPDDQVILL
 hRXRbeta NDPVTNICQ A..... ADKQFLTLVE WAKRIPHFSS LPDDQVILL
 hPPARalpha EKTIVAKLVA NGIQN.KEVE VRIFHCQCT SVETVTELTE FAKAIPAFAN LDNDQVILL
 hPPARbeta EKGLVWKQLV NGLPPYKEIS VHVYFRCQCT TVETVRELTE FAKSIPSFSS LFLNDQVILL
 hPPARgamma EDKIKFKHIT PLQEQSKEVA IRIFQCQCFR SVEAVQEITE YAKNIPGFIN LDNDQVILL
 hVDR QGLQVQTVAP QLLNSQGGI IATIGNGPTA AIPSTASVLP KATVPLTLTK TITQGPVGKV
 hER YDTPRFSE ASMMGLLTNL ADRELVHMIN WAKRVPGFVD LTLHDQVHLL
 hGR EVIEPEVLYA GYDSSVPDST WRIMTTLNML GGRQVIAAVK WAKAIPGFRN LHLDDQHTLL
 hPR MSIEPDVIYA GHDNTKPDTS SSLTSLNQL GERQLLSVVK WSKSLPGFRN LHIDDQITLI
 hMR ENIEPEIVYA GYDSSKPDTA ENLLSTLNRL AGKQHIQVVK WAKVLPGFKN LPLEDQITLI
 hAR EAIEPGVCA GHDNNQPDF AALLSSLNEL GERQLVHVVK WAKALPGFRN LHVDDQMAVI

841

900

rTRalpha KGCCMEIMSL RAAVRY..DP ESDTLTSLGE HTVKRKQLK. ...GGLGV VSDAIFELGK
 hTRalpha KGCCMEIMSL RAAVRY..DP ESDTLTSLGE HAVKREQLK. ...GGLGV VSDAIFELGK
 hTRbeta KGCCMEIMSL RAAVRY..DP ESETLTNGE HAVIRGQLK. ...GGLGV VSDAIFDLGH
 hRARalpha KAACLDILIL RICTRY..TP EQDTMTFSDG LTLNRTQMH. ...AGFGP LTDLVFAPAN
 hRARgamma KAACLDILML RICTRY..TP EQDTMTFSDG LTLNRTQMH. ...AGFGP LTDLVFAPAG
 hRXRalpha RAGWNELLIA SFSHRS..IA VKDGILLATG LHVHRNSAH. ...AGVGA FDRVLTSLVS
 hRXRbeta RAGWNELLIA SFSHRS..ID VRDGILLATG LHVHRNSAH. ...AGVGA FDRVLTSLVS
 hPPARalpha KYGVYEAIFA MLSSVH..NK DGMLVAYGNG F.ITREFLK. ...SLRKPFCD IMEPKFDFAM
 hPPARbeta KYGVYEAIFA MLASIV..NK DGLLVANGSG F.VTREFLR. ...SLRKPFSD IIEPKFEFAV
 hPPARgamma KYGVYEEIYT MLASLH..NK DGVLISEGGC F.MTREFLK. ...SLRKPFCD FHEPKFEFAV
 hVDR APSKVIIAPQ PSVVKPVTSL TAAGVIACGE MPTVGQLVNX PSAVKDEEAI NLEEIREFAK
 hER ECANLEILMI GLVWRS..ME HPGKLLFAPN LLLDRNQGK. ...CVEGHVEI FDMLLAT.SS
 hGR QYSWMFLMAF ALGWSYRQS SANLLCFAPD LIINEQRMT.LPCMYD QCKHMLYVSS
 hPR QYSWMSLMVF GLGWSYKHV SQOMLYFAPD LILNEQRMK.ESSFYS LCLTMWQIPQ
 hMR QYSWMCLSSF ALSWRSYKHT NSQFLYFAPD LVFNEEKMH.QSMYSE LCQGHMHOISL
 hAR QYSWMGLMVF AMGWSFTNV NSRMLYFAPD LVFNERYMH.KSRMYS QCVRMHRLSQ

901

960

rTRalpha SLSAFNLDDT EVALLQAVLL MSTD..... ..RSGLLCVD KIEKSQEAYL LA...FEHYV
 hTRalpha SLSAFNLDDT EVALLQAVLL MSTD..... ..RSGLLCVD KIEKSQEAYL LA...FEHYV
 hTRbeta SLSSFNLDDT EVALLQAVLL MSSD..... ..RPGLACVE RIEKYQDSFL LA...FEHYI
 hRARalpha QLLPLEHDDA ETGLLSAICL ICCD..... ..RDLEQPD RVDMLQEPLL EA...LKVYV
 hRARgamma QLLPLEHDDT ETGLLSAICL ICCD..... ..RDLEPE KVDKLQEPLL EA...LRLYA
 hRXRalpha KMRDMQMDKT ELGCLRAIVL FNPDS..... ..KGLSNPA EVEALREKVY AS...LEAYC
 hRXRbeta KMRDMQMDKT ELGCLRAIIL FNPDA..... ..KGLSNPS EVEVLREKVY AS...LETYC
 hPPARalpha KFNALELDD DISLFVAII CCGD..... ..RPGLNVC HIEKMQEGIV HV...LRLHL
 hPPARbeta KFNALELDD DLALFIAII LCGD..... ..RPGLMNP RVEAIQDTIL RA...LEFHL
 hPPARgamma KFNALELDD DLAFIAVII LSGD..... ..RPGLNVK PIEDIQDNLL QA...LELQL
 hVDR NFKIRRLSLC LTQTQVQAL TATECPAYSQ SAICREFKD ITPKSAQKLK PVLERWLAEA
 hER RFRMMNLQGE EFVCLKSIIL LNSGVYTFLS STLKSLEEKD HIHRVLDKIT DTLIHLMAKA
 hGR ELHRLQVSYE EYLCHKTLLE LSS..... VPKDGLKSQE LFDEIRMTYI KELGKAIVKR
 hPR EFVKLQVSQE EFLCHKVLLL LNT..... IPLEGLRSQT QFEEMRSSYI RELIKAIGLR
 hMR QFVRLQLTFE EYTINKVLLL LST..... IPKDGLKSQA AFEEMRTNYI KELRKMVTCK
 hAR EFGWLQITPQ EFLCHKALL FSI..... IPVDGLKNQK FFDELRMNYI KELDRIIACK

961

1020

rTRalpha NHRKHNIPHF WPKLL....M KVTDLRMIGA CHASRFL..H MKVEC..PTE LFPPLFLEV
 hTRalpha NHRKHNIPHF WPKLL....M KVTDLRMIGA CHASRFL..H MKVEC..PTE LFPPLFLEV
 hTRbeta NYRKHHVTHF WPKLL....M KVTDLRMIGA CHASRFL..H MKVEC..PTE LLPPLFLEV
 hRARalpha RRRRPSRPHM FPKML....M KITDLRSISA KGAERVI..T LKMEI..PGS M.PPLIQEML
 hRARgamma RRRRPSQPYM FPRML....M KITDLRGIST KGAERAI..T LKMEI..PGP M.PPLIREML
 hRXRalpha KHKYPEQPCR FAKLL....L RLPALRSIGL KCLEHLF..F FKL.I..GDT PIDTFLMEML
 hRXRbeta QKYPEQQGR FAKLL....L RLPALRSIGL KCLEHLF..F FKL.I..GDT PIDTFLMEML
 hPPARalpha QSNHPDDIFL FPKLL....Q KHAIDLRLVT EHAQLVQ..I IKKTE..SDA ALHPLLQEYI
 hPPARbeta QANHPDAQYL FPKLL....Q KHAIDLRLVT EHAQMHQ..R IKKTE..TET SLHPLLQEYI

FIG. 3c

PCT/US 96/20778

```

hPPARgamma KLNHPSSQL FAKVL...Q KMTDLRQIVT EHVQLLH..V IKKTE..TOR
hVDR ELWNQKQQQN LM VGGEPS KKRKRRTSFT PQAIEVLNTY FEKNSL: Q EITETAKELN
hER GLTLQQQHQR LAQLL...L ILSHIRHMSN KGMENLY..S MKC.K..NVV PLYDLLLEML
hGR EGNSSQNWQR FYQLT...K LLDSTMHEVVE NLLNYCFQTF LD.KT..MSI EFPENLAETI
hPR QKGVVSSSQR FYQLT...K LLDNLHDLVK QLHLYCLNTF IQSRA..LSV EFPENHSEVI
hMR PNNSSQSWQR FYQLT...K LLDSTMHDLVS DLLEFCFYTF RESHA..LKV EFPAMLVEII
hAR RKNPTSCSR R FYQLT...K LLDVQPIAR ELHQFTFDLL IKSHH..VSV EFPENHAEII

```

1021 — minimal end site 1025 1071

```

cTRalpha EDQEV.....
hTRalpha EDQEV.....
hTRbeta ED.....
hRARalpha ENSEGLDTLS GQPGGGCRDG GGLAPPPGSC SPSLSPSSNR SSPATHSP..
hRARGamma ENPEMFEDDS SQPGPHPNAS SEDEVPGGQG KGGLKSPA...
hRXRalpha EAPHQMT...
hRXRbeta EAPHCLA...
hPPARalpha RDMY.....
hPPARbeta XDMY.....
hPPARgamma KDLY.....
hVDR YDREVVVRWF CNRRQTLKNT SKINVFQSQ. ....
hER DAHRLHAPTS RCGASVEETD QSHLATAGST SSHSLQKYYI TGEAEGFPAT V
hGR TNQIFKYSNG NIKKLLFHQK .....
hPR AAQLFKILAG MKPPLL FHKK .....
hMR SDQLFKVESG NAKPLYFHRK .....
hAR SVQVFKILSG KVKPIYFHTQ .....

```

socr:<5>

Figure 3f




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8







Figure 9

AGONISTS


Retinoic Acid




Estradiol



Diethylstilbestrol




Progesterone

ANTAGONISTS


Ro 46-8515



ICI 164384




Tamoxifen



RU 486

shows position of extension group

FIG. 10



Compound

RCOX

TS1

 $\text{Ph}_2\text{CHCO}_2\text{NHS}$

TS2

 $\text{C}_{16}\text{H}_{33}\text{CO}_2\text{NHS}$

TS3

FMOC-Cl

TS4

tBOC₂O

TS5

tBOC₂O

FIG. 11







FIG. 12



TS-5



TS-8

FIG. 13









FIG. 14


TS-10




TS-5




TS-6



TS-8




TS-9



TS-10

FIG. 15



22/32





FIG. 17

23/32




FIG. 18




FIG. 19




FIG. 20




FIG 21




FIG 22




FIG 23




FIG 24




FIG 25




FIG. 26A Right




FIG. 26B Left



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 14/72	A3	(11) International Publication Number: WO 97/21993 (43) International Publication Date: 19 June 1997 (19.06.97)
(21) International Application Number: PCT/US96/20778 (22) International Filing Date: 13 December 1996 (13.12.96) (30) Priority Data: 60/008,543 13 December 1995 (13.12.95) US 60/008,540 13 December 1995 (13.12.95) US 60/008,606 14 December 1995 (14.12.95) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US). (72) Inventors: SCANLAN, Thomas, S.; 2525 Moraga Street, San Francisco, CA 94122 (US). BAXTER, John, D.; 131 San Pablo Avenue, San Francisco, CA 94127 (US). FLETTERICK, Robert, J.; 15 Christopher Avenue, San Francisco, CA 94131 (US). WAGNER, Richard, L.; 1704 Waller Street, San Francisco, CA 94117 (US). KUSHNER, Peter, J.; 1362 Sixth Avenue, San Francisco, CA 94122 (US). APRILETTI, James, L.; 11 Virginia Gardens, Berkeley, CA 94702 (US). WEST, Brian, L.; 142 Anderson Street, San Francisco, CA 94110 (US). SHIAU, Andrew, K.; 34 Hugo Street, San Francisco, CA 94122 (US).		(74) Agents: NAKAMURA, Jackie, N. et al.; Cooley Godward L.L.P., 3000 El Camino Real, Five Palo Alto Square, Palo Alto, CA 94306-2155 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 24 July 1997 (24.07.97)
(54) Title: NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS (57) Abstract The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three-dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as "TR"). Also provided are crystals, nuclear receptor synthetic ligands, and related methods.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/20778

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/72

US CL : 530/350, 324, 387.9

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350, 324, 387.9

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, BIOSIS, WPIDS, CAPLUS, INPADOC, JICST-EPLUS

Search Terms: thyroid receptor, steroid receptor, crystal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BOURGUET et al. Purification, functional characterization and crystallization of the ligand binding domain of the retinoid X receptor. Protein Expression And Purification. 1995. Vol. 6, pages 604-608, especially page 607.	1-9
Y	McGRATH et al. Preliminary crystallographic studies of the ligand-binding domain of the thyroid hormone receptor complexed with triiodothyronine. J. Mol. Biol. 1994. Vol. 237 pages 236-239, especially page 237.	1-9
Y, P	WAGNER et al. A structural role for hormone in the thyroid hormone receptor. Nature. 14 December 1995. Vol 378, pages 690-697, especially page 690 and 691.	1-9

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

•	Special categories of cited documents:	•T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
•A	document defining the general state of the art which is not considered to be of particular relevance		
•E	earlier document published on or after the international filing date	•X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
•L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	•Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
•O	document referring to an oral disclosure, use, exhibition or other means		
•P	document published prior to the international filing date but later than the priority date claimed	•&	document member of the same patent family

Date of the actual completion of the international search

13 MAY 1997

Date of mailing of the international search report

05 JUN 1997

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MUKUL RANJAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORTInte...ational application No.
PCT/US96/20778**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	RASTINEJAD t al. Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature. 18 May 1995. Vol 375, pages 203-211, especially page 205.	1-9

INTERNATIONAL SEARCH REPORT

Int. l. application No.

PCT/US96/20778

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please see extra sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-9, as they read on a crystal of a TR LBD

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Box II Observations where unity of invention is lacking

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claim(s) 1-9, drawn to a crystal of TR LBD.

Group II, claim(s) 1-9, drawn to a co-crystal of TR LBD and ligand.

Group III, claim(s) 10-28, drawn to a computational method for nuclear receptors.

Group IV, claim(s) 29-37, drawn to a computational method for receptors other than TR.

Group V, claim(s) 38-54, drawn to a computational method for designing antagonists.

Group VI, claim(s) 55-63, drawn to a computational method for designing super-agonists or super antagonists.

Group VII, claim(s) 64-73, drawn to compounds having the recited formula and pharmaceutical compositions containing them.

Group VIII, claim(s) 74-75, drawn to method for lowering LDL/HDL ratio and plasma lipid.

Group IX, claim(s) 76, drawn to a method of treating thyroid hormone deficiency.

The inventions listed as Groups do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I, II and VI are to materially different products that do not share a special technical feature which defines an advance over the art. The crystal of TR LBD by itself and TR LBD with a ligand are structurally and functionally different entities which therefore do not share a special technical feature. Similarly the compounds of group VI are structurally and functionally different from the compounds each of the groups I and II and therefore do not share a special technical feature.

The claims of groups III-VI are each to alternate methods that do not use the products of groups I and II. Each of these methods uses materially different process steps and results in different outcomes. The ISA/US considers that unity of invention does not exist between dissimilar methods which do not correspond to the main invention of the first group (37 CFR 1.475(d)).

The claims of groups VII-VIII are each to alternate methods of use of the products of group VI. The methods of the two groups use different process steps for achieving different final outcomes. The ISA/US considers that unity of invention does not exist between dissimilar methods which do not correspond to the main invention of the first group (37 CFR 1.475(d)).